var title_f3_39_3696="Shigella protrusion from the cell";
var content_f3_39_3696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/58781/shgprotr_conv.mp4?title=Shigella+protrusion+from+the+cell\" style=\"width:250px;height:266px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shigella protrusion from the cell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shigella within a membrane-bound protrusion (arrow) from the host cell surface, viewed looking down on the apical cell surface. The bacterium containing protrusions can extend several bacterial lengths away from the cell surface with the bacterium at the tip; they enable the bacterium to pass into adjacent cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcia B Goldberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3696=[""].join("\n");
var outline_f3_39_3696=null;
var title_f3_39_3697="Ultrasound of frontal bossing flat nose flat face retrognathia";
var content_f3_39_3697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Ultrasound images showing of frontal bossing, flat nose/face, retrognathia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal ultrasound images of the fetal profile.",
"    <br>",
"     (A) Thanatophoric dysplasia at 20.3 weeks gestation demonstrates frontal bossing (white arrow) and flattened nasal bridge (yellow arrow).",
"     <br>",
"      (B) Campomelic dysplasia at 22 weeks demonstrates markedly flat facies and retrognathia (arrow).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3697=[""].join("\n");
var outline_f3_39_3697=null;
var title_f3_39_3698="Sleeper stretch";
var content_f3_39_3698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Sleeper stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lie on your side with the involved shoulder directly beneath you. Keep the elbow bent at 90 degrees and use the top hand to help rotate the forearm downward (ie, internal rotation). Hold for 30 seconds. Release the pressure for 5 to 10 seconds and repeat. Perform three repetitions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3698=[""].join("\n");
var outline_f3_39_3698=null;
var title_f3_39_3699="Histology lung 1A answer";
var content_f3_39_3699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of an hematoxylin and eosin-stained section of lung (low power) from a patient with histoplasmosis. Note the granuloma and inflammation in the surrounding lung tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3699=[""].join("\n");
var outline_f3_39_3699=null;
var title_f3_39_3700="RA PA pressures pacing";
var content_f3_39_3700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Pressure waveforms change with ventricular pacing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 159px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressure waveforms during pacing and sinus rhythm. Left panel: The rhythm initially is paced from the right ventricle and the right atrial (RA) pressure tracing demonstrates a significant \"v\" wave due to tricuspid regurgitation. Middle panel: In the presence of normal sinus rhythm in the last half of the tracing, the normal RA waveform is restored and the \"v\" wave is no longer seen. Right panel: The effect of the rhythm change on the pulmonary aretry (PA) pressure is depicted. During pacing, the PA pressure is higher and has a greater respiratory variation than during sinus rhythm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Kern, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3700=[""].join("\n");
var outline_f3_39_3700=null;
var title_f3_39_3701="Palmoplantar pustulosis hands";
var content_f3_39_3701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwylFJSiuQ9UlVk+zsCMvnrUdB5Occ0AUAhf4SKfTKcKBi4pw6CkpfpSGhQaMfNSDNOpDDGRThxxSZPbmgZJoAXHNP47UnQ0uc0gEzzS0d6XHegBMUtBooAQDigYB4GKUn5cd6YfXNAXJCwPPakJBPpUOcDmkLU7Ese7AZFR5zj2prtTGPoaqwhxIOeKYcAZA56cUhNN5I2jJPpTSEKSKjPPSlIAXd1H+etamlaJeakTsTy4+uT3+lPbcSu3oZsUbyyrHGpdzwFHWu38N+Dn3effYLdQlbnhrQoNOhyIxJLjlm7V1dnb7mBzzjmspTvodVPD9WZ+naRGAoMQIH3RzgV0sVipK4RBtGMKoA+vvU1pArYABBx2q+sXlRAoCSOD9KiKfQ6LJFVLONdiqgIY9BSWyILiUsAQvC8DFWoSZGG0nPerGn6e00wlMRaBT8yj0q7PoN2itTQ0zTDdHIjwh6EjA/OtDVLGKwt0cOCAQH3H7pz29a2wttZWO234ZxuVS2dvoPrXDeIb1TdmEyyFV4IL5w3fit21FK5y071ZeRHe3yrMOUYNwApzge9Z905C+a+F3cKR3FVSC7FlOcHqfSqss5ZVQyZAOBntWE5aHV7NLYrapKipIeenAxkE14943vhc36woVKRrk4/vHsa7vxhqyWlpK2ckfKAD1btXkkjNJI7vyzEk1nSjeXOznrysuUYBkVKo+XB5poXmp0WtzltcdGoOAcdOuKlREHG1R9BQgII461KFHapZdkIFUAjaOtKqjnigjilxgZpIY0oMcgfkKQAAEBVx9Kec4pAM0ahoM2qP4RSYx0A/KnkfkKTvgUANUKM/KAfXFBAJ6DpTiPU0DpQAzaPSggdCMinhSQaQjsaYEYUI+5QOfakKgjBHfPIqTGM4pDk9qCbEe1VIwB+AowuelO9RikIphyoYUXuB+VAUEEEDB9qd2xScCmKyGbRgAKvHHSkKjPQflUhHfNNyOaAsMZQR0H5UUvY5ooCyGUooHWlFAAe2KWkxThjvSGC9fWnCgjjNOUGgBMetKB2pcHNFIpC/QGlA9aUcHml49aAEAx2pRwRRSigApVAwe1ApSOBSAMcUUYwKQ0AO+tMJyelIW4FNLc07E3An5uuaaXwKjLZJ96QtgAVQmx7PnFMLc01myaQt2IxTSE2Dn8aaT60jHng8VJbxS3EypChYnuozTJ32Iy2Ku6Zpram7JESu1SxJHDe2exra0nwhcXDB71vLjz91eTivQNN0K2tI18hcL3461EppaI1hSb1Zy2i+FYEKPcL5rdctXYW1oqjA+UHrWitugQIAM1Ygs/MAAGOwNZN3O2FJRK1pYurBkYEdcYrfsrRVZTIMHqxqXT9McRbgCB0/3jWtFZJ9nDCQh2XuO9NRbHOa2uVUg3fKgO3P8ACOR71YS2l8gDkqeN64wRV7T4Y4XhclsiMkc45qKScWyTpHhkc8p2/D3rWEbIzc23ZGn4a02xdWFwwD5wUPBNX7+8sdJglt2KSFvuZ/iH19a5OaWORBNHK4nAKsHPUdiD61l30rTRlSQeeo/iq4y5VZE+x55Xk9DSl1Z3lcwssRwTlTjp71zdxIXDuTkg5Le1SESW6kueCMZHNZ9zOVB8vncOc1jU13OuEFF6Gpa58h2GPmGK57U5RG8mPmHTBPftTZ9VFuhdTuJPfgV5z4s8TPeSGG0cbed7jt7Cl8SsjKpLku2ZfizUDe6rJGCPKhO1cHIJ7msU+1Kow3HSnKK0irKyPPb5ndirViJeM+1NjTnpU6L2FS2UkOVT6cU5RwKUL2FL0OKhspIaRR1604gEeho6nnn1ouwsNKjjpS4FGBjPFLtySc0XYhmCWOOhppHA9aeTgZH403b2HNCYDaUUYpKoBc+lNxSjk8UhFAC0hxQSQOlIAME0AIabTxSEUxMYaQUpFGM0CGd+OlJzg0/+8TxSDmmBGeOoopx69aKYEdO5xSUooEHenAcUL3pRSGKOhJ6Uo+tFKo9aQCryDmnDA47mjHoaVR3NA0GPzFHHXHFC96d2zSGNp3agClPJ96AEzSg9z3oyAuO9NLetMVwY84/WmM4APtTXJA9qjzkccU0hNjy3UVHuHrTSaTIZTnOe2DTSJbDPvTd1IeOvFaelaLdajINkZSPu7Ajj2p6LcEm9jNLdMc1oafo19fkGKJlQ/wATdK73R/CVrBhmjaST1bmuw0/TEVlDIob2FQ6ltjaNBvWR51pngxAyNdF5WBBxjAFdtpugQ25xboAp/wBnmusiswvBXGO2OtWYrNVAcZDY7Vm5N7myhFdDCFikUYUBSR1B7UqKvQE/7pGK1ZLZiWbG4DqRTYbR5mRY4iZCeQw/I5p2ubRSSM9LNiQQPnPYjtXSaNpW/Y4RvLHDN6/SrVjZMLR8x53HO/GSo6cVtw3KW9pDbxH5ojud15AHt71cYLqZVartaJItqIrbOVEoOfmPX0A+lZ9y4MByoAHIGcGkn1aKGSRbpGC5yi/3ff61hahqiyFkijLuGyrZxx7iqlOK2M4U5N6mj5+YlUscLwPcGsye4jD4kcqOQCOxqtBcvzGWPBJyT0/CnzyQmJhJGhY/dPoag25bMbPMjhNowoHr1piI0iDy1LMMkgc4qpc4Qqd3yHggVt2txBY6eWeWPGN27cBUynylTfKtDEupkG7cWB7cVyl87G6HlOVd/U9cVb8R+LrK1SYlV+bO0jqa8t13xDNqUpEDPDE2CRjBJo1mhusqa13LXi7WJnmeyTcmOXOeufSuYAPFPO52LOxYnqTyTTwox0zWqXLocEpOb5mNWPuOlSRocZPanxoCAcc9qsImcccHipbBIYiEHJ6VKq45yKeqkHPpxQFBz2NQ3cqwgGe9I+acSQCOlIynPPekMbtOKXkntQOeBS4PQdqAG57kcil2/wAWcZpMAE8Hnk04svTpQKwxlHX86YMjPoO9SY+X0btTelC0ENx1NNp+Mf4UhGeQMGquA2kPWnMKTFMAxleaQdac33QO1MGKAEbrRz3o68+vFBX35pgNIOeKQjge9PcDmmkjsMfSgTI8Z4xil6HFKRk8CkPXB60xDSBRTu1FMCKl6kZpBSrSAdt60oHakA6H9KdQNBTh2HpSAcU4YPTtSHYXtxzQpHUdTxSrx0p2MFDgYFAAvANLgk+1NAzk04DjFIA7009eKCcGo2fBp2JbHkj1qIkk00k7jkimMxppCFYn3IqMsKcxBHyk1C3AOaslseQdobPynihEd5PLRWMh6KOc1YsLKe9kVYlIUdWI4/Cu20HQVtyH2Dcw6tnJpSkolQpuexR8M+FTNKst8uT2TPSvRtJ0oW7OZWV9x+VQMBfal0uwKIM4zjsK2reyMkmHBAPQisZO52xpxiJDEv8ACgGO1akEKbCwwSPWiGyZQMAsB0zVuzieN8NH8vTJosU32CONgg2ZZmPIxyBV+2iBJTqR/COcn0qRLb7V89sSFHy7uxPvWrZ2bRT+WsMYkRcswJIBPSrULmMpowpdPYSSADaq/NIc8AVa0WOJZGe5GxVX5U/vZrbuLdLRHt5MGQ/dl6gdyxrnb+7kaWYxyqp6jAGGx3A9aqyQoSdRWNnVvLtNOgMa7Wk6KMgnPUkegrCS4ExSK2Rn2nLYXl2/wqit3fOGEkp8xgpZ2b7o/pUSyLufy2GwDYMMcse5pSk2aQpcq1J9VmIw0iAuowcdqy4pM7iDudskUai5iTd5oOeCoPJzWUt4YemCOwFYuV3qjpjDQty3AgmAm5YjggcfjTBeJISAAdvesLxFrtlYRB7lwG6qM8/lXnmseMrq6DR2aGGI5AY9atrm2InOEPiZ6F4h8QWFgp+0XI8zsick15zq/iu4vCUto/JTsWO41z0jNM5d2LMepPWlRPar5V1OSVeT0WgSvJPJvmdnbqSaQJg1KsZ3DvUixcDFGxle71I0QHvxUyRnOVNTQwgMAPyqULj5SOc9alsdiFE2np0qZB8px3p+ApxwTRgD5s5PpUDI9pUHHQ0jLg8dRTwMcN0PanYyATwBxQMZ26fWkzjOBTwOuBTeCeBzSAaByD2oIyDjj3qQRsVwMYNNwcYzxQAwcjqaQjhvTNOYdPagLlSe4phcazDHzcgU0egH4VL8oJJGRTWPy7lPAoJGe/TNNAJyp4anHqW9aX+JSOvvQBGfujjnNJ7+lSNnPTk8UwoAMHg9PrV3AaTkYpMcdKUgr16+1Kw6kEnPQUANxSY5zSv97ilwcnimAwjNNC5NS4OPx5+lDAA44zQSyIYB4pvGTz9KkHoOlR8H8KAGjr6CilPByOKKYES06mp156U8e9AC0oxnnpSLgnFO6UhoAMnHanDAHGKAD2oUcHigYo4NOPzCmjtT8gfhSEwAxyaNx70yRsnrTGcHjPOKYrjnbduBHTvULHHXinRfvGEfAJ6fWo2bgKfvd81SRLY1nz0pvJPJGKQtg8gVPbRPdFo1jDb/AOMjhcfSrJZWbKtjnOccVraVo092yu6kRf3W43VsaP4fU7JXQtI3XPT6119nZ4CApgY6elZyn2N6eHb1ZW0ewWMKAmSP4SO3sa6azgXaoCHI65ptvCFCb+p6Ej73+Fa1uihcdKyvc7FBR2H2kbJzGe/Q1rWrOn+sTg96hs7f96p3Ar/WuntYI5ABhQMfeppGdSaiypbZL8EAe9benaal6SswEaqMgHuas6fZWrqoeI4b8Bn61rR6aLVjLCWwP4JBn9a1jDqzkqVlsjLuNKnsYWazkKcZdQQePaq0DT2lkS8eWb5i27D5PrWtc6oir5ciCM5wEfke5zWLd35nfEZIhYYQkDce35VpZBDmkrSRQ1PXJby3cLGwkVgAMYG0dcmslpyq/bJ8NJuPlxrzk+p/2adqyPafN5qu0ibSuePpST3dlHarCmZZtwLgjGeMAAVjJ23OuKSXuopicAvczorzN9xG+7uPc/4VnTySGcMqjcTjavT6Vr6j9nhtEtV+e6b55So+WMn+Ee4rIkJhjxkAbTkk8D3qWzaL0uylfzfvf3qkDBGQQRXn3ifx1aWhkttNQzXC8bj9xT/WqHj7xVe3QltdNhkjswSjz9S/sPQV5sc8k9KqnS5tWc2IxfJ7kDUuL2e8naa5lMkrdWP9Kch3cflWbGTuq5ASOa2ascSlcvRKuBzVhI81Vh4YcZFXEfB5OPSspbmqHpCeozipQuTgjApEkwMHrTzIM9Mr65qGmVdDo15woyfftT9pBwOv86i8xTuHOT1xUishGRyaVikPVOM4/GkYFcFV4HWlPTk/N1yO9CnJ5bn0pNWAbgM24Dj1oCAAt78g0uV3bQ2CORSKd38WSOoIp8orjSq84PXkUnAHTB96d8pBxkHsKG5xgDn1oasFxqnI5PTilx6cfhQpGQrDgj1pjOMDBx6A0rBcTr2Oe1Ickknp6CkaTJIX0pFmXJzwPX3p2YhMYx165x3pzqv3hjb0yKj83I+9hu9NEwHJ6DjFFguiUp0U/UUxs5OByOCKN6hMMcY5XFIG3YIOCOtFguhedvzZyKQ8g5HPam79wyDgnrS+YMgDp3FNJoLoTp160mPmHJINI0vJ6fSmGUbDzjHWnqF0SBCO1HTk8k8cVGZMZJ69aUyDOFNMTZKQc49OvvTDjpjryDSCTLc/n7UpIAIHrQIjxg96Y/K8dvSpc5GQeDSMPl4wP60ARsvzZPUjiinHBUk5+WigCuuMU/3/AApiDinUwQ7bz1owQetIvX3qQEHPHSkUKOlIQc8UueSMdKcFIHNAmJgKM96RzgZ9OlDHsKjkYZ5AoRI1m5xnIPeoy3P1odvSomPOc1dhXHMeeuOeTSzfO29WLMfvbRzSwW8l1gRAE5xn0+tdJpOipAollBaRhhc/4U20hRi5szNP0yW4VZHAjjz0IwxFdZpOkrkmLYnOAv8AE1WYrSOOHMmQB0Xua1tPs02by2yVBlPU59DWLm3odtOgo6li1sBE6gr0HIrXt7MMy54FMsov3aFkYbFwAx6n1rasYA6Akr6kelJGr0Q2G2U4V8H1PrTfI8qQJyY2PX0FaKRbQWAJXoMUtvbs8mJRgA8CqUbijK2ty9puwlBtY7TwMYzXSJG6Q/uY/NduSwGdo7D0qhb6adkcbnaQv8PbP9a1I7q60YpbuwlhfGJI+o9B6GtVE5KkuZ+6bcUJjtISerAbonGR/wDWqrc3s8FqwcERKM7s9PbmlvtQ2Ro8U6l3HMZI3DAyTXNajdyXKhzn5sHJ9PpVystDCnDmd2M1W9Fyd5BVx79PpWL9okhkEnJwPut/SpLhp9zbdpC9cHrVWKVzIMqny/MA5yB71lJnowjZD3kSOeOfURkbSyJ1+bqN1VBMsUjXiHdIF+UejGrEts9zcNI0u+V2yXxgH0qW9sbVbJURv32eTnqayRd4qxhpNI7Nv5cjLHPOfrVDXpYm8rT1lLXDLulGfuj0q/MTaRZXAY5RAB1PrWX/AGKbmV5ZmP2sYKuD1PrSjpqyZy1Io/DduYsTIrR47Vjax4K065LGO3EakDGFrr7G8Meba/HlS42q5HDf/XrT+xgxfI3mrjjPatr3Whi0n8R43deBIUYKFcE8hk6D8Ky7nwhcxMxtnLr6Ec17dPAAiGNeT3HrVOe0WF0OAu4/XBpKTW4vYxfQ8MbTL2FgphP4c1ABIMgxPn3Fe36pp0RiEpjTORyB1qk+iRmPcYhzzytHOL2HZnjpkOQG4+tKJ9xHK8dBXpdz4dhlk3JBGdv3uKifwtA0Zbykx16dKXOhOg+552kwYnk56Yp8c5AyDz0xXfT+GrZ4fniUYHYcis258KK6bopGUfSlzIXspnLLcL8x3H6dxStKeGJ2nt71uHwsVY5kPI+9USeGiz/NKS396ndB7KfYyPObBP8ACe/pTUmy+FySPTvW6fCzAc3DEd80ieFpYgdlw6g8kgUe6L2U+xjzz7SueM9/SofNPfnBrf8A+EWklYb5Dk46cVPD4QUKTJJIVHcUe6w9lPscuZxn+XtTWuC/IBLDqBXoVn4UsTH/AKoO4/iJ5q2vhy3S5DLEgUegqXNRH7KXU8zj82YjykkPsqnmnG3u5B8lvKecdMV7DBo8e8FECgDjA71YGlqByKn2vkP2L6s8YGmajgE20mQfSmSWN8SD9mlB6HjrXtX9mA5wuc1EulpjlOc9hU+2fYfsfM8WeOeH70Mikdipqu0rb+jZznGK9sm0lCcFQwPtVOXQIGyRDHjv8oqlWXYn2L7nj/mkuSvBHNOEwzk5Ga9YHhy2Y/6mP/vkVDN4ethx5CY+gqvbLsHsJdzyhpgSCetBk6k9DXpg8O2jZJgTP0pP+EXtHB/cJ+NP2sewvYS7nmgl56jGKXzM16JJ4VtCf9Qpx6VRm8H27ElNyfQ0/ax7C9jM4oOSvFOWUk5HeugufCM6bjBN/wB9LWReaRf2pJMW9PVapSi9iHGS3IVfbxnNO8zdkd88VTDlWxn5vQ04PgA9wabQky8D8zDuBRUKvkg9Ce9FTZlDV9u1O69ajX1p9ADhilBx1puOKd95c96QEjE9eppCxxTS/wApz1qLeOlO1xNjnPFROylmHems3PGajZhjDAHFUokuQpJ6cAVZsLGS+nUAFYycZo06zkuWBAKoec4613GnaeI7dBsCqo4A7fWiUuUulTc3rsRaTpkayIsMQaNByPU1vGy23KupUoBlQB0qWxtxEifwluM+taq25kkQsAuPSsm9TujBR2KMFqWlyy7gMfTNa0FuVQep9P6Vbhs9sYGPlI9O9SRRgOAAcZpl8xNFHz932OamiBR2GCVU/MQOlXIECReYy5J+UZ5Aqxo9gs10FcAoBllJ6gc1Vn0I5kk2XrNBJND5mBCDnGMZArQtLJ7mRZYwpaVz5ceOf/1UG13ShlAx3YcBCe2PwrT0K2nDyXH3Y1BClhyPXFaRi7nJOel0XtLtny8AmjDqDgbenufWrlxbqCUnVRCwzwemB1+tKlsXeKaKWKURjPy8E/UVj6zfTXkiWcZWNpWZjj+FQMn862vZHNFOctCvq9uGDNBJujH3QwycdzXO3ctxbNGG8tkK++cVt3VwrWolZQSwwAMgKOn61h6jtZo4kIYg5PHUY5x7Vz1HbVHbSXRlOQylsYUccetOWOVFZWRGZgCTjPH9KezKrxhTudgSxPQc8VoWYZyT5abZvlBOeKi6Zs5tIzYopNvVVLHkUTQHceAVxz9amLbpSu5Sc46cU5UI+aQ7U9SOtQ2tkTe5iT258xbiU5wcKPQetTMd1tlV/eFsZB7e1Takd67Y1wzfKB6mp7eFFVY5tykIRketKL1sO2l2Z9/Al/YuvlgSrySTzkVU0u5dJBFfSMoGAkuMgj3rVkRmeeYD5xgkeo7ms+4RlQMqnaG4bGQK0trcpJNWNF0aOTDkFW+ZHXo49RUNxabmSReq8/MKaHWW3Uq4TdhjH2B9R6D2qzmXYyH5ghCkZ7USJV1qYVxFMdkagEBslT/Sr04kKqsac4rRWGOS5V2VgVyTk9KW72wsJckxjjOMYFSomnN0sc1e2/lQnb94j5iKr6dNvjZSuSDg5rZuxHIzHB46DNZdtBHFc5JJRs5570mjaKvHUqzEZIYA7iRT7SMrEzIMN0+boa2JLaEsoKhznII425ont1VQBu64AHB4pcrTI5laxzVxbZjDt0LYOKfdWHlsPKDEN0Oa3JrUPZuWGFxkZ9amlsvMtI3jIJQBht/KmoMObUwBaszKD09+cVs2VvAibDF5rY3cdKf9mkUw5+UFsbvf0NacaxmQFovmTqEOP/11SSRM9dDGnsY5V2LEBzk44IqJNLUqyhnz1rcSM4zDbspdzhsg/pTjEzsIwe+Ccc0xXsZUGmqgDBjvHFSWlsrF92Mj361qmNEjxGecZINP02zXyGlcjHIXis5K+hDfVmbDbDzZNuQetWEtgyjIbGKtyxrGpOBluSAamtAkkfC571FhN2VzNS2wx9vWovsoMi4J2rzW9HErAnvUDRAT4wGB6GhoSdzMktAcYU59agktQAccZ61qmMtnBwuaiki6eoqWNGQYCq5IAqvLbbiMc8jJrbaNdwHODUEiKDjNCRZhxW43sMdDirDWQIGARVxUHnufQ1f2qycAVVhS0MJbMAkgDHvSvZBiCFH0rVkTaFFQv8zD0p2DUwbmyxuwO3asySyQ53Dk9j3rsZoVdR2H0rNmtF3EqOnShqwJJo4LWvDcF0jBYgJDyHXgiuG1XSrnTnxKpaP++P617XLbkg5AOR2rI1bTUnhZXQFWG0gjrVRqOJjUop7Hj6EjGOTRVvVbFtOv2iI4PKn29KK6U77HJtoysGHTNO3cCqhkwfwpwdhyQcetTYOYtF8dKbvxnB61XLHAIzycYpBIwYYGeePehIXMTl+Dj8RUTMcDBxShXJ3KhU9Cc8fjT7exurxgsEW4Zxnt+dO1hXb2IGkIU+tTWdu9zJwpKjqSOBXRWPhJ1Eb3suR3UdK07S0iWTbEvyJwo/rSc0aQouT1LPh+x+yLE4VSQykf1rcmytwYk5BPGOwqK2Ta6KM444reFtFn5ASE+6B29awerO+EeUitLcSMu8/MvcVtRLtAOOvciqtuqKhB/Emr8HzLtH3QM81SWpUtS4rbgoP4HtQqI03GQPWlt3VkITj61bs0jjMZc53AtjrV2M9iTyGaCJArBSSWOK07eNoWxHsJGMnuKSwikmliH33wTy2AK1La3YXjXryhGH8Hr/TFaRizCUraMuIkdu4ibDLtA3g559alacxxoq/wksGJIB9uO9Z162y4LJIAcEocdx2PtWLNql3FJuSQ5T7q9Rg0Sly7kRpOZ1x1UtL5NpEiM4G55BwB68Vz17LNNqV9Okwjjgj274xlQSemaqm4lmCSyz5kbGVVdox3FMuZpFsWtkyPMcFsdD6U3K+5pCnyOxJNNLcQhWYFI1DP9TwKpu5EJ2BQJRt9yP6VSSRpJpEUkJuAx9O9WIoxiWYuWiQ7VB43Gs2+ZHS48oSMdpUkDI9KdG12NPOWLIDldvYVAzGW4REzljt9s1avIjDHiOQNGgzz/FU2E+iHWED3V4kIBIUh5MelXL1y7EAHHIAPTFZumyzJEjk7TMTlc/eAqzf3kYtg8QbIHI9KI2ijOUW5Iq26iS9BcELEAWB9T0rX0eBZb2eOXDAwk564rDtneRkjACFgXZjyePWmxal5bySDlQhHvzxU3SZcoOWiLocC6VApYlHxn9M/lVGOITlU3fu2U7sHoe2RUM1y0kbYyCeQT1os5CbkIG2hxg/T1q73LUbIvC1UxCBOSrcMOnvUNuywX5t3bCtwxHP0p6uVnREdRsJyfpSXlvCb2B4C2443ZHeghLWzL1tEqySmWRlkwDleePcVWuSJFke4iJQEBYgenufetC2tnYbogGkycHOVx3GTUAspbpXa3XBA3D5+cA8jHehhBq+rMue2aSIFWCjGMVkJHmQ5Pyqc4rokJt43xwzAkZXk1kSErMygDByaVup0QbdywsWwEkkowGSB0pzRFgWy3yeoxihSTGEPXsf6GmzsWfbuBHTI6j2oJa1JJF/d8suJBg+gp0P7uEKzpvVcZzxiprBj5px8r4I6AikjXdEwwp52kHj6GmjJvoLP80sEpGxThsn+L3xWiLVpLaS5Ug5PAx1x1przAR20ka8pGFcFe+arQ3vlyDD4OaltC1a0IjE/nJJuUHOMMuDVqJhv/e4YHqVHpTHdXcea4xnIxUzzxggRNjPtgUuYG29CvIsaptLMFBzmk0w/6NK3JTdnFSzKrgK8maqxfunmVd3lt1Ydqm4t0TECQvsAxt5BpLAsi7cfLzk560yGRRv2nPqTU0ahl3DaPYUim9LEvnHdwOQOnrTghkwScD2qNRgHaM0om2qR6CpZHoLs2rgAepqN9rBSOtPMnyk96buCtnvSAryDDAYJ+lRsv7wDH/1qsyyZbPRvaoi64yOc9aaZVyq0W1mOO9SDOSQOvSo1kQOxbualZwSO3oKoaGSKeMnK+lVmHJ9KsTSbCw9emKijn65UH3xTGPRAYyWYDHY96qzLh/mNWTcFgAdoIHy8VBKA+N2eO470PVCRSZR5mMDj171TvYMoflxg5rVXMZQ7cd89c1XvJA6yA/NkHGKiwpPseUePrbEccu0Aq+OPQ0VP8QJQYFjz95s8e1FdNF+6cNa3NoecQsWUEqGycAHvVuBwY9xSN2J2qOmK2tO8NyzsMkrt4PbGa6nS/DEEDYMXmMvIG3hvenKouhCpt7nC28Nwy7oo2OTj7tbFpod5eMpeGKJWwNwXB9816Ja6GVgIjgBPY8cVHATZ+YXidY14ZQN2M+vpWTqGqpoxLHwlbKVE6+cQQAv8Iro7XTLazURiPaAcgDgYpVuQrqY2BB+9gZx7CkvrmWVUKrgAHBzUc1zaNOxTvf3rLtACqCeKz7O3IhLADPrV11bKgdccioxxP5fRBgcU7nRShZlmCEjaT0xzWzaTrswPpioLaMLHn7y9KuxwAsVZMZ7jrmhKzNG11LdnGrSqzqSn3Rt65q2Y/KcqMkcc4qvBEUVQr8itACRI2L7hznkflV67md7E0UCMoZcqCM8d6sIuXjBbBUfL9az7O6zuijU4HXPXNallEk94qPJ5anBJP17U4yT2IatualijTSICGbzcAFe+OxFWLy7UK0MSkIMBt4wc+n0rOZil35MceCHOG3YK++aa+HUfOZGJ+YnOSatSMeS+ol3LtbZCWZSNxHTFZvzu+TncCPYtVqZfnUSRuGU4Geo+tSQqisdyB8HpnnJ/wqJJyZunyoW2nMaFT8uScADmmXMjFyewGc+9PnmMTiPOwv0xyT9aqvhWVQ33jlgewFSpdEEe5CIDDGNp+djuOaNT81IY4rdt8a9wc5J6mrYLFlZmPGf/ANVGxVGWHbIB70S1Vi+dLcoW3m4G/LNgn6VfuoYotNUup81xxk8iks4WkeRkBLKO1Z91JI135LgqxYbQzcChaKwn70tDUMsQhiaOQxvHGV2lRk57rWOxdVAkwUJwD6Zq1aQLLO6yocqh24Oce9RQqrZZi2FPU+1OW1y46MZcSlYpY4yCsgGWxy2O1UZGP2d9xwMAsen4VfaJcbh3Pbt71n6hGzRsseQTzWTXU0i1cSwu1YhSMbxtAA6D2rQijZmTYu5C2wE8Vjaep+RiD8owfUfhXTwqHCyLGFCr90HOeMZ+tVC9ialosbb2jbgI8tMxwpqzaW00t1ttwxkUkfKASR0/nV6wi8qKVncCdF+Q4+6SOnsat6DaxJEsknmhD0CjLPj27DNaR1aOac7JsrB18hraQNtQ591Y/wBKcshhjbZKGL5TaEzjI5wO2Ku63CskkUbW5jmBCuqfdGehz2NYqo9tdGUloXjchQ3OT61Un1FBqSI5LSRId8iO3XEh7/8A16zwBBIxZBIPfityVy1lEqOzDO7yx6k8kVk3KbWIKk4GeTx7596UvdRtBt6MpxhkeVGO1sAjuKhkk3Hymwr5yCKtGP5QycnuMZ5qGS3USlyAxxnPofSs0mzW6NW1mihstzJl1PLHqfSqczhy04XCnIY+hHamrOHtzAYAdv3mFUHu9sBiDcZPyepPeiUkkYqOpqfbCLZPNyQMHjmq8rRqUfcCW5PPSvK/EXjuSG6ktrAq4QlGY/dz7VjL4w1RgD5ygdhtzSUZPUh1YR6nss06/K6ngH1p7X0YZGLqMe+a8Pm1vUpXLG8kXPYcCof7S1A4P2mUc4I3VSpyZLxET3d9UiY8OnA9MZpk2oI+fLceWe2eDXhY1PUlzi4k+hPSpI/EOrxMAs+49gVyDSdNi9vFdD2xL0kEE9e4q/BfRpGFbk4rwkeMNYiOC64P+zUh8d6sBjZER6il7KQnXgz3KTUEKEfd96rvqMSZbeARzXhsvjLWZPusq/RSaqPrfiC8YgTXBB7ImKPZPqxOsuiPeZdbijHLDB7mq7+I7YMd0i9PWvCHtNduD+8S+Y++cVXutO1K3kZZobpWHB4Jp+xXcn2r/lPd38SW3eVM/WoT4ggII3rj614I8U68uJgPfPFM3TKp/eOP+BGj2HmJYm28T6Bh1iFlA3g/0qwmoROuRID+NfO0d7dxZ2XMqjpw/ercevatABsuXOP73NDoPuUsXHqj6CF4hHDDPuaQ3MYbO7HFeEReL9XjXc0sbexFWk8famigSRo4/EUexmP6zDue4C7jUfeBJ6YpjXgQfORtHYV43F8QroD57UZPTD4pZviFcyZP2bLHuXzT9nMft49z12XUI2XI656msLVtWiiRi0yqRzycZryufxdqlx8kJRCSANo5JPSna9Zx2evQWGsavJMFC/bpY4y32djyVUfxYBFUqUupnPExt7o7xTftd3wRkkQp82HBXk+gPbHeioPE1pd2esyQ3l2byQRxtHc5J8yIqChGeg2447UVty20Obmb1PVINLVJjNEN6qR8rd/bFbLXKJtVVA3AbVxj8/pVkGISoVjjcHB456UsUMYlV9gXnv8Aw+5rjudWhNE52xhSFB6gDOKp31lHNuK4Rm5Y/wB72x/WtoqsZG4Keg7YplyhePhV5+6R0NMSOXltyjKYsFiMZXnPPGfwqtPAY5S8+CynkKeK3JrdFcNt56jH8NUtSiVTzlmK5JPrQdUOxm3AWUqVBz6Co7K3jV9jtlhnGamiOG3eg6UyZHtmMo6t7dKa7nRGOvKW4rgwzAhVKAjII9Kuy3qG4/doQp54NYolBfbk/Nya1LCESTAOoKgZNK8hygo6m1DksNq/Mp6VqvP9oGxl8sr1HXNUbKJh8uASeoB6VbDoX2Pjd/erbc5Grse0aTushG08BtnFaFtbBmjO3HGBv6Nz2rPgwGbnI7EVqfbZFt1xtMJO5doxn1x7042TIld6A6vHvEg45BXHQjoaWNNxYDoOcUX08r2alHnmKnPzqNo9/WqKXMkj73+UMcZPHPpSbswUW0Tyx4O4bt3Xduzg1FFKsRKuSXJySRximvcbmwdyjtkcE+1MnDN94AHuBSuaJdySWRJI5HO0EcD1NVi+1XZ8hjwBnp71n6rd/Z1VEUux4yOMVl/bXdxuRi5PygtwPc1k5crNo0m1c6RG2rkthepzUf2kuATznAAHrWdbyvNDknkHt0q/YwrtWVyyhW4A5yau90S1ym3p1y1hbpHt3yyk/KSBxVCa1RoJL28IALbjHjrjt9KjvCk8io2/cgO49KWNo5US3vQTEDkHd+lDfYxtb3kRSTIU8y0Hll0+bBqkQzxBBxgn7vrVu4SMSulsAEJ4GapXB+yyNHMcMDwB3zR01N426FmRwkYLb1KnIIA5+tZ17cGcL5RYKTgkDpVqTJhwNobirenWSSkbxKoORiOMseO5pKLbBSUdShFbMzokY3yNweOfxrqtLtIpbiMbwAiAyMOgPt7VR0DTxcSzN5pVWYhC56/5xWrb2TG5aKEb8vtV2OA2O/0zVpaaGVapdk8NvHPPIkSvIN+S/Ynv+Na1xciSaBIo/KkhUrl++O3FWLHTTDIkQeQSHc7Z6DHcUkYW10wyrKSZclY2AO9s4rSMTilNN9zNhhC+a5DSSSDBEj/cyOp9aymPnWwub7cCFMakdWPY4rVvUmeWNYYEjDuQ5VueOppmrRGD5pGLgDy2JXBJ9Vp2VjeLs7GRdIBb26bf3m0AM3HHaq8lnH9nnX78iEsuevGBj6VpSoxt3e5QgRIqhgeevyn3OKo37gSvKnVAM5P3Qex/rWbRrFlKOHy+WI5GeP8APaoI4jJlUAaQ/wCeafcXaC5b5GSPIAB53ZHOPao4X8iVWAYRjhznk1F7I1aa1GRpJBM6MvbLAdK4fx5bXdwjR2MwimlYAMvHHeu9uVcgBdwPVjnmsLVNPWSTc7t5qAMo6g+xrNi33PH4/A2p+YFLIck4xnJq9b+ELiNfncA/Q16YEdRggKRzkdqQQoUWT52duxHAq/ayexnHCwW5wcXhJwcNJuB9B0q5B4LyQGlYg9eeldykEkcYbA5744qeCMFegOTyTUOpIr2MOiORh8CWrYLyM2OvJ5q0ngbS/wCJScdt1dPIhGAGIHfFIzEoFAVtp6kc0c0iPZLsYSeD9IT/AJYofqc1Kvh3S4eltD/3yK3CECZPXsBUMkRMbdPxFJtsagkYw06087bDBFgdcIOKm8mOMhUiVQOoA61MgKqAv3s84q59lHlFjnd2NCjc1skZUhG7btOfc9KgmDBgShIPABNaSQHZucc9zSPAJHjCjJXnpmnyl2SMsaeZsq6RjvjbmoTpUcjYMSMAMABB/hXTm2ZImJjKkevFJbqDER8qjoadmlczepx1x4VsJgS9pEGPXC4yapN4J04ow8g7m7hjxXffZ3mDKgKlQTk9AKX7KVhHGTjqO9SnLuZOMX0PMp/Atij/APLUMegD1B/wgdqM5eY5/wBrpXpC25llYnoOOakFsgIIWnzy7idKD6HlsvgKAH5Z5l+uKqT+Ayo+S6IJ9VzXrbwgk5WoHtxnJXg1SqSXUn2EOx49N4Mv4zmOSNsYwehz612UvhjUNTKX2reC57q9dVLyW16IknwMbmQ8gnHOOtdd9kAYEgcEHmtjV9Pgv757hdWtgZMHazt8px0HtVxqvqZToRVrHhPim01l9euJdV0421yFULAgykcYX5VHsABRXq2oaZHHctGsqTKAPnTlT7c0Ue1Y1h/Mt2aRNMFfcN3ATGMe+a2ZLaF12Mqnj6GqtxBAyukakDqW9KsWPzAEndjvWQrEdtBiRVblR0J5q9eBVi2r/HgGnkAsDtximXMgKgEDKAke9McdzHcjDkMc9sjr7VUvlMgVQcH2q6iliQeoG6oruJjbo6Y4yufWkjri7Mx44Nrk8jcemO9XjBHPG6lthAyAe5poyoZwKVAeo5x+tUambNYOZd0OFb09am064Md1slUgr3NbNmiMMnr6VaFrC4Zmwc+1UldaDdXS0h9rMsi7h+FNdcOeaqrbyxO3lthB61II5lbDcjuQc1SZHKk7ouRjao56nkCtCKL5ECT7twJ2Dn8eaoRwBkHQk8A5xitCOeSBVj8iO4fbjLA5X3pPR6kS12LMbFFKeXlwO39ahuIRn5VwpPr1NOt2KrICu0OOQGxj6VFyWO2Q8dBjoPrVGfUQKyLs6g9ietQ3SuFOw/MfbpVx5mVQHXI9artcJuC98Y56UhqTuYU1uZJg0h3kZxnpV6PRvMtlmdhuIyMdAKkmcg/LjjtiluNReO22BACAFrNW1NOebVkZIkKSLHGAMcfWpxqDwOuxdqeh7mooRljMCQTxnHStSKwge38x2wyH8KVn0LlJL4iOKZZOWDAjqSe9LIwIJFMZCH2s+1ByCvVhSpaeYG4kZT2B4HrmtE7kWRGssbsscDFmbqoHT3rQt9ClumimnJEso/dof4gP4vYVNFptxDaARQHER2yMGHz+gx7VckuJbPyoGRorkxrknOCOvT0pWt8QpS6RJVsLS3iAnYGbeBsAz07sat3FyGtcxI0UbjavO3Hqao3ap5vzje65w+eCT3FRWsMszebO7M4TK+YePUACtEzO3Vmhp0bRuws4QS7koufkxjBxn+datgVt7hy0sSSrHtjjYbgcdf1pbZ/sdpJNNGHdh6jA9qisY447/eMTARlwfvd+nFXZIwk+a50dld+ZBtjO6WQ5I6fX/wDVWHeuTIkUqqbeIkcDgNnI+lOluzLcNJAY4QQDtxj6mkj+zO8kt/JgSEHEfQD3H9ap2ehjCHJqJp8UTxW806Euxywzgn0p99ZtqDO8kgSOM4x973P04qW+ubeKHy9ODTE4+fGT7c1AkV3boI7xiys2SF5Yepb/AAp+RUZNPm2MmWIAF958uQ4hRhzj+9UFxG6TEIoYSfKO26tnVXM1vGkLK4XG8njGT0xWfqTRxRjc2ZC+QhU5x3/+tUSsjeE2zGuIkku0Q7YmVizb24U/57VnTu25lUNtJ6kDJPrWtOim4VdqbWYcg8Edf8mqU6o0rs8mVLEgDsazduh0RYyEMzqrEFpB0HoKp7DJqDblOxRjHqe1XzGvnLtAIxkNnIH0pbdAJU2qrOxJKtyGFRyhczL+1Z9qxj5pOM037M4uVjYACMcsp61ueQ11P5k3cHG3vgfpU+l28clwpuVSOMZU88sQPT+tLlWwvaWRjmIyou8/KowAfSnNp8oR3EMnlL1IHFbd5DGpjQvthVQ4A7nPrU6W7T2bySvIVBYBDJwD2wO9Cp23J9pZXRjPpzC3DpBJEMZ3Oc5pItD1OUfuYiemRwNxP8q2ZYIorMASOZMjfwQQfb2qNWtvPmi3XqK6BlJJxu/wqowTF7R9DKfRJYrtorqNjOnB2ngZ6VFf2skVuVLqMjhsZPoceldJGwkQpAuGChhI78j1OTWbqiJA5BYOJEV1ccZ3c81NRKIlNt2ZkT2CixRwHJ3LnA+U/U+tWotNeQMjlY41XJ3dfbA705iTbrCknmxvKNpPCn1GPY96RnmS5kdFAMI4/iAXpjNVoitTJEWYFkyQCdvPPNIHCHbvLMO4FWIl3Wsmc8kFeelVWSTyyQuNw2ccZx60G8ddx4LSykNk8YJNSIiDgqu1B37VFACEBxjv15q/NAYZZhLjIC7l+opkS7D4UITjB38dakMYDKCCc+9TWqLGgCFShxww+YmpguxyR/CtS0jHqYKxZLcAc9qUwthivOBVi3AzjbnPWppFCLkAZ9ay5TS5RaIAjPeo2RSOABg9qsMrOfeoXTgjGKZQ60mNozD7PDNv/wCei5x9KmGoZOf7NseOuY8VFGmQcqcAdc96sx27smHPQcbqpeRMorqZ9zi4naR4I41OBtjGAMelFa9zZQog8uUyY6jZj8qKOVk3XQy/JMoZULZJwT2FaljaiOIhE74q3DbeWnKZHYirCqij/ax+FCRySkUHj2cdajnh3Io2gnpWt5A27mB3YzVd0yFJG0DPWiw4s5y5hdGVgmPkLY/p+VV0JkicNwA2fqK2rxd0art37VO/HfI4rKdW2FQPlAzn0ptHXB3RUdFz3K9gO9M8okbSdnP5U+RWIGw81YCkpwSBjoaEa7Iihtyh5Y/UUASxzlXc+WSME1OmeeCQeORV1YPNQb+ccD1px7E83cnSJJITtKq596c1sfIBHEoOePWovIMIEkDHjruqVpZgxXa24DkelVZme+w62i+8JEBNW2KvCgdRu/vDqfTNRhmKLtK78ZO0cj3rRtbbzo2eVSuB97ouff3p2Jk+pnzfJHguB3rMWcRygP8AePANaNyYwNm0bs/ez0qjL5ZblQVHPTkUjSGxOxZ+TnHaoZeEJI78D+tVJLuSMjagcEZGe1Qvej5Rtdm53Z4xSZXIyWUkqGyBjrzVS7uY9nr+NILe7u2Ii3KgODxxz0q3FoCC4xLITx6jg+lSrmq5Y7spi4ilUeSmFUYJ56+9TSpNJGFMm2NOWyelbOmaNbQf8fKFFONqqclm7HB7VrXehArbK+C0m1hF90bvUn0qlF2M5VoqWhk6Vp9vPLb2yszyPgZckL69K3L7SbiFrVILsR4yzKigA8+nXFXJbdzJG5WFfs6YjCHaDxz7mr2nzyTsrWaRCU5UmTnaO/HpWsY3Vmck6jfvIwEkEakmSRpRIDHu+7jPPFLcR/a/PupNolY7DgYwO30FWL+zt9Ou0edJZEJLOdvU+oH9KzVuA8zhWBt5PmIAz9KXkyo6rmiXo4yroto6zOB/d4UfxHn8a3NJ0uNYBM2WUHao7kevtWXIs1vCxhiDQuoXLD5mX0HpW/b6jELdFlfZIByvXHt61rGy3MarlbQlu7RpxICVNvjAXp+NYxuYLKe7DSeTIzZWQAdvcVdfVozbhSZBu5kYL938PeqENu99e5WFEtz82WG0ZHf3NTLyJgml72xatLmEyNftH5hI2ojg43E88j2p+oWRvL6NrFQMqVdgfkB+tS3N9DGsUFsqIiv+8Yr8uPb60yz1Gd54xZokds2cs/cLznHrRbuL3r88UW7S1tLfT8BiCWwxBAbdnFPGqwxzFQ8YT+IHnBxWJc3kNpPJdlSGd/ly3X8OneqFtqJSPz4iGm+bzUcAcf7PrxRzWGqLlqzT1G1tobkGNGYrF5jMG4JboK5nVfMEKyfPJlup5Kj0x6VpRXdxehwysInwzSycEjsMCsRnmSV/tMUizA4Vj91uf0rKbWzOmjBx0fQXTbWW7eJllCAcvGflYfn1qvqVqou52B5LYYMec9cirSXDW27cuW9untmoGIkuV8w9eoIzn0qVa1jbXmuSW1s6Q+aqEiQZVc8gVPa2jG6aUxqCijaN3GfT34qzaXnkRyYCtJgpHlex4/Cs4XJ5GclW3dPmFWmoohts195NiXURBtgGAOVyarR20eHklZw46Ajg/Q1S1LVEhhIQKsjjkqOAKz08UIkSo8wKDOQ9RNpkqErG/dFFtVQDK8AErnnuatQ3Gy0AYR4VSm1kII9wfWuJl8TRFAvnqVThV9KkHiWBk+WZR3Khs8+tRzW0HyaHafaIGb97hsryQeh9aqm7BnXAfYuSDtLH2Nc0utpICyyLkc/eFJJ4hmygW4cIODhuv1xVc3UOTsddeSxHfcSyXUqgAkrBtAIGOc1j3d0J4NyoQqghfX6msg6sZcEznHXBc4pP7SPlFIVLc+nSpnK+w4pR3LsDkWgGFLK3B781PLeKkU0qHEhypAHYjmuX/tS5inKSxNs+8rAVJNraPFIpGGI5IGM0uYrlu7mxarvt4wjY3EDn1HanMmIjHLj7+a5+DVQ0K+W+yQdCasR6mrOVaT94OeRx+dNSLszWjibK4Xg9hzTbpn80HknAB/Cs1NTAnUqzLgc+hpJL2Mzhvv7uCAxBFVGSFbU6GymL4Mn3VGB61d85ZQVA3EjqOMH0rnfttuY1KtIrL07gVYS6Vl3rIcH1/wAKTIcbu4+AgscN90nNWpXRQw6t6VipeKlwyZ7ZOPXNTT3sJI8tQGznc56VCHbUuY2Drzngd6Ydr98kdfrUEdyrpkHnuKSOVeSM8de1MotBsEZOOOvpW/MPsZuZUtxhNsNuGG4SMf4veuYVw3THNat3HDbQSAyXMk1o6Kzl8AZ67R2+tVFmVRXsiXVZVju2jChG2qWUdFJHIorM1JRBdCNWLxsBIjN1IYZ596KG3cqMVZHSrnYxBA7f/qqMr8nPWnvLzgdAaWKRQd33hRE4bDt7BTknBqpOuVKsDkr+tWGlUghDwaoXE21D1znjFKTRcEyrJICXQYDBBu7e1Z4ikEi+YWWA5BI/iFXbWBpWO7hmBJPXHpUyksAuw8Lj1IPf6U4q5upW2MORQuV3Eenekt8ysqxks27lQOgqe7j8tgByqjAz61DZbo5TLG22UdEb+Kl1Nk9Ljn+0Qy+U43RA5XIqyjfu8OcL29akLXE8e65C/L8qsvGPrSO0bkMFI7c9z7VZL1RdtDGqNypHQEmpo1BdWVgADzk0yGFHjIYDnoRVxF8tgCWR1GQSOvtVxZn6Fy3MU0qpHGqSE8Ecj8/SnagLqO2dT/qsgCQAqCfSnWMSzW0jISrsrEEcAfhVCzDqQLoyPLnBcHdjiqsQld+hQlikmnIyS/HQYFPm0t/MX7SBEHP3pTgAY7V1GmpHDG2+RQs/LuRuIVfT3rLXyZbadZZXKKxZFA3lh2H/AOqiUbFKrK9uxhSJbJLthkSZU/5aDoT6CpRZqylpQF3jHzJgjPrVqDTQH3S21vZxKpkkzk7Rx1xyKje4W/lZYf8AVZCoSSQcd/XFQm1uauV/hI10+WN0MZAXIwHOEJ9GNOMqm7jjmt1tthMc+58pn2IrTs0lu0kRyG2ZUjOAcd6jexeKVbmS3VkcZVD0PY5FO19iedX1Ib6XznSIsVdsKxcdgeCD61emuB9tiiGWSIbmdDnIArNWC2EvnW/yMhLGNhlQPT6VPNIHi81ZGjf76rt2hh6UJW3JaRp3LQR26tnCdFIOTtI6+9VYNSgtDJDBbyly2dxPHHfis6zuTLt8sJu5+QsAPzq0l9BHMWZcOMEqADu+h7Crb7CULaMTUdUnvWVZApRMfvCMlsdqp3sCW4VYkkV33FHGOfUfnVa6vD9sYKgj3MX2D7oB9D6055Ljz43RBcRqAQoX7p96hu+hrGFrWLaX9wWjhmLs33QgUkdOtEt8xniDgfKefM5UjHr6U3aHaGcMIJIyTtBLAGrF60EnmR3KsZnQJvRuOnBx0AofNbcl27Ba6gN7BGVIpNu5Vyw3dxk9Kfe6tdyK+1m8styDzkdOPSsfzHW3VSwZY/3aYXr61Xvr1jwj7S3G0DP4UrleyT1OitNRedMSxNIiLtXEnf3qK4mlvpIGEPkQKSqkDrgZI9zWfpkE0VsJLhGWEkbcdTzzgVqLbyyQxmMbgScbmwqn1ppkNKD0NO0is7oR2z+bJcr8yoT90dcjt+FUruzX7VuKLd724MXHlge3Y+1DwR288kgl8pwuVDfxN6qRVvTbSaSZLqXOCfmI4yT0JFV8S1M78utyqxusTeWGXGG2E5wP89qzLucebGBKXbOCHUDJ+prrmkkgndkZTGFy+5fun2PvXK6iTd6lI5jWMyneDkbQcHge5FKSsiqUuZ7aGWYpZLpcIpDfwhslvY1FbZaZy0eCvHJ6HNWAGQRLC4LMdxPQg+lPiO8eVGV8sK7NkfNuJGB9KyWh0XKzuFKvnaTwcHpTNVkMSGYn5sckHg+nFXo7VEtxcZBIO0oBntWLrkDz2LgMUbHHt7GplJkp3djznxR4wH2uW3tE3FThnJ6fSsKG/uJ3DSYJPfGar63oF5p145mUtExLLIBnPtVywhSBMtuzsBKg9DWsYprQ5KlSd2nsSv8AaCOZWIzxhR0+tNeG5OQJWGeh9avLJgDaV2A8KeVx9al89Y2z5SiMjB+bINVysz57mYYrlGIEsx44O7inH7cnP2ibaeAQelXvOUAYMaFM43rwR9aUTRgiN0BDdQp4BpcoczKEcuoqX8u7cheefSpl1bV4gXjunweeRmrQkWVGAIAU4wR+VCMsQkRHX5RyuOM0uUOZjD4g1hVDyMjxngNimnX791DOsRJ6g8ZoQRhpGRXBUbimNwZe9NlSJQTF8ysB8rr90+lHKVzsifXLlgf3MY4z1PFQPrN4ScYB+pxUo2t9/CFcqxxwB61XaDyY1AZCFcrzwR6GjkGqkkPbXtQVMjCqRnJ45qNvEN8T+8Kk479ajkjLE+WBt3bXA5ANVzE7YdgCudoYjAWnyoPbSXU3LbxI402Z5GjW4jI2ocneKqr4yvEBPlKMHoGNY0kLAIAp5JGegzVYx4BG3BQ4alyIPbT7nRP40kaRWkgIbHJU9atw+NYJH2zrMqt1IGeK4oxnaFyp29M8E1BtyBg89aHSiwWImj0v/hL7HHy3QxtwvY/jWlZ+KrIwg/ao32jHWvHyONwJx1FNPBGO/f8ApR7JFfWn1R7WniO1JPl3MfI4G4V3cF5eSQkXemQTSyhTu89R5mOhIzzXyxt2OpZAwVhkZ4YeldhrNvp+u6pJqtr4os7GCQKTBcu6S22ABtCjqBjjFP2VupE69+h7HrE17G5ub6EIHbblcFVPZeOlFeS6p4gtZ7TxDPbahK324QW1vASQ7mPG64bsucH3oqXS8y4YhW1R9COjvgZx9RipREUU5+UY796k3Kp65+tJI+5AWPHv6VNtDG5CIlEbbME5qJ4wyZA6HmpC6KWG7gVHcTrGmFAycHg9QKWherIrS9hs9rMmRyOv1rNubhJQvkg7j94+tMnkSRWYqAM8c9DVaaRI2VkJGeopKTZ1wgl6j55ztA2qWA4UDge9RIp8xC4JI+Yf/rqQDcRxgZyT6U5vLR13MRExwT6GgryRKBvRV3H5j+tOC7FfeoGCCCRzUXmJFKSrbghO0/1okaa8VpGI55C9z9Ka7hFdyZLkxzRoqsSQTtT1rTtrpJY1t5Y5I5UcCUseWzWfpMTxzPKyZ2YOSenvV9rgy3ry43szZz03VrFimlsdrpdogt1Zj5aBcbVGM+5Hes3xJbSFWEbrDGQSXb+gH8zVC11TUI1ESSI0j8DZ29uajfXbtnEU0EhdVZGOQFI781cpJxscsaU1LmLGiWby6eZbj/V7sKwJVm/H0FJfzHT5WFvJHJNIArbBgkDoc9KbYahdGOLBaVPT0UDpzTLm4ieTiORG3Y2MnLfSmti7SctRsunz3gCK6s6AM6Iwwfr60sFltCySxTGRMLvjwDt9wPSpoIpZ490C7ZPursOBnuG9venfaYUkEAiljlcfdRsqr+vvSauNzeyKIglM5ktpGCkcn7pP1HUVLNIYbcRSzNu3YZD91foaZc+IGEkSXCJ9pTgyRdZB2DCqt/e/bo8HbGhYkqP51LaWw0pP4kQT3ZT5AQUB2bx9PT0qIyCVUFsX8pRypOefaszUHdrhQzBgAFOwfe471MJnSBkTcFBGMHBX2rNyvudHIraE4LLccR4CnsOnvnpmq73MstySwbOck44NWtOnlt8ieNniPAxgVJLLCQNrM6EZIK4Cn61WrVxN2lsQzySXC74gSuzEiheAfb1qjBJNIwWLOR0HTpXRPfW8FgFWAbyDgg8VzTsDnAdN3p/Sl1uOm21saEF4uGLTOsg4IxkE1cjuEZYkcpkdCeAK5rItySSzODwD0NWlmnnKkplFPUAUc62ZTp9TQvbl2LRqFbB4IrIkaW3vIrlFD7T909DnirDy+SXKsN7HA9fyp0ELb2ZtrYHAzzn6VMpFQ91Fy1uPs0LNMGZTnAznB7GrNrqge22SGTcAcYGefUVnwjaWSaItH1B7GrCQQqjPC2ExuAfjJ70rt6Gcox6ml9sdomjRw7A55TBBFTwa1cSMi72V48YXdgAjv71h3ExKIsX3gMFs43UQSvAoZPvHnB5pqbuS6Sa1OyS7jOnXC3abnlzIG3ZO4fyrFlAQLJHIueeh+7+FUTc5jJCtkjkDtSWgZziJgN45DDrVOfRkRp8pWn8wyhwWBBwS38RPUVrWttFHbK8iFnPU45xWTZlpbqZN4AUbzuGQccYx6itmGCSfzlRW2omcqOpJ4qejKq9EZzMYzIUOEOQQfSqk8YuYA0WdrHHTjNaOpxSWdo5ePLK2ORzjFVrJS0AYEq7HcF6Ae1Z2vqxJ6XRl3GmoIWSZAT3PcGsn+xLOVS4jwCcEkV0c9yC7oxO3OGwOc1DHbxzqplZto7dPpTfkbLRXZzf/AAj1mw2lML6DpUJ8LWxIMZdD6BsD8q7qOyhMZKSLuHvg4qKW2iiVmEhJ7ZANNN9zNqL6HDv4Pjw2yWTn15xVV/B+0KRdMHDZDEc16PawE5AUkhck9qabPzpmYD5AvBPrTU5LYz9nDqjzN/DMyyZjljZhkNkYBB7Gq0nh3UkPymPA+6wIBx6V6oumrFAGwrscHgdal/s5NrF4zyego9rIylTgeODSb62wxtiGAKnYQRj61QlguEULJbzbs9fX3Ne3vpMZJ3R8Y705NChMYzGD+FHtZdiHTj3PCX8yIEEOYyeu3kf/AFqiWZsSRv8AvHUbTv5yPY+te7toNuF5RSx7EYAqhc6DbbsvAhGfT9ar2rW6F7JPZniyyEqGLuTj5DnAb/69Rs6s4fjLnOG5APcYr2CXw5Zbgfs8WR0G2oh4dtc8W8YP+7R7ZdivYeZ48xDKUAUQuxDDb91hVfBZwGRgwDDIBwwxxXsg8P23msfKTA4GBU8WjxDO2NcdiRS9t2Q/q67niiWrMYiYJAfUISBVeWym27RDIcncpCGvdV0pBzHEA3TNNGnRg/cwfTFHtn2H7Bdzwh7SQyjCOsmOBtODUJt5tmRE4ZTuKlete9yaZDjhBn6VA+lxkY49elHt32F9XXc8G8pc5fKxuwDEjG3nmvUb++nsX1+1sdFsQNNSCa0Q2gfz4CQGbOMtnOcjpXQS6DbTDa8Ktu4yyirl54e0qxv1VbjVVvLVBGs0Dhdo67Vz/Dz0qo1r7oiWH7M8h8ewv/wlUzlAvmwQy+QFCmIFAdhA9OlFb/ivwp5l5PeWFxdTFvm/0pt0jt35/lRV+0iZ+zktD3KSTLYXr2qRg7RAc7e5qytuvOBn3pzxso+U4z2NZ6laFJofk3n8fpTJocoTgA+nYir0gynAAyuMCo3QMhLf3c8/yqbMpSsc9eJ5eQg245xisqQgybpSxVRnj1rS1OQyTrEDzjk1nTx4+Xbg9ak76T01FjuS/wAq8sxxg96tuWMTb8DbziqFvbLvVn4cc5qyzb43GeP4Se9V0CW+hG0nmAY6+la1hIiojc+Zt247H61z1wXhZWHOeuK27cgwwlHEgnTdx1Ug9D70KzHUjpoXVdpWfdkkDaQDV+Jo9gZ1GO2Oq/So7dAVBUgSZI56jjjNMtgFYhhnBx+NXFdzF6m9pUfnzoREBl8sT0x9K2dXtYp0lWC3ijkjBcfLy/HY9hXOx3klqy/Zz5sz4+b+Bfate3+0FRNPIJZiOGLYCj0x6V0R2scs4u6lcyI9ReGAlGZmHDM+DwBUMM8s1wj3BYMh3EbeinoPr3rUOlxzMJXK+Zn5t7fIx9gKSSzuILZxM5MhO5/LHGex/KpUWaqcehn285tnnDSlcHcMDls9/aqct7KyhXcMEPykD9c1LeFZ2DgBXUYLtxn2NVoFTzFZ9mB1HYVDuaRSWrIFOLjd8knmEjBXBX0IpkiK5VIT5TAElj0JrRMMO4+RlpSTyKrTQ7j5IBLA9F/lQloWpXZkYdrhhIoZ1HXPX8a2khR0ZiHyFyZDjBPpTTbRx28nmAxzqM7mIJaqEdwEVvOBJHJB6GkkkU3z7Ed3FKkkZLB1IyQOv40wsNuGJUnldvX6U+S6QsANscvUH+/Wddy+VITt56Dnmp2Liruxp4Evyxng9c9/aqc6vEGLRkIOPpWfp1/dPdeRCGYMc4A6H1rRkeWQlJCS/Ri3ei99iuRwdmUpAz5YsGHYYq7a27RYkbKnhveo0t1Dja6hielXmhVbc/vckfwNn+dTy3d2OUuhn3io7uXdgSOvX9KltWdUZgjyEAEuxxgetVroSAhWIK87R0x9TSQwSSwsQZG2dEXn+dS9y+X3dWaKyBkCFmV85xntViPyAxUrubqRn9RTNJWIRsJAFfBwHGcD/GpiYILmYKgaNlHHrn0p3djGTV2kNuYQVyp8xM52g+v+FVtruinrt4I3fMB64qeK2Z2KyFcHg565p8kXyrtU7lOA4Bww9M0rdUK6RLFuiyysyiRdq/Xp+FMfzUlUMgQ8AnPHPc01ZUdkjk+XB2/N2qaacDau77o2HJ4wP6VV7rQl3uP0mNoNTMLr1BYoxyGGOea29NBjkWRZnjjZiDt9OzY71yc92TKJoWYbOFz3qxa6vKsAXeIyB1704y7kVKbkdTrE8Fx+4tYiXA3M7nlv8mqtvbW6WgUwk3LEv5pGcYPSubXUZDKUBKAnOR3Pbmrf9qOjjlmderA8nPrQ5E+xa0RdEVndahcrdqAWbCoo4IxzUkluqTxk4MTk4CpkgdB0rOTUGYyeYscrO4OcbTj0HpTZL1UuV8oSCPOAFODSukaKLuaMsBlkSFUUKM/MOM+mTWi2lxLGdqjIPBI6e9VLaYu24y+crD51YZ5/CtvTFSaKOMMNxJzg8n86EkzCpJowJrVg9wsZAKA/Mp646c1TsPNFozAFsFuK6O9iXbO/lbXDrnb021RjiCJOEUbCrYAxlfrSasOM7oyJ7vEEKMijDDDHk9O1WEPU8gH+VNvbEv8AZnC7cnjB7Y/yasNbkABcc9fWoZb5baE0ZQP0IJ9e4p+9w24gjjGTzmk2/Iu0ZZRg47ChdyqOSR2zTRixsisWBK44PfOajeASICzYz27ipyHbYF4xk8+nrUaxkkK3bigSKb26sxPXHeoWQHKnPNXpYypCnGaaqBSeATg0ktTVbGdDCAgxg9aeI8fMwBHoKliAUDH3ecU8xgqNnrRYZWaMEPj5QKiMYyBgH0qWVWyOO+c0iIWOTk+1UVbQiaIEYQDJqu9qce9aIhwMd6cIJGOCcD3p2FczFgzgEfKfTrW9eR3Am2w6fHJCqgRs0O4lcdzVeG3hcubibyVH3cKTmrDRw8Z1SYY9Fb/GmlYznqzldctXknbzoFgcgZRU2genFFaWrRDefLmacYGJG6mioLVrHTFWz9TkVFMGO4dlqYLzycgDAoJG1sDJ6VqcZVkXAUhgOc896hnJEb7u68CpbhtoTHSs2XEauYyfnOeuealspK5lTkCWQnl6qtkuSSTnn6e1TXDEHCjcSeaZIrGMhDnjJrNHfFaFedtxOeMDgCnQgMBtO1e2KhQh1DdOoq5CoWMFPSqRb00Inh3ZbAO4DBPUVPZlVfeAeuOTgGklTevy43DtTtPZYDhs7s7l5+XNNJJ3E3oaUdx5QKHBcg8D+dWYckAswJYYwKzpnhOwCNkl6+3ParltK0iSqk0Q2/MY2+9+FUmtzJrsaFu0nz7OTtIGexxwKZLqBSW2uF+UeWD5cvO09Dn+lVWLlAxJDDn0BNRSx7jlyC3+1yDVNthGCvqdfoVpI4e9vXx5hzEue3qR2+lTapK1yUgUFDjDkdW+n+NY+h3clnaKtwW2DhVbqAT/ACrStriW51KR7lY0t1OVz14/pVqpZJWOWUGpX7FSXTIvJbzE3RJyw7fjVZzbyRAqzHy/lAIwD9K3NWVv7MJjwxbG7b0UE4rAktJncRxRs6x5DbTk4/z2qp6bF05cy1Y1kAQspXnoAORSrZlYyJkfzODsx1B96f5dxbOjJGAi4Id+1a8gaeFWUYDL8pdT8vvxzzRFNhKdtjCazhRCduSQWJ6gVTWy3x5xnaMkA9a3Yre4uJCqlCid2GN1WfsrW+4B0aVxjAX7o75NPlK9pY4y3SFZwJo+Y87VA6E96i1DTUYLIH3s3y4Hb3rsZdIRIxN5SHf/ABA4INUzYIysYkwI+vzc5NTyotV+qObtLQ6crCCUqXX5m96qSoUmEkj+2RyK3b8h4WUqFdThZCvOfTiorayabCSyCJBuGXFZ21sjaMtHKRgzG48xliCNGRkkin213NvEbDeXbjitu1tXSMxMYmjYlRIv8RFWLjT1tjE3lvGGXI5GCfaphGzLdVbMx7uITOxmz8/PC45rW022jMJ2zpCQuFDLkE+9LPZPtDuPmJBz61Zs4t8g3Q7osEkD+eatw7mc53RV+wyCISqVkCnazKcZqPcvnuu0KdpC8ZHHarlu9zbI+wH7OzYG8D5ue9S3lt50gljTYzEDYB9045H0o6WRmpPqUppIpisjb4Z1+XJ5DADripAZBcLYo22LfuG4dQR3qe4szFOkhm3kDnaMg+x9qpanFLAFnhZXjIyGHQe3sRUWdtRpqWiItQsDHcGNWXzOdnP3SKz5GcoRcgbnByAc1Zmnd2Ejsd7DrWbIwLYySehFS0t0awTSszPv7qO0gdssADkgmqdreySfOFO3PBIrmvGeuJYahFFPGzjlwoHvTLXxlAQFWOQ4wOAKnlb2JlWUXY7uAyAAsDt9u1TI5AONpc87s81yMXiiLcfMSRfrWhH4hsA2JXCN3zTcZISro6e3kIONrHdwQcZB74q3DCN28PkdcPxXPW2tWEhASZG7j5ua2LbVIHAy25cccg0teonW7G7YymP7oKgnPHetGORc5AXcf4h1FYEd3EQDGwA9RVr7SNuQ/wCVUtDnk7m1ct5gD+Z0OOTxj6VDEGbeyPg5JIJxmqK3AdTGTjjrTYrgb2U9fT3obQl5GlLF5kcIG3Kkj8DTxHiDJXPbcKrLc5jG5uT29DUwuf3QTjHf3osibjZIWU/KTgjOPWnkEw45z6VD9qQOdzKoA4HvTWvI1YYK4PWpHdk1upV1z0FNfBY4phukDdcKe9Qyzxn+IcdaNAV7j5ixH8jUUL7c5xyCP0pkl0hTaSKi8wBWI5wKEzRCxMrbeOAO1OaXntgdhTYmVUBBBB9KTei/MnHagq41yGXgUIQuMjpUUsgJODz7VBJOEPHJxQWi3LcGMgheO5pDfZIxjA9azjK0mc89sVCxwQOo9qdylFdTah828L+QgYr1OQOv1p7WV6VI8kZ9d6/41gDO8KOASOtbsiabbpdq0U7m1KrIRJgnPcU1ruZzfLsZ2oeZbM0UwCsACRnNFUfEk0VncMka7ICismTnIIzmiizEpJncjGVA4wM0yRv3TKo5OSaQkBTu+9SM6rGT3xVM5FczLyEpLy2OOKpzfKvKkp/OrVzMXyI2Ak28EjjNV7ubaoLDhepqbX1NkZEm6SRgxAx29qjiz5rIODjcPem38yiV2LZ75qnHcjzkXdx05qUdi2uiOCZVEwkGGVskVbhnUqRn6VmXQ33cq7lz2INCeYjrwCp6mmbWTVzpdLKys8m3JQcCq92+8b1TYzEjb6VUt7hosvG+wdgR1NQ32qK8qB1IUggleeaWqeuxkovmujpfDtuLhCZQMpxyf1qnqEyQ6gfNYoEyGKCq2nazFGkSMmzAG78Kj1spdTtMjZVlzmnFp6IiMXzu+zNWK58xUZSHRcHg8/SpHYSPljwDkD2rIs2SBV3ZZOpFKupxLMUlBOPusOPwNXKVinHsdPBN8qRMVZFI2jHIHpVi3cRo6u2JUGQrHk81lyTpb2gbZ879CTnFZ/21TL83ynu3vV3S1MVByOludUkgidcKDt6Z6mtHRL9JbZ5JGESNgknguehNchHch4g8WGbkNnmkjkckgjdC2MIT0PqPSr5gdFNWO3vtRtDbtBG4LbgquRnvVSbXYY75kVGc4Axjknsf/rVzYk5AiZgNpPPJqrc3Mm+R+VB6sDkn3GKUptLQI0I7Hotte2piWOORRIsfPHGf71Mt/IuFYAEZGXc8bsHnivPbS9uLadWjlYIwxngnFdDaXhmdUdm2YJPPXnpVRnfcynQcNjp51K7WZgFPzFcZNRw2/kzul1Gp8yPeGUE9+/pWTqWorB5ai4WaBvm8vbwMH8/zqZdUlmZJGcoGARjxk+3sKtSRj7OVi9HZWgkee7XIZckAZ+hPvWNLapAggZVldmOyXdnC5yM/hVuW/BlFvDndnBPUAnnH4VS1q5jEQjt13PtAZgRhQeoqJtJGkFLmsw0m0TyztG87zIN3YHg8VoQwQSXMrySrsgQKAWyAe+KzNHuTbIZXyyIMYB64rbsYf9HCSR5ZlYhSOAT2+tTBWQ6l09StpCrdXlwGlwsZBDqBj8qiuWxdRiHezq/+rVeqnrx3ptpLBYXsxH+rX5cE/wAXsO9OluY/NS/VhhG43cHHp71S0QP4rjZwt0jwwptWMGUjOcUSIZFt1jbLmLft7nNM0y8TzJljbYZTteUjt1wK0tKe3SKeUDc7IflY8AAjAz+tJK+rFK8TmrmNzbyEN86sCTuIXPuKpJ508SedIsceMFEHH51vw+TPYyKyo0jNu+Tjbknj3qG208W0nmBeZMv5bDgKOhqHHU2U9Hfc5e4ic4S3UA9tx7d6jFsI0Ix87ckiumNsJbiOG2QCQ8MTjLZ6/wD1qpX1oLZpUOPkJG8+3aokrGqqJ6HnnjHRINRtZJZQ5liUiMR9SfT6Vw2l6fDCjGaMqyttIxkjJ717HBam4QylPm5ORweaxNV0K3uZG/dMknTcvH/66cZcmjM6tFVHdbnLwWyRxgYDISRhTjPuc046XEwVQgIb7qnkg+lXm0a5gYiFxIgPfg49OaqyrcQlUkjcAnc3HH1zWqnFnJKjUjuim2kIyl0AQ5Ksv3eKrjTZ87YJZI5Tynz4X6GtRJo/NCSODIoIV2BCn0zUhkVwu1lZZBtIJAGfr2puKZlzSW5irPq9uxKXTBcdGbp71aj17Wom2M8T7eVB/i+lXS2PNDbjIpB5GRj+tDQRb3CMpGN67jwB3wPrU8iZSqMavivUVUbo0J6kA1ah8ayrhpVYBcBtvb61RazxOz26qzhQwUrgYPWoLiy3qAgUOUJKjGCPqfSl7JFKqzrYfG1unNwHVT0bGV/Or3/CZ6dxumAyOMmvOJNPyqoUHI3rknCnHQiqhs5EjyRuTPRB90+tT7EHVPSrjxdpbLk3iD+lVX8V6fjP2tSuevpXnUlukag7z5bHByOc/Sm/ZSXIZAjHIwB27Eih0F3GqzPQ38aWSYH2tVzxyDRF4ysCPmulKntXmcts6qTPuY7toGOAR3NQmEuTtAztyB06dsVPsEV7Znqy+KrCT7lzHn61MPEkW4f6Qh4wMMK8nWDeA4HBHULjP/16Pssokb5G8rHzNnIPvR7DzH7buj2CLXo3XBZf++qlGrQkDEhB9M149CJIXXyid2Nr7TkEeo96maORkws0mS3ysW/Q0eyYe1R6udUDHhx+dRjU0UnzGBz3zXlK+YZFaS4lUgYfbksOPSnyIUKBzKARtJD8Pno3NHsn3LVex6uL1QMh1x9etRDUkzywHtmvJczKHUPMT65Pb0pqlsnMsm0jAyTkMPWj2YfWPI9Zk1eEclx+dXNQ8RNZarBb3k1l506LFMr8oB1Akx/F0NePWsEjkt++UKNzOAWVfTP41191badq8q3d/Y65a3Mv7ydYLbekjAAZBP3c1Spmc619kVPG2r6rLrc8d5tjjICkRcrtxxj2x0orN8R3L3mszyy2s1iDHHHFA55VFAC5z7d/eir2M9We/TXS7VbP4VSuLxBkljVGRgcnccGqM27fwSc9j0rJXLTSLVxqCBgwYA9yDVO71RJIXO4Be9V3jQHDY3GqV1aoyhkYDjBX1otoUppFO6vmJJJA/niqn2kMCScjpx1HvS3ESR/MGJ56e341Sd0j6YzjGe5o5TrhWXQtrctn5SPMH61uaY6q4+2MFZvuoxxXG/a4gWDhkcDgipn1dpYo0uWEmz7jdCPqaTT6FSnzKxv6m5S4Kru254x0qgt1suEMik4zjA5qjNqiOfNZizYzjGNo9Kju9ThmVTBFtIGSDTepcaqWjOmtLuG524GCP4SMGpruQ+ciugMWPnHeuRh1RUkyH2OOeP8AGrtxqzXCiQvkj+JajluS5WZ0hmdVDbMgrk7ugqtlnTMpCBuDnn8ayo9UjuUxcSIpQccdauwXqfLtI5GeKUlcfM0bttOZNkbO+4LtXPQAVWuEmNwdgdlHXjvVBr3ec52tntVtLw8kM+5up9aeslYSlZ3RPbXMkTknCA/erShuZHmR42Hy8DjrXPXpG2Nt2PmyR3qxBqKII1yGJ/Sqi7blSXNqjoGupIZ0njIEitnJHX8Kpy3JM3zP85JYnpWdd3yywHzCB83ykHqaz7qQtKsQchiM5zVOWlx06d9zpI2zJuGwlepOMAVbS9SNZACJF5BKnkVza20jKA4OCvHvVi1McCsJWz7UlJ3sJxTNeCcyACTcoUcZ+YgfWta2mZQ2WVEddpLDn6VhWTK7BgTjJ49quyXTD/VnIUYya0WxnOz0NCObyJWaIlWK7Q2efwpy2mZBLJu2kZw/U1lQSu4BII9u9a1vdboXRnHmRndkDOPTJpaS0ZDvHYr3s7KIlhUAAjAHAznn8a3TdTC0SZmCuxJIY4Yf/rrkLuZpbmMMAeecdq1ra5Tconk2gLgZNO9gnHRMjeaWa6VXBOCSMe/fPtV+6WMWWTdBnPRFbp9R2rPlvYoJCbcK4I2nI/l7VXkuDjfHhQrc5HU1C0CzZdSTZOkUKqCqH5ieSxwK176YQ6OYIHC/LtcdWbuea5S2uQt6WySQOfWr+paiz26rvCqnCrgd6pS7hKDbR0doYbuCG2tXy/X5V5U+9WJnt7LUPIm2zRMDzuyyiuPtLpkJ8tljIHBB705rl4rRnaTczDk9/pRz30M3Rbe5s6M32ia4YEgRH/WEj5VHT86XWot9smwlmkBG4tndjqaqabqC2+n7Ht1jLt8sxGeO4IqDWbu2u7i1S1DKdp8x84wfTHpSS01KUXz32EUBYE3wJIpGF+Y8f/XrLuZoF5MnLHJUjP5Vr3ds8WnW8kcwVn3Mu3jawOKo28STb2mVnC8AsucHv0/nUtXNoNPUqSQhljAQgZ++h4Jx71WubQNbs5jfAH3gOBW5dW0OY2glZQ393+L3Aqhq1rPa+XCd/wA5GWHQj0Io5dC1NM55rOJogZFDSEenFUbjT1JMUSp0yxK9DXWzDybdA0KKOcSbOT7e9Zlvb+aHbkb2J+bqBS5bBpLdGDFokp27Jm+XselNfSbmNnaN41YY24wfw+ldDKdilQQV9R1qLCuwAjCsKFUlHqZSw0JbowJbK8WWJPLjbap+YvuA9qjFreKMJCrbSCqlc9eorpfI8ofvIgpPON1TJCwwAOW6H0FV7WSIeEh0OKnWe3YLJC7BAdpOeAeo+tQpHLKwKJKGdiD8uOOxrv49PE053qNi+ozk1Ya0j6RqAe5o9s+xg8NFdTz06dcmEg2j5yDhlzzmiXS7lz81u6ID068HtXoItwvGSzeuKX7MTgYz9aj28ilhonmTaXLIceTIGJ2smw4IH8WfWoPsZ81g+N6nDhhjnGOD2r0+S0Uk81RutLhmzvQE+uKarvqgeFXRnnotWiUy8NhcsvTkd/rimJaJJIuG/eFiwDAjA69OldRe6QYd0kIOFXoTkEemKxQgkTy03MyHdHlu/cY/CtoTU9jnqU5U/iKEcKxp5yFVKORKOxB7D2pwttzvEuQCAyk8Bsdia0LSdHnaNSSMEFXXhl64+oNIyKYX8oNG0Wfk3dgemKqxFyg1uf3bF2TaGRhgZB6g+4qMW7IHjkAVQQPlUttJH8q2Ps7TmJiiGOUHhuNrEUQxPGIDKhDTHy3BzgUikzMeBS6fIcNGQz7scj0HTIqhJD5puECh2B3AjgnHB49e9baWoIEEr+UgJVtw/wBW+eDUZSTzY2xtkIKiSPDfOvr9aQ9zPUyIojiupo0mZVcD7kmOQSPUHtXaXgi0+5S1u/FeqRSyYDYjJWNiPuk7uOo4rlQTGQ3k/J5wEoPYjuB6967NdOXVQlzqOiSzTTMHBS6WFZ8Dhwjc/UCmiWYXiTRA0dw66lLf3tmE+0LcptYxt910bJyvSim6lqs6rqltNZiHULz5Dk8RwpjESj8OtFS2NXO1mu4oxktgexrNvNftIlzvC4OOTXld/wCJbqQ5DqB3zyRWPcam0pBld3PoDQoMzdRWPSNT8X28ZIiYSN/dzk1y2peLr2X7rCMY/hHNcnJO7kkZb39KgZiRjHHr61fIZyqmndeIbq548+cYOc7+aYmpXmA0d05PqzVh58q4Kn7pNXo1yB60PQ1p6q5e/tW+AUGYNg55HX2NRvqF42f3gCnoAOlRhOnapFj49ajmNbNjv7QvvL2+aCPcU06jqAj2IyFT1yOtP2jFOESkZpc6K5X3Ej1G6CEAAA8nirUWs3KgI0YI7YJqJIht6c1PFboMKVyrd896XOh+8upYg1raSJEbB7kdK2rTVAYkww+bvXPQ2nzkAFgnOTV2G0RUUtjjJ5HfNG4/aSW511tfK6hQwA6c84rUiuIyAd444B6ZrzedZII4vJmcyMhdwegyeAKu2OoXIiRn2lehycD8KfKXGsup6DAUkjfdIFOMAMeTUSQp5obI2k8ZrkLbXlyRIjDBUYA5OfSr7+JYTwxKyD5I124zUOOuqNo1l0Zv3MBYrsOAG45q2sao+9sbx3NYVjrdnKg+0SlHXoc5ANQXurQ7iomG7PHzcGk1fZGqrJ6XOrvbxlj3RHG45OOtUZLiSVQSnIPJPGa5yHWJpoX8sxqqdyw5qX+3YCqnz1YkAkZ6e1CT3CNWKOz0y6ZYPnUgk8Y6CrL3R8veWwK5OHVVVVDlV6A7iOKnl1eBU8kOmQ5BYNkN9KuxHPG9zpVuDLbu24o54xnFV7e4u7V/kbyw4I55yK52TVxHsKzJj0J6+1LHrSBiRJGXX5sZqOVsftIrsdXagu7Avg7cZNRfaXVsM2VUfjXN/wBusEZEkDK/LkKePTmmPrYktgArtj5fTOe9NxbJ9vFbtHRwO0s+/LYXjHar0cixghnO3qcmuNh1gxDaFLEei9R6inS6pKzsAhCAZY5GM9l+tO0hPEQ7nV2c6m5dzwCeT1OakvZg7R/OME85FcbFqJiRcmTcTkqByD6Gpv7QkLGY5IUcEjAB749anlkNV4N3udhBOqqQwXPQEMeKdfTBoAVJ5wcDmuPGptEcs4C43detKvim3kjMYfnIJbHYUmmilUi3dM6Wa9uEuVUMd+05HqD/APqpLG78pfNm+Y9Dnnqa5my1uGXVQQ2VAIyO9a1/exxpuiC4Jz+FQm0aKcXojp3vRLBHDv34JbO7t7e9JFNsVmYSGPpnO0qD2zXOxTeaIpUI6cHoM1oC6VkKscYIOCOtacxLikdEjQXFoqykS4yEVXw4z/Spdbs7mO8svtk5bcAYQTkhfRqw0nSRVcDDMeCvUU271Se51GJJZJGZIwi7z6Hp9KbkrGVnfQ0vFVvJb2Vu3mMY3coqYxtYjJx+HWskIUgy4IJX5SOMkVo6vdf2he2ql3kjjh4DHO09/wBaUW4dB1KgYC+h71MtWVGTjFKRgSBtiluh9KI1KEYY+2K0761EcG51ycfKAelZ8cMjY28/Wlc6IzuiWKJJnzLlm+9tXq1abW23UEhxtUKDnOevNJotowmMmAp6ZPJreubcw3mCASsQCqR60+lzCpU1sUILUiEtgZJppXABxkkc1oO2ICpHIY/hWdLvAyMD0qWZRu9xpiG7djinrDuGAKTc2ArVatwQOnNCL2KklsSnAOKiMRJIK4Hrit6IKUAOM06a1wvGMGq5SfaHLT22bWYEZGPSuJ8QaatrIJo1ZSeXx/P2Nem3rR2+nSKmGZm4xXKanE91FKXTOAecZzTty6ouNpJp7HDkgkkKpcbSWB5P+0PepSwZVyzELKEWQqM46lW/xpTbGJUmbONpfGMZXPX8DzTpImELeaVZi6twvBJPVvqK6FseZJcraQ0ZMLhgZMT+WUbge38+Kn8oB0hcu0TkbWDdGHcUXGY3uNwZy+0ssnOMHghqlKSLcxjfujlO9AOFPTJ+vrRYEytcKTbykq3nhP3vGQwU/ex2pJBmP9w0YMzCUJ0zjqvHSrbnKDy3kD+ZsBz84AOGA9fpVGT97DcQKWDibzCirgMmMZGeRSaGiMOm4ldzMpDNHIPvr1IPuK3NX09dZvpriLU7LyZV8yPzptktvwPlA64GO1ZRtZbqORrSF7oQskjIIyXUHjBA/nT7nR7yYswsblJo0ZFIhbMZzle3IPSkA3xC9vrNyZLeRZVghjRLnBBlwoBJ79aKd4tJttdQrCI2hs4mniRdnVBn9aKGNPQ8bznvRnFNBxSnmug4B4Y5BzzS0wUtTYCG8UlN46g9qmtpQ8YIPNIwyMHpVW1bypniPGOlTJXRvRl0NaNuKlUnNVUNToTWDOuLJkwc1InpjNRKQBT1bHIqGjRMnTnGasIoyA3B4A+tVFzn1qzGC2EA5Y+tSMvBFJdFOB94H2HWtSIySmE7UAk3KN56H1NZkGSGZQMhiox3rQh/fLEPKBU9COCe3Jq4kMfc2sUyRyNH8qAEK3y7u2B+PNPl01PMSNUVE27hjqvGfzzVgLHKrSysSwySoGenGfpWjEcoskqBZVXz8sAQV6KtaIyZiyaU8xjbCRMmCzAfdPQUk2isse5WBaAc7u5Peumht42u50fCxFVbeDnqclj9OlSKpneUlQzT4QrxkEHqfTiqJOO/4R9n+1LMNhBGCPujP86qjwzOkbGWUeZyvloOVHq1d/GiSoEESBdrD5Tnew/ipZoN4ljhy4wrliuDu7/XFOwuZnn7eH5YV3sVJChgCucH6Uz+wLiC7y6hXAzgjgZ/xr0pbQzK6IAdwVAo+8c/5zTxZwGQwqqszSfI7j74HanYXMzi7fw86OVmKqzMN4xkYxmpZdAIiicRbVB+4eMbun0rtUhxH+9I84FioZcLg9/ela2WTYqDJfYVT7zZo5Q5mcKfDzQT+WUD7mCkE8r3xk1oQaRhkjli/eN8w2nOQOAK61LfMLYbcI5PlbOOvc5p1vbiKMRq4EoOdxAOfQCiwczMNNKcbUnjZWUFiuOPpUn9lb45B8oCAHaBhlz2roUhCI4ZQJIzjJ5+YnPNN8sLdSIRs3kDAOT+FOyDmZjQaVHtkMYVljwcN6f4+1TtpOWSMK5DfOF2/ka3IEZnEUgUIwLdgC2MAk0iIxSFo8ldrRyBep98+lFhczMwaYZZwqKHD/KZOPmGOcntUD6XllWNGlxn5W5xj/Ct3gm3+faANrbV4U9j7n3pTiELICshiO50bsT2Ap2C7OaOkRncdqu0Y+UsDyO4+tUL3w6jLuRCUwNyrwVB9K7FfMIEZYgux2A/KI2P9PrTUhjlR4xEw2AuCBwp7896myBSZ59JoAiwUkZY2BA/vH3I7U10ulixuJQDjd1bHc13wtVYIuI/NkjHlleGJzyCar3VhHsIZNsUh+Vc9D7VLgmUqjRxVrqk0SvEY3CbcsByM1pWfiCLaYWUxEHDZGSGrWvdKR93mKcgAoQOWA/r71Wn0dSId0IWXG9WbjcPRj3JqfYo1WIkWo9VjKlFcFuOAelNubzzLy3kDZQDb9KoNpSb8JEY2xuCgdfbPemfZpU2Kcpuyyl+cj0I7VnKi7aG0MUup0az+ZJHKWYbTghRk10ljOsiDaST0+UVwNhqDW5QzQNhuM4x+Vb9pq9q8Yw2wZ64qGpLcqVSMtjp5LdLkbXUHnAIP9KatiUQg49AB1NZceqwAArMnHXnk1eXWUZMM6E9iT1o0J55bI1bKFYQdmAoHOah1K43XaKH3bYx07c1ROpREYBAPpmqstyrXKMTgkU7q1hq97s0zkPlvwGaqzE7uDgelI1yoBy3NRGYH0PpipLg9SZWBBL1OkuFGOgHYVnmYbegNNS5w5OeD2obszRu5qicqp55649albUI1QCd8ITyB1NY096qjGQKyridW3yeacDqGOBVpi5Uy9eX6zSMCVSIZ2iuf13UD5cVvZuRMx28H19qz7+/DsAjYKnlh0A+tUxFIMzb97MpZZl45HaqScn5BUqwpqy3J9SQW7rAZA/2eMLlB/EetBMQUT5YsVy/+1HwMj3BpMOZJJI5UlcBW5yOfpT3ORJIQRImSgUffDD5hn8a6Njy+uojqHuBJHIhuEXY8bAhHPY/8CFNa3XfHGq4gkhZwrHPlN0zkflT4kL+Z85WUKsY3ceZt5APuO3rVohGWYopyQxVGG0oT95T7E/rSAzbotLbFFO6eAK8vyfOCP4vftSOxlnS5DNGoUGKQ/wPn5lNWZAPOjUkCR7Y7JMncCBwSeh9KhAVCyyRBAYlZn7Bs9fwNSWNS/uba5ma1ne1uShT5D8k6jJwcd8VNHqGrvGbqC/u5EkgC+S0x4Yd6t6XFHLDc6hdxid7b98kUZxG7k7c59OOnvSmC11WzE+jxtaX0CNJJaKxIKnqyg9QD2pi0Oemne92Sm5ea8ZPKV3+YkAYZG9faitLxLaRQami2sSQqLeOQNGMFZSgPT360UrFHiOactNUU4VucIopaSnUAFVL1SsglHrg1cFMkQOjKe4pMcXZiwSBlBFWUNZdm+CUY/d4rRjJxXPJWO+DLKcjnNSKe1Qq3FPVuRUM1J4uTz9DVmEjAJIGDz71TRufwqyv3gAeOuazsO5ehPB3EhFI4HUgVqwfvRFvlKq0e4DsAM8ViwMSzL03KQDWrBI8ixqyr5ITeB3AU4OaqO5LNW2QyRQ26ALIq4d8/dQkHJ/lV0ojJeSuq7fJCAE8Kc4GPw5rPibA2PgiSEhj3Ut2P0qyPLa2kGwtJIcHaflXHANaIzZpbhtnmLYV7YKGPUlT1/SrgiKaeGiJ/ehBtxjA64/GqUOyO2tHlBz5DEr68mr1s2LW3E24x4a4UnJ3EEbV+nFWiGTbir+bFGMwoIgFHUscgn6VLLmKS7fDu1t8sQx3I7/majUsY5ZJN21/nVR7jJ/EZ4qxL+7gCQlZNgAkI+YO7A4OfUDHFUQCJlvmYKygIm1eApHOas2wUi0MCsPLDOWY43YODj6CiRdnniJcP5K7lyBhhjjFSSeWs0qx7TGIVO/OVRjjIH1NMRHAhFxbzEbzJ91ySMKCcUDMLQPDlWZG3s3+90qYEASj5imzyyAAuHB7e2OaCCskyxfPCdrYY54z0pgAh+0bGULukiOxc/KBu4qeIG4MoUqZcgBmO1VUDGf50yMEWsu5SzrtEascH2/L0p8TlXExLFXTYSvOOP8AHtQAxirxx/xMZSGx/ER1H0xUjxoHVvmMW4qcjJPpinEo0ZMJGAV3IQQST79qa8JKiJjswxJy/HoD70AImQ0hUI0ajbkjH0wO9Tr5gX95t3OQox/Ap6g+1MXbmdiig7shypIJHpVrJYTySL5kbYWQg7c9+1CERNxDcphw27IxyCB0H0pzZVmYsEZzhRtBADYGOKnkEkc/I3JIoLrGMqVz0PfjioIyRG7rlY2YowQHdgentTAjKFI2VsH7Od3+/nvk9QKULvmDAbLdgQq56Y9fY1KiKkSfKPkCFN3VfqO4pr+V5vlZZsyBmJ4Ix0wOlIBiFxA7EgMXIVM9MUSRnEUMRUqW3I46kjqDn8anYbJkCquXyVOc/ORySajIJtFVmKTHhABgcHkn3NMLkMyZ+0rjayg7dvRm7kHqOO1DxYt5mMW3oqnPK49AexzVsBZB5cuI45DvVjwdwx0qIBZU+ZWIiILJ3bB5IFAFZreIusckbGQNsDHkY7fQiq8lhtbeFDSxgDa3fJ61okfuUEkbSbyDuH1yN1BiaSOZ/MVpF4DKMZOeD9MUNDMNtP8ANDp5fyucn5vuP6/Sqsmn+bKN8ZYP+6lYfLhh3Hp9a6qRVZSqsWDjzVbG35sc4/wqBod4M2CyqwycfIR3U+9O1wucnLakhmH3kG1wq857An+tQm0kRvLk8wA/MZFOPy9q6e4tNkkoGVzkEA5+XHAPtTJbby9pZRmMhSynIwehx3NRyoak0cuYrhCmJZkGMEE5BJ6N9KVJbzqlw+VYZjbBzjg4Pr9a6IWo8sJkblO3D8ZU+nvVN7NczblLx43tu6uv97HtS5F2KVSS2ZmQ6nqKsfukBipPXB96tDV7qNlaaEhT0IP86etqquofaUIPzNlQygcHile0QqBEFKbSATgeYB0P+8P1qXSiWq0kSHVicDqWzgqCRkdvrVSTWrnaGjjQrg/xc0q2mZCFDqCd+GOQD0Oaf5YWCHcsKvkdu/o3bml7GJX1iRUuLm7ulj+ceSc7WU96iRN+FEjyHG5SwI3Y6jHrV02qYIgKhfM+Qngpnnr3GakMUjtIGjDEMSc8AnHTPrxVKCRnKrN7szUhRlURAp5uVcHlOOR+NSxwbdsjOwO/DcYUEjHIrWit0y6OxCOokiYDjI7H86ebUCNQ2SSFO3PJYcH8MVdiL3MSVAhkjYqGJC7gMANng57j1qy6kGVSg3qykpnhl9R6irYgVjGSODMwYlcgEDj9O1RpEFgTALK+dh6FXHUA+lICGSFWLJKA0bvw+c4XoD9RQXYsskg3SpF5cijnI3cN+lWQhKjyzh2BYAjhWHJU/UZpBD50gCEJvUKM8kjGePp0osFyCcZlTcymLzMDIwF3DkY7c1TjkeOVpljORiN43PVOhP0q1CX2LIFV9+7zGHIz24/lUPzYKMpaaJN6Ybh0LcD+dIdyTR11GzuXXTImm28SIU3gBvXHBFPstM1W1MEj2V/FdozIkqRH5ef5Giwup9P1COSBZHiViGQDJKn+EjuOaHi1eLfMkOoRRRyktHuZgUJ4APc4NIdzP1e4vptQkbVU8q5Z0U/u9p2hflJHbIoqvMTs8x5N4R/LzIxLHuFbP86KkpHjo606mjrTq6DhCnDim0oOaAHUHpSUUmBRuV8q4Djow5q9E+QD0plzGJIWHcDIqvZyblA5GO1ZzV0dNGd9DSU5qVDVdDUymsWdaZOpqaM56mqympY8ZyelRJDLsZIA2nDDgfSrkUhCyMhIXYRnuR0IqgjZORxnirluwPlgKQCxDE/3SKlMGbMbjzzuPI2b8jkjA4rTgVllljkAIVTAxHAHOV4rEtjuBlLYJwm33yNpratykTFBiQi4ADbv4sZGfWtUZs1ivm3E5hRS8RReeQBja2PbnNWNgcMoUk28CpGnVWG7g/Q1lZwrAZMihtij+I55z64Na4/dhvMlwJCkQcNjaNvP5GtEZsvRtGk8s21mZLdSEYcNzgkfSnRgLIkSsPJhfeQq4wAP1Peq8SCaNUkfEpiVQDnBVWxgn9TV4OshluFYeQwYJk9W+5kj9atGY6NZHthcHgSK6PM3JYHnOOxotIjDIJFUGKODzGUjPJ4HHsafbjYsi4yUtykhYHl+hx79OatxRKbmFJCHkkI3B2wpUDgZ+vNMRW8uUAlF2FFCyhmGcNyfx5qwAWab926OWxHnnBUYAH4URqMOiAtGkXmlh0L5wPrUkasLlSyPvQB5A79GI5+lAA4nlnhSGUDCl38zHB6foKWNorfeQgdUHl7t2Fyfutj1p/lskiQu0SeWjEbfusCM4J9aQYeAHy9jb0QHgLwM5PfNMBBCFBjYlw6jbkbcEnigI6vASqiVXKZyOOO4/rUqCXzW2x4SJg/I+ZhjGMntTTAfsx/1fkSkNuGeGPX8qQFQMF8x1wxkyGDN90nuBWokSGdAVQI4MbLztzjrVdVUugkCtH/qSSvUYyOPXNTQJItrhiiRrMRI/wDEvTH4UAIiGFlb5mniyrccN2/LFOfMUkghZlAO6NW53nGMU4p8s8YypljG4nOTIM8D0yKcioGiZQpjijBEZOSQRyCe2KdgZCm57PIkaJoUOVxyx9DUi7Ua3+WMyKu/I6MuO/vUiRgXo2oJFlG9GyQckdM0KnmKYwPNYRhXHRt2ScYp2FcSKNSkMDIVmb5hIOjKfWmTMizMsADeaVKnPYe9S7XCFgG+zsQg28kHv+GeKZdKRJdKjKgwpb5QcfT0oQIileJSJIl2qCS0Tcke/sDSSoyHAAAmk4ZB90HqPpip5EfzbmFldpQqgnHBHv8AhTZ40i8to97RtKAmc8gjBHtRqFyNlWO6hbeSvmEYB5HHAP8AjSWxRpSW3RkErE7kEA9wRUroqMyODgKEj+UjJGcfiMU1RjYZDvAHlkhc/Mw4+ppg2MjUhI2jdFeIlWUj72T1I/wpikwhxGBvgJLDruBPHFTMDHI4bOAnzIQc8dRn+tRJtJgZ2ZSWKNxhsdufyoGNIYRhSqsIyV3sCFOR0Hv9aaipliB50DxhgCvPHBI9wakuMB5VuQ/mmYB2DfIQMcjHQ9KbIJ1vZwi7/LGSic/KSM4oAa0WYXJIZSVJOfmRvXHpUbwIhZ8iRYQMHpuUnqPw6jvVkxxlyqMo3/IpLH5COmfY0xgzxysymOTyN2T0Djt6YNJgUEhcSxKgAYBth25DYPT24pqwp5cJVTEGJ24wWVT2Oe2e9aDxhJHX5SeJhtye3K8fnURbKNGjhmiVpFfH+sUdqQGbJDtLBYwZospkHAdccgj175pksbAtFE3Qh1XPEnfFacsXmRzQrg7grojHpkevbFRsqyI5YoEYLEy9SpyMNx796AM540aY7gsRkB3oV4LYyuPrSoiL+8UvvKK68ZywHP41enAM0sudj+YokGMg7erD8eaaFEaBFZwUlZjtGcH1Hsc0ARJEQUSFlJwMMemDyd3pRGv2gW7Bgpk3pj0Jyc/pxUif65SrqAFYIy/MDjnDevWoIs+TFkhZNjGM44B7D6ikAqIznhN+45mRT029x74ph2ywIG5hlcea2SNpHKt7HtUwkZJJni2CXYNuP4nB5BHY81Az/wCr4KyxoU6Z5zgYPpg0DGyMws5nkJIEo+ZCMq3GAfwqpeK6C4RGO+BvPXb0wOM1daRFuVZI/wB3M6o4B5yBgnB+vFUHYbhEXKSJtUuD1XkYP+FADLvKyzPEwWPajptOAxDDP8zUV1GjxS7MljNth46EHpn0xmrVwvzvuVRJtZHjI+Vx2IxVclCodckECJo2PXjG/wDPvSGamhySLNf29vPHHelFW0ml+UsN2WXJ6HHANTy6fryX0ciTTQ7gQzvdLtB/hJyfXrVC0jt5rOe9v42lNjEEMSvsLSbsKS3YY61ZuLS11PSbqfTlcbsvNZyNvKkd1PUjihCZQ8QeVJq00kYjmWUxbmThXmUbZAPryaKTxBbQ2l9cLaSFYZ7eOZYhy0b7RuPPrk0UykzwIHmnZ5xUYp6+tWcg7FIBS5ooAWigUEUgHDHeqGPIuio6NzWgo9araimYw4HMf60nYqEuWRLG3SrCE1Rtn3Rg96to1YNanfFllD7VIOmR19KgU1KhGRzUGhahbgZ6k1ci+bIIwC2T7is+NvmHHvxVyFxg5OSBkfT0rMDaimhFoYmUi5dwrSZ42jpx/Wr1tMsjRuTsHmE/TA5JrChyrPnI2xg5/vDsK1l/dRwkA7kxGeMjdjP65rRMhqxs2hM08eX2OxZwx55BGcfUVpQ4ZJSFRoV80lsfxEZU/pWNGzLLIyHIhRRHgdGByAfzNb1qkcMIPBdWyc8AArkr/MZrRMyexbhlLskSEyMLc4kz97JBIHv2q7sicAKM26yKCgYYGfvD+VU7Xy5FikTzQQyFcnARn421Z02IARQuN0ZndZFzhRjp+vNaIzZP++JuBu5ebyyzHAK8E49AMVdj2yiRI4uVQGMj5tqZweT3qpbsrRSyTFvmAj3Y+8Cwy3PfjFXBiWR4GYqzQ5y/90HK49KoATCzx2crSSNswFQ9cDg/rUgCyO2CQViRXJOQ3JyeOtR71d/OLmQMgiAjTHBONw9amGLd9zsxiiDQndweBkcDjqRQkIVA5ttkLPJvddqhBtII7Z+lTGONjMBiKMfOA789OVHvUCQzYiaIsApPyseAQMt/OliUkwzyBo2YluOWcf0p2AHZLhxIyyxF2VNynJxt6fpRGswijReC534duCRzkfhU5UtPMpZSDLwfukEjhs/0qLyfNiCrGd3Ijz1kYcN9KVguRTMjtPIPM35yyg8fjVmKVGll8wMyyKFHYA9M4qj8nmBUGOAxIJyABgr71PAw8pA20vEjfe5zg8j68UgJgHkUhlUSRqNgc4JYE9fU4qxA3mOVDKqTAhkbg/KP61Asq4851Ds7gEuOBkcH644qVFW5JCsu6eUYHQbR3+lUA2KdZUE6h1ljwGduSB04HpUkRRLllwEDsSGBJ2EDk++agCLJ9qlEbhwxUkHOPb6VZZYYbmCGJmZGD/d6oSuetBIhjV0jhOAfM+YYOCAc0Z/d+bwAgcP5n8XotSqwltV2qdjZBM/Bkxxu9BTZlhW4ycSiXG0cooxx8x9KYC2ys9tCUd0BTe5PJ68e+O1JNGJLVdqoiBchWJG9u5/Cmw7vs5dAY5owSpUcHn1PXHpVosIZAsYEkcgLEHkE9wD70CK9xja0jRsG3DeC2VXHf6c9aidQtwIYlSFHAk+YkKrD0J4IqfYI3uUICtuBEeM7lxkqKhdtuybZviMhGzHCgjjAoGMLuU89oxGckHbyMYwTj0NSkJLI4UDDrkgjODjt9KSJY2JRBmN1xhf4T7g1GylAzPIUZCFjcfdDDsQPWgCKQrNtIOJUQ4PXzTn/AA/lT5HzLGxcpNvw0i8ArjAye4zUhVXgQsGKjeVAzlDjkVHEDiWOaQbXhB6kLz0wexzQNCOA/nbnh8xWVmQDG7B5xn1oVQGaIoIFcMiFzu564PqOeKkYbnVnfKsFOSuSjDggnvx3pqI0Sq7fvQjgFex7ZB79qB3K8MjbYJMILpJvKIBxuAGMNS+U+x4ypj2O3ltgAByPu+uMU+eBzMMNGY3JDnaflZeQ2euaWZd7GKaPbvId2Zs+UR0b3B4pWC5DGu45IjTLG3ZT02n29ahuVZIyxASJyIkI5I9V9c96dJtxIskieacTF9pGCCM4prszfdEhmLhgTwsjA9fY80mBUmcpmWUch9u3or7eufTIpwlMBLIR5sE4IZuAynHB9cA0s8g23DOT5c0gjdXIKhu5B74qLLrBHvdSVkZVl25wuO47g9KAFkKxhm8tVPmLIEJwoLcce1M2kT+WxXkEoWGPmB5FDKqC5RV+TChPmzgkfyOakmRGkKKhEU2M7SDtcZyB6GgCLa0ryE8SSrujbHIcDofcioQ7SpIYmyxHnAMMMhU8giprncI7hfMaSMgIrL97hQVJHf09aRnCXKSSMVLp8sqk43AdM+h5FIZSZkMcgUkx/NIqg8HoevYiorgxSTO6/JDchNrL/EQCcEdj2NTn5VheQcRtsnwMjGMngex/Sq4VY47ZiVKLMdjg8MpJ6n6UAM3kTQyw5aQfPtHG6PHUD1zxUKpHcwoySEhBtJ6FQSSAfXoafAzxBAxCSIDFHvGRvznn2wabKnkxW8qKSYXaIp0Jbrtb174pIZJbX02nXSzsI2jul8uZXG6N8fdyPfiorO9ns7pZUJjmCM2VwcFR0Htg4rV0izhu4doUzRjb5SO20M7EhUJ9M85/CnRXpub6W1kjsJWCtJFF5GwSlRiRUYDI6EgmgLmXqeoSaleGe6hWGV0CtsHTgA4/HBA96KZqSJYPP5UgltZYo3gZzhmUg/KT2Ycc+1FFyrHhIp600U5a0OMWlFHalWgBfp2ooooAduzj2ocbxtP3TxTRUg7UrB1MyAmOVkY9DxV+M8c1Qu/+P4f7oq2vQfWspo7ab0LSEYqZKqpViLv9KyN0TqQCBnjrUynJJI9BVZeo/wB2rA6N9RWchmnbEsxBwW3AD8q0LR8KC7Hbhix9+itWVF91v97+laX/AC6yf7p/kKaJaNkyvPLMcgNtQAA9X4GTWsGzb3PnsxhaRULAdAow2ffkVixcancAcDyYz+PFbMX/AB8zjsbZiR6nI5raOxk9zTtNwS0aRMYHlN7EEEMfXg1opIymBiVBjn+ZFQ84GM+/Hesi1JNzPk5/0Unn/dFaWT5EXJ/48o/5mriZvcvXTn7JLEy7nhxJuc5wpOBj8KnTfFeszlVjUIZSwJ3IR2H4VXtyf7Pbn/l1H/oVWrH5r7LcnbjJ/GqIZJLGqRYUOQ6r5QP8OTuGfTipUeS4jIKORMGwH5BzyMenFV7Ak2Vtk55j/wDQmq1bE/YrXk/eH8zVdRCJIDukXIY5+ZySQR9PXBqa1DSWpQNvIxGgJOQRyPwOf0ogA+0XBwMgyYqvAT/Z7tk7t8XP/ATTAtFVDwqbhhG53yhV6SVGkaq0JmZh8zYQtkg9A1WXAFhpxAwTAST+IqnNza3ZPJ2L/wChUCRXu0jWOMFsEKdqg9Hz3Pv7VYsopHWdFIG35gAeST159Kbd8ySZ5w3HtwKu2fEs57iRMH04FQlqUyKWNXSJlV9oCo8hwAGGcVMySzuUH7uRZNikDaA3BwT2yPSmaiSbU5JPz9/rTXYiFQCQDGDj39asRbyk1wWUAwSgoRIduPbJ659ahaF/tkqk7jblWVsdCOg4+uKnlVXsLIOAw2t1Gf4TViMAX2m4AGVOff5RRYChvcwjY8ZNwhKpnG3nnrT2/wBbAYYiwY4MbnOCBlj/APWpbIA2umkjJ/edf96lhJF5bEHBMz5I70APssKx3KVaYMVk9Rk846Z7U1wfIdXGCi7QuOq54IHrUlsA1pGGAIEz4z24NQQsTYkkkkOB+opiJZMCN5jlkjlBwcsycAZ+hqJ0QmVVAezDKytnlc/4GlvyU1CQIduXTOOM1HccXjAcD7QOKkaIo91w6rMRkEssgO0rjgZ9qeFzAsqxlnRtkhz3znFNj5WHPcMD/wB9VLphP9sKMnBc5H/AhTAkk/dXKz2yl1fn5TwwAzj60zaFaORA0iyocgr8qrngGp4wAkeB/wAtGqGFmQbUYqDOQQDjjbQBGFKQoEk5/wBZG7ZGP9k/yzTZwFeT70e9A6Kp+UMD60kZJ00ZJOFYDP1qG7VWV9yg4iyMjpzQBafbJPsZVZZ1EuVBO5l6jA9elVBuLiSMgsyuo3jd5qdlPuDxUz/Lqny8Yj4x24p0IBjsMgfeloAqSIyo5kR8QOqFGH3M4DZ9RUDZYSop43kpKwzh1PAz2+tXnJNpdknJMbEn8qrXPEWpgcDaDj34pDRBjalu+2NIpGUSKDnbIOSce9VHUxQ5O7ch3I4G5SQ/IxWhfACe9AAA8sH8cVUBP9ozLn5cocds5FIZDLtie4aMbZMLIFH8S55A/H8qQ5jnhKKDIJS20NgBzyFP1HQ1Tsv9RcewfHt81XnAD6Uw4LeWWPrx3pARQrgxxwPvSZ92x8/eXJP+FMA862VBjEqNIjY4V8fMD+H61PJxaWxHBE+AfTLHNMhGNVjA4B38D8KYELl5TaSxNlpmCZJ4cBMYbHftmqbMFsXkEWfLxHJGeVyG4Ptnp+FWtU+UyhflAaXAHH8AqSQD7fcDHBtEJHqcigZnXAMJlj3B7dyEVlP3WYZ3Z/IUyNsFi5kHmHOGGdskfXH1GTSXfEJA6faF/wDRYqVCTqEmT/GtSMn0G4Nr50EshjQsskU3DeXIPmHHdW5rRcRpM1yItNhG4st0twZPL3cPsTqDzj2zXO2n/ILJ7iNSP+/hqbUQBAcADMrdPeOmgsVdVdb2W6YAJbEiJEIyQsYwpb0Yd/Y0Un8DnuZUz+KHNFTYd7H/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3701=[""].join("\n");
var outline_f3_39_3701=null;
var title_f3_39_3702="Fenoprofen: Patient drug information";
var content_f3_39_3702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fenoprofen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/52/27464?source=see_link\">",
"     see \"Fenoprofen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nalfon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nalfon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, swelling, and fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702110",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fenoprofen, aspirin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have poor kidney function.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12467 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3702=[""].join("\n");
var outline_f3_39_3702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170444\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170445\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029739\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029741\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029740\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029745\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029746\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029748\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029743\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029744\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029749\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029750\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/52/27464?source=related_link\">",
"      Fenoprofen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_39_3703="The role of Epstein-Barr virus in Hodgkin lymphoma";
var content_f3_39_3703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The role of Epstein-Barr virus in Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3703/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3703/contributors\">",
"     Richard F Ambinder, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3703/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3703/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3703/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3703/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/39/3703/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL), formerly called Hodgkin's disease, is a neoplasm that arises from germinal center or post-germinal center B cells. HL has a unique cellular composition, containing a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. It is separated from the other B cell lymphomas based on its unique clinicopathologic features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epstein-Barr virus (EBV) is a ubiquitous herpesvirus, which is spread by intimate contact between susceptible persons and asymptomatic EBV shedders. The majority of primary EBV infections throughout the world are subclinical. Antibodies to EBV have been demonstrated in all population groups with a worldwide distribution; approximately 90 to 95 percent of adults are EBV-seropositive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathobiology of HL remains poorly understood. The role of EBV infection in the development of HL will be reviewed here. Further details on the pathogenesis of HL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS SUGGESTING AN ASSOCIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early epidemiologic data suggested that HL develops among persons with a delayed exposure to a ubiquitous infectious agent, Epstein-Barr virus (EBV). The following sections will review data suggesting an association between EBV and HL. Mechanisms thought to be involved in the development of EBV-negative HL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Association with infectious mononucleosis and EBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial epidemiologic studies that demonstrated an increased risk of HL in patients with a history of infectious mononucleosis were further substantiated by case control studies showing that patients with HL had elevated antibody titers against EBV antigens, which preceded the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Subsequent studies showed that EBV could be detected in the tumor cells of a subset of patients with HL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. Finally, in a population-based cohort study of young adults with infectious mononucleosis in Denmark and Sweden, the risk of developing EBV-negative HL after infectious mononucleosis was not increased (relative risk 1.5, 95% CI 0.9-2.5), whereas the risk of developing EBV-positive HL was increased (relative risk 4.0, 95% CI 3.4-4.5), with a median incubation time from mononucleosis to EBV-positive HL of 4.1 years (95% CI 1.8-8.3 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/9\">",
"     9",
"    </a>",
"    ]. In this population, the absolute risk of developing Hodgkin lymphoma after infectious mononucleosis was approximately 1 in 1000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased incidence of HL is observed in immunosuppressed populations, including iatrogenic immune deficiency following solid organ or bone marrow transplantation or the treatment of autoimmune disease, and HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. HL in these populations is almost universally EBV-associated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and the HL is usually of the MC subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/11,12,16-19\">",
"     11,12,16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peak incidence of HL is four or more years after transplantation, in contrast to non-Hodgkin lymphoma, which most commonly occurs in the first year after transplantation. In HIV infected patients, the CD4 T-cell count is typically much higher than in other EBV-associated lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506291#H1560506291\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clustering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the suspicion that HL results from exposure to an infectious agent, reports of case clustering have generated great interest. Clustering refers to the occurrence of cases close together in time and place at the time of diagnosis and is characteristic of infectious agents. Apparent clusters of HL have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], but not substantiated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8227303\">",
"    <span class=\"h2\">",
"     Association with genetic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the many healthy adults that have a population of B lymphocytes with persistent EBV infection, a very small minority will develop EBV-positive HL. Several studies have suggested that patients with certain major histocompatibility complex (MHC) region variations are at higher risk of progressing to EBV-positive or EBV-negative classical HL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genome-wide association study (GWAS) evaluated the association of common genetic variants with all cases of classical HL, with EBV-negative classical HL, and with EBV-positive classical HL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/26\">",
"     26",
"    </a>",
"    ]. This study identified two MHC variants that were independently associated with both EBV-negative and EBV-positive HL, two MHC variants that were independently associated with EBV-positive classical HL, and two MHC variants that were independently associated with EBV-negative classical HL.",
"   </p>",
"   <p>",
"    These results support the theory that persons with variations at certain MHC loci are at increased risk of developing HL. The association of some variants with EBV status suggests that there are both common mechanisms and disparate mechanisms of HL pathogenesis in EBV-negative and EBV-positive HL. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROPOSED MECHANISMS FOR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathobiology of HL is a complex process leading to the replication of a malignant clone of cells of B lineage. As described above, EBV is present in tumor cells in a substantial fraction of HL cases. Other factors in the development of HL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incidence of EBV positivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemistry and in situ hybridization can be used to evaluate formalin fixed paraffin embedded diagnostic tumor specimens for the presence of Epstein-Barr virus (EBV) in tumor cells. Using these techniques, the rate of EBV positivity varies by geography, ethnicity, histologic subtype, and age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nucleic acids and proteins from EBV are detected in the malignant cells of 25 to 50 percent of cases of classical HL in North American and European reports and in a higher percentage in other parts of the world [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/4-7,27,28\">",
"       4-7,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      EBV is most commonly associated with the mixed cellularity and lymphocyte depleted HL subtypes, and less frequently with nodular sclerosis HL. In North America and Europe, EBV positivity has been noted in over 50 percent of mixed cellularity cases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/6,29-31\">",
"       6,29-31",
"      </a>",
"      ] and 10 to 50 percent of nodular sclerosis cases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In North America, EBV is more commonly detected in HL among Hispanics. Nodular lymphocyte predominant HL is virtually always EBV-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"       \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with HL have a different serologic profile of antibodies to the major EBV-associated antigens than do healthy controls. They have elevated titers against the viral capsid antigen (VCA) and early antigen D, indicating viral activation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/1\">",
"     1",
"    </a>",
"    ]. In at least two cohort studies, elevated titers of these antibodies preceded the diagnosis of HL; elevated antibody titers, but not EBV seropositivity alone, predicted for the subsequent development of HL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Timing of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In EBV-associated cases, EBV infection appears to occur early in the development of HL. EBV DNA that is detected in Reed-Sternberg cells is clonal, indicating that the virus-infected population arose from a single infected cell [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/4,6,8,28,30,36,37\">",
"     4,6,8,28,30,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Expression of latent membrane proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV infected tumor cells express a subset of EBV genes including latent membrane protein 1 (LMP1), LMP2a, EBV nuclear antigen 1 (EBNA1), the BamHI A region transcripts, and EBV small nuclear RNA transcripts (EBER) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/5,6,30,34,38-43\">",
"     5,6,30,34,38-43",
"    </a>",
"    ]. EBER and LMP1 are the two EBV markers most commonly used in epidemiologic studies in HL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link&amp;anchor=H10#H10\">",
"     \"Virology of Epstein-Barr virus\", section on 'Transformation and latent proteins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Research has focused on the potential pathogenic role of those EBV proteins known to be expressed in the tumor cells. EBNA1 expression is required for the replication and maintenance of the viral genome in proliferating cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/45\">",
"     45",
"    </a>",
"    ]. An additional role for EBNA1 in the pathogenesis of HL has not been determined. However, LMP1 and LMP2a appear to play a role in the development of at least a subset of HL cases. Reed-Sternberg cells sometimes harbor crippling mutations in their immunoglobulin (Ig) genes. B cells that lack functional Ig would be expected to die by apoptotic mechanisms. Expression of LMP1 or LMP2a may help these cells escape apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     LMP1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latent membrane protein 1 (LMP1) encodes a transmembrane protein that resembles the tumor necrosis factor receptor CD40 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/47\">",
"     47",
"    </a>",
"    ]. In germinal centers, apoptosis of B cells can be delayed by signaling through CD40 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/48\">",
"     48",
"    </a>",
"    ]. LMP-1 can function like a constitutively activated CD40 molecule, providing a mechanism by which the expression of EBV genes could facilitate the escape of Reed-Sternberg cells, or their precursors, from destruction in the germinal centers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for this theory comes from animal data demonstrating the induction of B cell lymphomas in transgenic mice with constitutive expression of LMP-1 their B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, HL tumor cell lines have shown that LMP-1 activates nuclear factor kappa B (NF-kB) by promoting IkBa turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/51\">",
"     51",
"    </a>",
"    ]. The constitutive activation of NF-KB has been linked to the growth and survival of classical Reed-Sternberg cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link&amp;anchor=H5#H5\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\", section on 'Activation of nuclear factor kappa B'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     LMP2a",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latent membrane protein 2a (LMP2a) is an integral membrane protein that co-localizes with LMP1 in the plasma membrane of EBV-infected lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/52\">",
"     52",
"    </a>",
"    ]. LMP2a contains an immunoreceptor tyrosine based activation motif that resembles motifs carried by immunoglobulin molecules. Expression of LMP2a on the cellular membrane produces a constitutive signal that prevents apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LMP2A has been shown to prevent apoptosis of pre-B cells that fail to express Ig molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/53\">",
"     53",
"    </a>",
"    ]. While not all EBV positive HL tumors express LMP2a, all reported tumors that contain IgV gene mutations preventing the expression of BCR have been EBV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/54\">",
"     54",
"    </a>",
"    ]. In such tumors, LMP2a expression can rescue cells from the programmed cell death (apoptosis) normally associated with BCR loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3703/abstract/52,55,56\">",
"     52,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathobiology of Hodgkin lymphoma (HL) is a complex process leading to the replication of a malignant B cell clone of germinal center or post-germinal center origin. While some steps in this pathway have been elucidated, many remain unknown. Epstein-Barr virus (EBV) may play a role in the pathobiology of a significant fraction of HL cases. Other mechanisms have been proposed for EBV-negative tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial epidemiologic data suggested that HL develops among persons with a delayed exposure to an environmental or infectious agent. These and subsequent studies proposed EBV as the most likely inducing agent in a significant fraction of cases. EBV infection is associated with an increased risk of EBV-positive, but not EBV-negative HL. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Factors suggesting an association'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of EBV positivity among HL tumors varies by geography, patient ethnicity, histologic subtype, and age. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Incidence of EBV positivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EBV infected tumor cells express a subset of EBV genes including latent membrane protein 1 (LMP1), LMP2a, and EBV nuclear antigen 1 (EBNA1). EBNA1 expression is required for the replication and maintenance of the viral genome in proliferating cells, but a role in the pathogenesis of HL has not been determined. However, LMP1 and LMP2a appear to play a role in the development of at least a subset of HL cases by helping such tumors escape programmed cell death (apoptosis). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Expression of latent membrane proteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LMP1 produces a tonic survival signal, perhaps through the activation of nuclear factor kappa B (NF-kB). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'LMP1'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link&amp;anchor=H5#H5\">",
"       \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\", section on 'Activation of nuclear factor kappa B'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LMP2a is an integral membrane protein that contains motifs that resemble those of immunoglobulin molecules. Expression of LMP2a has been shown to prevent apoptosis of pre-B cells that fail to express Ig molecules. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'LMP2a'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/1\">",
"      Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989; 320:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/2\">",
"      Lehtinen T, Lumio J, Dillner J, et al. Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study. Cancer Causes Control 1993; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/3\">",
"      Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 2000; 82:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/4\">",
"      Staal SP, Ambinder R, Beschorner WE, et al. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease. Am J Clin Pathol 1989; 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/5\">",
"      Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 1990; 46:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/6\">",
"      Ambinder RF, Browning PJ, Lorenzana I, et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood 1993; 81:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/7\">",
"      Chang KL, Alb&uacute;jar PF, Chen YY, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993; 81:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/8\">",
"      Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989; 320:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/9\">",
"      Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/10\">",
"      Goedert JJ, Cot&eacute; TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/11\">",
"      Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin's disease after transplantation. Transplantation 1996; 61:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/12\">",
"      Tinguely M, Vonlanthen R, M&uuml;ller E, et al. Hodgkin's disease-like lymphoproliferative disorders in patients with different underlying immunodeficiency states. Mod Pathol 1998; 11:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/13\">",
"      Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 2003; 98:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/14\">",
"      Siebert JD, Ambinder RF, Napoli VM, et al. Human immunodeficiency virus-associated Hodgkin's disease contains latent, not replicative, Epstein-Barr virus. Hum Pathol 1995; 26:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/15\">",
"      Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999; 93:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/16\">",
"      Levine AM. HIV-associated Hodgkin's disease. Biologic and clinical aspects. Hematol Oncol Clin North Am 1996; 10:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/17\">",
"      Herndier BG, Sanchez HC, Chang KL, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Am J Pathol 1993; 142:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/18\">",
"      Audouin J, Diebold J, Pallesen G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. J Pathol 1992; 167:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/19\">",
"      Pelstring RJ, Zellmer RB, Sulak LE, et al. Hodgkin's disease in association with human immunodeficiency virus infection. Pathologic and immunologic features. Cancer 1991; 67:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/20\">",
"      Vianna NJ, Greenwald P, Brady J, et al. Hodgkin's disease: cases with features of a community outbreak. Ann Intern Med 1972; 77:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/21\">",
"      Vianna NJ, Polan AK. Epidemiologic evidence for transmission of Hodgkin's disease. N Engl J Med 1973; 289:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/22\">",
"      Grufferman S, Cole P, Levitan TR. Evidence against transmission of Hodgkin's disease in high schools. N Engl J Med 1979; 300:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/23\">",
"      Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 2005; 365:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/24\">",
"      Hjalgrim H, Rostgaard K, Johnson PC, et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci U S A 2010; 107:6400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/25\">",
"      Kennedy AE, Singh SK, Dorak MT. Re: genome-wide association study of classical hodgkin lymphoma and epstein-barr virus status-defined subgroups. J Natl Cancer Inst 2012; 104:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/26\">",
"      Urayama KY, Jarrett RF, Hjalgrim H, et al. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst 2012; 104:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/27\">",
"      Glaser SL, Keegan TH, Clarke CA, et al. Exposure to childhood infections and risk of Epstein-Barr virus--defined Hodgkin's lymphoma in women. Int J Cancer 2005; 115:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/28\">",
"      Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987; 129:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/29\">",
"      Hu E, Hufford S, Lukes R, et al. Third-World Hodgkin's disease at Los Angeles County-University of Southern California Medical Center. J Clin Oncol 1988; 6:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/30\">",
"      Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991; 337:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/31\">",
"      Gulley ML, Eagan PA, Quintanilla-Martinez L, et al. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood 1994; 83:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/32\">",
"      Carbone A, Gloghini A, Zanette I, et al. Co-expression of Epstein-Barr virus latent membrane protein and vimentin in \"aggressive\" histological subtypes of Hodgkin's disease. Virchows Arch A Pathol Anat Histopathol 1993; 422:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/33\">",
"      Murray PG, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol 1992; 166:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/34\">",
"      Weiss LM, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991; 139:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/35\">",
"      Uccini S, Monardo F, Stoppacciaro A, et al. High frequency of Epstein-Barr virus genome detection in Hodgkin's disease of HIV-positive patients. Int J Cancer 1990; 46:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/36\">",
"      Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989; 74:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/37\">",
"      Gledhill S, Gallagher A, Jones DB, et al. Viral involvement in Hodgkin's disease: detection of clonal type A Epstein-Barr virus genomes in tumour samples. Br J Cancer 1991; 64:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/38\">",
"      Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood 1992; 80:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/39\">",
"      Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993; 177:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/40\">",
"      Gr&auml;sser FA, Murray PG, Kremmer E, et al. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 1994; 84:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/41\">",
"      Niedobitek G, Kremmer E, Herbst H, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 1997; 90:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/42\">",
"      Young LS, Deacon EM, Rowe M, et al. Epstein-Barr virus latent genes in tumour cells of Hodgkin's disease. Lancet 1991; 337:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/43\">",
"      Murray PG, Constandinou CM, Crocker J, et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998; 92:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/44\">",
"      Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/45\">",
"      Gahn TA, Schildkraut CL. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 1989; 58:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/46\">",
"      Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/47\">",
"      Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998; 17:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/48\">",
"      MacLennan IC. Germinal centers. Annu Rev Immunol 1994; 12:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/49\">",
"      Jarrett RF, MacKenzie J. Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Semin Hematol 1999; 36:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/50\">",
"      Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A 1998; 95:11963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/51\">",
"      Sylla BS, Hung SC, Davidson DM, et al. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A 1998; 95:10106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/52\">",
"      Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007; 110:3715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/53\">",
"      Merchant M, Caldwell RG, Longnecker R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 2000; 74:9115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/54\">",
"      Br&auml;uninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/55\">",
"      Bechtel D, Kurth J, Unkel C, K&uuml;ppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 2005; 106:4345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3703/abstract/56\">",
"      Chaganti S, Bell AI, Pastor NB, et al. Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 2005; 106:4249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4701 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3703=[""].join("\n");
var outline_f3_39_3703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS SUGGESTING AN ASSOCIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Association with infectious mononucleosis and EBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clustering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8227303\">",
"      Association with genetic variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROPOSED MECHANISMS FOR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incidence of EBV positivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Timing of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Expression of latent membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - LMP1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - LMP2a",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=related_link\">",
"      The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_39_3704="Major side effects of beta blockers";
var content_f3_39_3704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major side effects of beta blockers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3704/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3704/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3704/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3704/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3704/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/39/3704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the major adverse effects of beta blocking drugs result from beta-adrenoreceptor blockade. Many signs and symptoms can therefore be induced because the beta receptors affect multiple metabolic and physiologic functions. Other reactions apparently unrelated to beta blockade can occur, but they are uncommon.",
"   </p>",
"   <p>",
"    The major side effects associated with the use of beta blockers will be reviewed here. Beta blocker intoxication (overdose) and the clinical use of these drugs for the treatment of arrhythmias, hypertension, myocardial infarction, and heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/19/33081?source=see_link\">",
"     \"Beta blocker poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H22#H22\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Beta blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADVERSE CARDIAC EFFECTS DUE TO BETA BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major cardiac effects caused by beta blockade include the precipitation or worsening of congestive heart failure, and significant negative chronotropy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the data about the importance of beta blockers as therapy for patients with chronic heart failure, beta blockers may exacerbate heart failure in patients with decompensated or precipitate heart failure in those with preexisting myocardial dysfunction and borderline compensation since the maintenance of cardiac output in such patients depends in part upon sympathetic drive. Increased peripheral vascular resistance, induced by nonselective beta blockers, also may contribute to the decline in myocardial function in this setting. On the other hand, drugs with intrinsic sympathetic activity (ISA), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    , may be less likely to impair myocardial function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these concerns, only a minority of patients with stable heart failure deteriorate after the initiation of beta blocker therapy. As an example, worsening of heart failure was observed in only 6 percent of patients with chronic heart failure who were being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, beta blockers are often beneficial in such patients, improving survival in patients with systolic heart failure and improving diastolic function in patients with diastolic heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another concern about beta blockers in patients with HF is the occurrence of other symptoms, including dizziness due to hypotension and bradycardia. One study that reviewed data from HF trials reported between 1966 and 2002 found that, although beta blockers were associated with these side effects, the absolute increase in symptoms was small and did not necessitate withdrawal of drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Negative chronotropic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slowing of the resting heart rate and the development of sinus bradycardia is a normal response to treatment with a beta blocker. This effect is less prominent with drugs with ISA. Nevertheless, all beta blockers are relatively contraindicated in patients with symptomatic bradycardia that may be associated with a sick sinus syndrome, especially if there is a further reduction in rate, unless an artificial pacemaker is present.",
"   </p>",
"   <p>",
"    Beta blockers also depress conduction through the atrioventricular node, potentially causing heart block. Use of a beta blocking drug can therefore lead to a serious bradyarrhythmia in patients with an underlying complete or partial AV conduction defect (ie, second or third degree AV block), especially if the patient is also receiving another agent that impairs AV nodal conduction such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or a calcium channel blocker. Compounds with ISA may cause less impairment of atrioventricular conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Beta blocker withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute withdrawal of a beta blocker can lead to substantial morbidity and even mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with underlying coronary disease may develop accelerated angina, myocardial infarction, or sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This can occur even in patients who have no previous history of coronary symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These withdrawal symptoms are due to increased sympathetic activity, which is a probable reflection of adrenergic receptor upregulation during the period of sympathetic blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/9\">",
"     9",
"    </a>",
"    ]. The degree to which this will occur depends upon the relationship between the rate at which beta blockade wears off and the rate at which the receptors downregulate (the latter has a half-life of 24 to 36 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, a hyperadrenergic state is most likely with short-acting drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ), since receptor upregulation will persist after the antihypertensive effect has disappeared [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. Gradual tapering of the propranolol dose will diminish the risk of withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/7\">",
"     7",
"    </a>",
"    ]. In comparison, withdrawal syndromes are relatively unusual with longer-acting agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We use the following approach in patients who must stop taking a beta blocker:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For beta blockers with shorter half lives which require twice daily administration (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , short acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ), we have patients take their usual dose once daily for one week, then every other day for one week, then stop the medication.",
"     </li>",
"     <li>",
"      For beta blockers with longer half lives that are administered once daily (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      , long acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      ), we have patient take one-half their usual dose once daily for one week, then one-half their usual dose every other day for a week, then stop the medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADVERSE NONCARDIAC EFFECTS DUE TO BETA BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs, peripheral blood vessels, glucose metabolism, and central nervous system are all affected by beta blockade although the clinical magnitude of the last three effects seems less pronounced that originally thought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased airways resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockade with nonselective agents prevents bronchodilation due to bronchial beta-2 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/11\">",
"     11",
"    </a>",
"    ]. This can lead to increased airways resistance in patients with bronchospastic disease, a problem that is less likely to occur with compounds with ISA or beta-1 selectivity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Beta-1 selectivity is not absolute, however, and may diminish at higher doses. It has also been suggested that combined beta and alpha blockade with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    may be better tolerated than nonselective agents in patients with chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All beta blockers should be avoided in patients with severe or decompensated bronchospastic disease; nonselective beta blockers should generally be avoided in susceptible patients with mild to moderate bronchospastic disease, while the selective beta blockers or possibly combined alpha and beta blockers appear to be safe and should be used with caution. Therapeutic doses of beta-1 selective beta blockers are generally well tolerated, although some patients who are using inhaled beta agonists may require an increase inhaler requirement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/16\">",
"     16",
"    </a>",
"    ]. This issue of beta blocker therapy in patients with chronic obstructive disease is discussed more fully elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17898?source=see_link&amp;anchor=H81297784#H81297784\">",
"     \"Management of the patient with severe COPD and cardiovascular disease\", section on 'Treatment of CVD in patients with COPD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exacerbation of peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies with nonselective beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ) in patients with severe peripheral artery disease described a variety of complications including worsening claudication, cold extremities, absent pulses, and, in some cases, cyanosis and impending gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/17\">",
"     17",
"    </a>",
"    ]. Raynaud's phenomenon can also be a manifestation of nonselective beta blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It was thought that both the reduction in cardiac output and blockade of beta-2-receptor-mediated skeletal muscle vasodilation contribute to the vascular insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/20\">",
"     20",
"    </a>",
"    ]. Beta blockers with beta-1 selectivity or ISA do not affect the peripheral vessels to the same degree as the nonselective drugs.",
"   </p>",
"   <p>",
"    A meta-analysis of published studies in patients with mild to moderate peripheral artery disease found no exacerbation of symptoms with beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the concern may be overstated, particularly in patients with mild to moderate disease treated with a beta-1 selective agent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/22\">",
"     22",
"    </a>",
"    ]. Although selective agents can also be used in patients with severe disease, they should be used cautiously [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Facilitation of hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epinephrine, acting via the beta-adrenergic receptors, has important effects on glucose metabolism. It increases glucose production by stimulating both glycogenolysis and gluconeogenesis from amino acids, glycerol, and pyruvate. It also increases the delivery of these gluconeogenic substrates from the periphery, inhibits glucose utilization by several tissues, and, via the alpha-2-receptors, inhibits insulin secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of these actions help to protect against the development of hypoglycemia. In addition, epinephrine induces early warning symptoms of neuroglycopenia, such as sweating and anxiety.",
"   </p>",
"   <p>",
"    Studies published in the 1960s showed that nonselective beta blockers can retard recovery from insulin-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/24\">",
"     24",
"    </a>",
"    ] and that the reactions are more likely to be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The latter effect is presumably due to diminished or absent early warning signs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, later studies showed that the effects on glucose metabolism may be less prominent with beta-1 selective drugs and those with ISA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] and that an increased risk of serious hypoglycemia among patients with diabetes mellitus was hard to demonstrate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/30\">",
"     30",
"    </a>",
"    ]. Furthermore,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    appears to promote glucose utilization and lower insulin levels in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catecholamines have potentially important clinical effects on potassium balance, primarily by influencing the distribution of potassium between the extracellular fluid and the cells. In particular, stimulation of the &szlig;2-receptors by epinephrine promotes the movement of extracellular potassium into the cells, thereby lowering the plasma potassium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"     \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These effects on potassium balance can be reversed by &szlig;-adrenergic blockers, which will tend to impair potassium entry into the cells, thereby raising the plasma potassium concentration after a potassium load. This is most likely to occur with the nonselective &szlig;-blockers (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ); in contrast, the &szlig;1-selective agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    have little effect, since the &szlig;2 receptors remain intact [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the administration of &szlig;-blockers is associated with only a minor elevation in the plasma potassium concentration of less than 0.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    as the potassium that cannot enter the cells is excreted in the urine. True hyperkalemia is rare unless associated with a superimposed problem such as a marked potassium load, marked exercise (which is associated with the release of potassium from the cells into the extracellular fluid), hypoaldosteronism, or end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Hyperkalemia has also been reported in renal transplant recipients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Depression, fatigue, sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression, fatigue, and sexual dysfunction are commonly cited side effects of beta blockers, and may be one reason why use of beta blockers is lower than desired for some approved indications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/38\">",
"     38",
"    </a>",
"    ]. However, these associations are primarily based upon case series and randomized trials with methodologic flaws.",
"   </p>",
"   <p>",
"    The best available data on this issue come from a systematic review of randomized trials, which found no increased risk of depression with beta blocker therapy, and only small increases in fatigue and sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/39\">",
"     39",
"    </a>",
"    ]. The review included 15 randomized, placebo-controlled trials involving more than 35,000 patients who were followed for a minimum of six months. Both patient reported symptoms and withdrawal of therapy were investigated. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a small significant increase in risk of fatigue (18 per 1000 patients, 95% CI 5-30). This is equivalent to one additional report of fatigue for every 57 patients treated per year.",
"     </li>",
"     <li>",
"      There was a small significant increase in risk of sexual dysfunction (5 per 1000 patients, 95% CI 2-8). This is equivalent to one additional report of sexual dysfunction for every 199 patients treated per year.",
"     </li>",
"     <li>",
"      There was no significant annual increase in risk of reported depressive symptoms.",
"     </li>",
"     <li>",
"      It has been hypothesized that lipophilic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef82571 \" href=\"UTD.htm?14/26/14766\">",
"       table 1",
"      </a>",
"      ) are associated with a higher incidence of central nervous system effects such as fatigue and depression because of their ability to penetrate the central nervous system. However, lipid solubility of the beta blockers did not affect the risk of adverse effects in this review.",
"     </li>",
"     <li>",
"      In trials testing early generation beta blockers (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      ), the risk of fatigue, but not depression or sexual dysfunction, was higher (relative risk 1.78, 95% CI 1.08-2.93) when compared with later generation beta blockers. However, the number of trials was small and the confidence intervals were wide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One small study of 96 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    suggested that erectile dysfunction was possibly related to knowledge about this as a side effect and the anxiety provoked rather than as a direct consequence of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, among those who developed erectile dysfunction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and placebo were equally effective as therapy.",
"   </p>",
"   <p>",
"    Thus, although beta blockers appear to cause small increases in the risk of fatigue and sexual dysfunction, the risk is much lower than previously thought, and beta blockers should not be withheld based upon concerns about developing these adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23772956\">",
"    <span class=\"h2\">",
"     Lipid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers interfere with lipid metabolism and are associated with alteration of serum triglyceride and HDL-cholesterol concentrations. The effect varies based on the receptor selectivity and pharmacologic profile of each individual agent. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=see_link&amp;anchor=H4#H4\">",
"     \"Antihypertensive drugs and lipids\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of eight randomized trials of beta blockers versus placebo in hypertensive patients revealed a median increase in body weight in the beta blocker group of 1.2 kg (range -0.4 to 3.5 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Most of this weight gain occurred within the first few months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS UNRELATED TO BETA BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effects unrelated to beta blockade are drug interactions and severe toxicity. The latter condition is most commonly associated with suicide attempts and accidental overdosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined use of beta blockers and other agents can result in a number of adverse interactions (",
"    <a class=\"graphic graphic_table graphicRef77171 \" href=\"UTD.htm?30/8/30861\">",
"     table 2",
"    </a>",
"    ). Drugs which depress myocardial function or pacemaker activity, including calcium channel blockers and antiarrhythmic agents, are of particular concern when used in combination therapy with a beta blocker. These combinations are common in patients with ischemic heart disease and arrhythmias, who often have underlying abnormalities of myocardial function as well as depressed sinus and AV node activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antinuclear antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers have also been associated with the development of antinuclear antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/43\">",
"     43",
"    </a>",
"    ]. A cross-sectional study of 1500 hypertensive patients found a prevalence of antinuclear antibodies of more than 10 percent in those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/44\">",
"     44",
"    </a>",
"    ]. However, rheumatic symptoms (generally persistent arthralgias and myalgias) are infrequent. ANA titers and symptoms resolve after the cessation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempted suicide or accidental overdose with beta blockers can result in bradycardia, hypotension, low cardiac output, cardiac failure, and cardiogenic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3704/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Bronchospasm and respiratory depression may also occur due perhaps to severe circulatory impairment or a central drug effect. The myocardium in severe intoxications may become relatively refractory to pharmacologic and electrical stimulation, resulting in asystolic death. Changes in mental status, convulsions, and coma have also been described.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    intoxication differs from that seen with other beta blockers. In addition to hypotension and bradycardia, patients have significantly prolonged corrected QT intervals and severe ventricular tachyarrhythmias. Intoxicated patients should be managed with intensive supportive care in facilities equipped for continuous cardiac monitoring and ventilatory support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/19/33081?source=see_link\">",
"     \"Beta blocker poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       \"Patient information: Dealing with side effects from medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2813805\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    Major cardiac effects caused by beta blockade include the precipitation or worsening of congestive heart failure, and significant negative chronotropy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers may exacerbate heart failure (HF) in patients with decompensated HF. Beta blockers may also precipitate HF in those with preexisting myocardial dysfunction and borderline compensation since the maintenance of cardiac output in such patients depends in part upon sympathetic drive. Increased peripheral vascular resistance, induced by nonselective beta blockers, also may contribute to the decline in myocardial function in this setting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta blockers are relatively contraindicated in patients with symptomatic bradycardia that may be associated with a sick sinus syndrome, especially if there is a further reduction in rate. Beta blockers also depress conduction through the atrioventricular node, potentially leading to a serious bradyarrhythmia in patients with an underlying complete or partial AV conduction defect (ie, second or third degree AV block). This is especially true if the patient is also receiving another agent that impairs AV nodal conduction such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      or a calcium channel blocker. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Negative chronotropic effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute withdrawal of a beta blocker can lead to increased sympathetic activity (most likely with short-acting drugs). This hyperadrenergic state may lead to accelerated angina, myocardial infarction, or even sudden death. We use the following approach in patients who must stop taking a beta blocker: (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Beta blocker withdrawal'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For beta blockers with shorter half lives which require twice daily administration (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , short acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ), we have patients take their usual dose once daily for one week, then every other day for one week, then stop the medication.",
"     </li>",
"     <li>",
"      For beta blockers with longer half lives that are administered once daily (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      , long acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      ), we have patient take one-half their usual dose once daily for one week, then one-half their usual dose every other day for a week, then stop the medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While beta blockers have many noncardiac effects, their effects on the lungs, energy levels, and sexual function are the most common and significant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockade with nonselective agents prevents bronchodilation due to bronchial beta-2 receptors, leading to increased airway resistance in patients with bronchospastic disease. While therapeutic doses of beta-1 selective beta blockers are generally well tolerated and can be safely used in most patients, the risks and benefits should be considered prior to initiating treatment in patients with severe or decompensated bronchospastic airway disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Increased airways resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression, fatigue, and sexual dysfunction are commonly cited side effects of beta blockers. However, a systematic review of randomized trials found no increased risk of depression with beta blocker therapy, and only small increases in fatigue and sexual dysfunction. As such, while the occasional patient may need to discontinue a beta blocker because of one of these side effects, beta blockers should not be initially withheld based upon concerns about developing these adverse effects. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Depression, fatigue, sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/1\">",
"      Taylor SH, Silke B, Lee PS. Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful? N Engl J Med 1982; 306:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/2\">",
"      Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/3\">",
"      Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 2004; 164:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/4\">",
"      Frishman WH. Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med 1983; 308:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/5\">",
"      Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 1981; 102:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/6\">",
"      Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975; 293:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/7\">",
"      Rangno RE, Nattel S, Lutterodt A. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule. Am J Cardiol 1982; 49:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/8\">",
"      Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/9\">",
"      Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 1984; 310:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/10\">",
"      Krukemyer JJ, Boudoulas H, Binkley PF, Lima JJ. Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences. Am Heart J 1990; 120:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/11\">",
"      Dunlop D, Shanks RG. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother 1968; 32:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/12\">",
"      Beumer HM, Hardonk HJ. Effects of beta-adrenergic blocking drugs on ventilatory function in asthmatics. Eur J Clin Pharmacol 1972; 5:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/13\">",
"      Singh BN, Whitlock RM, Comber RH, et al. Effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther 1976; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/14\">",
"      Skinner C, Gaddie J, Palmer KN. Comparison of effects of metoprolol and propranolol on asthmatic airway obstruction. Br Med J 1976; 1:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/15\">",
"      Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/16\">",
"      Khosia S, Kunjummen B, Khaleel R, et al. Safety of therapeutic beta-blockade in patients with coexisting bronchospastic airway disease and coronary artery disease. Am J Ther 2003; 20:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/17\">",
"      Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy. JAMA 1969; 208:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/18\">",
"      Simpson FO. Beta-adrenergic receptor blocking drugs in hypertension. Drugs 1974; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/19\">",
"      Zacharias FJ, Cowen KJ, Prestt J, et al. Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J 1972; 83:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/20\">",
"      Lundvall J, J&auml;rhult J. Beta adrenergic dilator component of the sympathetic vascular response in skeletal muscle. Influence on the micro-circulation and on transcapillary exchange. Acta Physiol Scand 1976; 96:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/21\">",
"      Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/22\">",
"      Thadani U, Whitsett TL. Beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med 1991; 151:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/23\">",
"      Heintzen MP, Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J 1994; 15 Suppl C:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/24\">",
"      Antonis A, Clark ML, Hodge RL, et al. Receptor mechanisms in the hyperglycaemic response to adrenaline in man. Lancet 1967; 1:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/25\">",
"      Abramson EA, Arky RA, Woeber KA. Effects of propranolol on the hormonal and metabolic responses to insulin-induced hypoglycaemia. Lancet 1966; 2:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/26\">",
"      Reveno WS, Rosenbaum H. Propranolol and hypoglycaemia. Lancet 1968; 1:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/27\">",
"      Lloyd-Mostyn RH, Oram S. Modification by propranolol of cardiovascular effects of induced hypoglycaemia. Lancet 1975; 1:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/28\">",
"      Hirsch IB, Boyle PJ, Craft S, Cryer PE. Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes 1991; 40:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/29\">",
"      Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. Br Med J 1976; 2:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/30\">",
"      Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/31\">",
"      Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/32\">",
"      Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokalemia: the role of beta adrenoceptors. Am J Cardiol 1986; 57:23F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/33\">",
"      Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/34\">",
"      Lim M, Linton RA, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 2:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/35\">",
"      Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol 1990; 33:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/36\">",
"      Nowicki M, Miszczak-Kuban J. Nonselective Beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 2002; 91:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/37\">",
"      McCauley J, Murray J, Jordan M, et al. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol 2002; 22:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/38\">",
"      Gheorghiade M, Eichhorn EJ. Practical aspects of using beta-adrenergic blockade in systolic heart failure. Am J Med 2001; 110 Suppl 7A:68S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/39\">",
"      Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/40\">",
"      Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/41\">",
"      Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 2001; 37:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/42\">",
"      Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007; 100:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/43\">",
"      Stephen SA. Unwanted effects of propranolol. Am J Cardiol 1966; 18:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/44\">",
"      Booth RJ, Wilson JD, Bullock JY. Beta-adrenergic-receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther 1982; 31:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/45\">",
"      Self-poisoning with beta-blockers. Br Med J 1978; 1:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3704/abstract/46\">",
"      Frishman W, Jacob H, Eisenberg E, Ribner H. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J 1979; 98:798.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 967 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3704=[""].join("\n");
var outline_f3_39_3704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2813805\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADVERSE CARDIAC EFFECTS DUE TO BETA BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Negative chronotropic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Beta blocker withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADVERSE NONCARDIAC EFFECTS DUE TO BETA BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased airways resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exacerbation of peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Facilitation of hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Depression, fatigue, sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23772956\">",
"      Lipid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADVERSE EFFECTS UNRELATED TO BETA BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2813805\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/967\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/967|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/26/14766\" title=\"table 1\">",
"      Properties beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/8/30861\" title=\"table 2\">",
"      Beta blockers drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=related_link\">",
"      Antihypertensive drugs and lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/19/33081?source=related_link\">",
"      Beta blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17898?source=related_link\">",
"      Management of the patient with severe COPD and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_39_3705="Food allergy in schools and camps";
var content_f3_39_3705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Food allergy in schools and camps",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3705/contributors\">",
"     Anne Munoz-Furlong, BA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3705/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3705/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3705/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/39/3705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food allergy is estimated to affect 1 in 25 children, and is an emerging public health issue in the United States and other westernized countries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. There are currently an estimated three million children with food allergies in the United States alone. The impact of this disorder is felt in daycare, preschool, school, and camp settings &mdash; environments that are integral to a child's life [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common food allergies in childhood are milk, eggs, peanuts, tree nuts, wheat, and soy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/2\">",
"     2",
"    </a>",
"    ]. Peanut allergy is of particular concern in the United States because it is implicated in fatal reactions more than any other food [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, many foods can cause life-threatening allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of food allergy appears to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. It is therefore crucial for medical professionals to understand the challenge that this disorder presents. The avoidance strategies in place to keep a food-allergic child safe will often impact the entire classroom of children, particularly in the younger age groups. Many schools have chosen to designate classrooms as food- or peanut-free. Others place restrictions on food brought in for birthday parties or implement bans on peanut products brought in by other children.",
"   </p>",
"   <p>",
"    This topic review will present an overview of the prevalence of food allergy in school-aged children, provide data about food allergic reactions in schools, camps, and similar environments, and discuss strategies for managing food allergy in these settings.",
"   </p>",
"   <p>",
"    The information in this review provides an overview of the components of effective management of food allergy in schools and camps. Various detailed publications and educational programs are available that provide further resources, such as additional forms, letters, training instructions, and examples of policies enacted by schools and daycare centers. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other aspects of food allergy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safe management of food allergies in school and camp settings has become a prominent issue for many families and communities. The following observations about food allergy are especially relevant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of food allergy in children appears to be increasing. An American study conducted in 1997 and repeated in 2002 reported that the prevalence of peanut and tree nut allergies had doubled in children during that five-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/7\">",
"       7",
"      </a>",
"      ]. In a survey of 400 elementary school nurses, 44 percent reported an increase in children with food allergies in their schools over the last five years; only 2 percent reported a decrease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/8\">",
"       8",
"      </a>",
"      ]. More than one-third of the nurses reported having 10 or more students with food allergies. The school nurses ranked the challenge of managing food allergies on par with other serious health concerns, such as diabetes.",
"     </li>",
"     <li>",
"      Sending a food allergic child to daycare or school can be terrifying to parents. They must trust that others will be vigilant in helping their child avoid contact with the problematic food, despite the realization that it is difficult to supervise or be aware of moment-to moment activities of any group of children. In addition, the widespread misunderstanding of food allergy among the general population generates both resentment from other parents and fear and confusion on the part of staff members.",
"     </li>",
"     <li>",
"      Food is ubiquitous in most schools. In addition to the food served in the cafeteria, there are snacks in classrooms and on the playground. Food items are used for classroom activities, such as art projects, cooking lessons, and math instruction. Examples include craft projects, such as rolling pine cones in peanut butter to make bird feeders, using empty milk containers to create cities, using candy as counting items in math class, or using peanuts in science class. In addition, school supplies may contain hidden allergens: modeling clay can contain wheat, and egg white may be used to smooth finger paints. Holiday celebrations, birthday parties, and other special events traditionally involve food items prepared at home by the caregivers of non-food-allergic children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"       \"Management of food allergy: Avoidance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Characteristics of reactions in schools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insight into the nature of food allergic reactions in schools has been provided by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/2,3,9,10\">",
"     2,3,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although allergic reactions induced by food in schools are not rare, preparation for managing them is usually inadequate [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/2,11,12\">",
"       2,11,12",
"      </a>",
"      ]. In a telephone survey of 80 schools and the parents of 132 food-allergic children, 39 percent of schools reported at least one food-allergic reaction during the prior two years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/2\">",
"       2",
"      </a>",
"      ]. In the same period, 58 percent of food-allergic students experienced a reaction at school, and of those, 30 percent did not have clinician's instructions or medication available at school at the time of their reaction. Preparation for management of food allergic reactions in schools may differ by socioeconomic status [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Milk and peanut are leading causes of school reactions in the United States. In one study, milk was reported to be the most common cause of allergic reactions in the preschool setting, and peanut, the leading cause in children in the kindergarten through high-school years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Food allergic reactions may take place anywhere there are students. A review of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      use in Massachusetts schools over a two-year period (2001 to 2003) reported 115 administrations of epinephrine [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/9\">",
"       9",
"      </a>",
"      ]. In 20 percent of these cases, the allergic reaction occurred outside the school building: on the playground, traveling to and from school, and on field trips.",
"     </li>",
"     <li>",
"      A significant percentage of children were not known to have food allergy upon entering school and had their initial food-allergic reaction at school. Two studies found that 25 percent of the food-allergy reactions in the schools were initial reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/3,9\">",
"       3,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Special event and craft foods are particularly problematic. A study of peanut and tree nut reactions in the school setting showed that the majority of the reactions occurred in the classroom (79 percent), principally from food brought in for class projects or celebrations [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fatal food reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut is the food most often implicated in fatal reactions, although tree nuts, milk, and fish have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/6,15\">",
"     6,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 32 fatal food-allergy induced reactions, four (13 percent) occurred in a school or child care setting [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/6\">",
"       6",
"      </a>",
"      ]. In another study of 31 fatalities, 10 percent were associated with school settings [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 13 fatal or near-fatal food allergy-induced reactions in children, four of the six fatal reactions occurred at school [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    should be administered by intramuscular injection as soon as possible in the setting of anaphylaxis. Delayed administration of epinephrine is believed to be a contributing factor in some fatal reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/15\">",
"     15",
"    </a>",
"    ]. In the study mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/15\">",
"     15",
"    </a>",
"    ], six of the seven children who survived anaphylaxis received epinephrine within 30 minutes of ingesting the allergen, whereas only two of the six children who died received epinephrine within the first hour.",
"   </p>",
"   <p>",
"    Fatal food allergic reactions are most common in adolescents and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. Possible contributing factors include increasing independence and decision-making, risk-taking behaviors, susceptibility to peer pressure, and ingesting risky foods at social events due to the desire to \"fit in\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/17\">",
"     17",
"    </a>",
"    ]. In an internet-based anonymous survey of 176 adolescents and young adults with food allergy, more than one-half reported purposefully ingesting a potentially unsafe food [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, 17 percent were designated as high risk because they both ate foods that \"may contain\" allergens, and did not consistently carry",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    . These individuals were not identifiable by age, sex, or the nature of past reactions. As a group, the respondents felt that education of their peers about food allergy would help them cope better with having food allergy. Thus, one strategy to reduce morbidity and mortality in this age group might be increased education on a school-wide basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy of avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict avoidance of the causative food is critical for avoiding an allergic reaction because trace amounts of the food allergen can be sufficient to trigger symptoms. Complete avoidance is prescribed for IgE-mediated food allergies as well as food-protein induced enterocolitis syndrome in infants (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    ). However, absolute avoidance is extremely difficult, as demonstrated by multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/2,10,18\">",
"     2,10,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of peanut-allergic individuals, researchers reported that the majority of children with clinically diagnosed peanut allergies had subsequent reactions within a five-year period despite their best efforts at allergen avoidance [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 132 children, 58 percent had experienced a reaction in the past two years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients often develop reactions from foods they thought were safe. Allergens, such as peanuts, can be \"hidden\" in candies, desserts, cookies, cakes, and other bakery products. Milk or soy can be added to canned tuna fish.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because avoidance is so difficult, food-allergic reactions should be considered inevitable. Schools and similar settings must have plans in place for effective emergency management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGING FOOD ALLERGY IN SCHOOLS AND CAMPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schools and camps should be proactive in planning how to manage food allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/4,19,20\">",
"     4,19,20",
"    </a>",
"    ]. Planning ahead can save valuable minutes when a reaction occurs and may be the difference between life and death for a child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Institutional food allergy management plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The food allergy management plan of a school or camp should include policies regarding the use of food throughout the day and in various activities, where medications will be kept, and protocols for contacting emergency services and parents during a reaction. Guidelines for managing students with food allergies, developed in consultation with a number of professional societies, have been published (",
"    <a class=\"graphic graphic_table graphicRef78534 \" href=\"UTD.htm?1/42/1710\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Preliminary evidence supports the usefulness of such policies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Education about food allergy and its treatment should be provided to all staff who supervise children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. Staff to receive training should include teachers, coaches, administrators, transportation drivers, dining",
"    <span class=\"nowrap\">",
"     hall/cafeteria",
"    </span>",
"    workers, camp nurses, counselors, specialty area workers, volunteers, chaperones, and anyone else who may offer food or be involved with parties, events, or activities.",
"   </p>",
"   <p>",
"    It is essential that the staff responsible for the safety of a food-allergic child is able to do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recognize a food-allergic reaction",
"     </li>",
"     <li>",
"      Obtain access to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      rapidly and reliably",
"     </li>",
"     <li>",
"      Know when and how to use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      without first having to contact the child's parent or retrieve the school nurse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Training and allowing a variety of staff members to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    is recommended because most schools and camps do not employ full-time nurses. In addition, nurses are often in charge of hundreds or thousands of children in a large physical area.",
"   </p>",
"   <p>",
"    Many schools and camps are including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors as part of the school's general first aid supplies, in the event of a first-time reaction, or if a second dose of epinephrine is needed.",
"   </p>",
"   <p>",
"    Food allergy management should be viewed as a process, not an event. Some schools conduct drills, similar to fire drills, for food-allergic reactions in order to provide the staff with opportunities to practice implementing the plan and using the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors. After any food allergic event at a school, the staff should formally discuss the events and review the institutional plan to see if it was followed and was effective. If not, adjustments should be made immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Personalized food allergy action plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each child who has a food allergy requires a personalized management plan. Most schools and camps will have standardized health forms for documenting food allergies. Action plan forms are available from the Food Allergy &amp; Anaphylaxis Network (",
"    <a class=\"external\" href=\"file://www.foodallergy.org/files/FAAP.pdf\">",
"     www.foodallergy.org/files/FAAP.pdf",
"    </a>",
"    ) and the American Academy of Allergy, Asthma &amp; Immunology (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"UTD.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    ). While the standardized forms are preferred, easy to follow written instructions, recorded by the child's clinician and signed by the parents, can also be used. A personalized action plan should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A recent photo of the child",
"     </li>",
"     <li>",
"      List of foods to which the child is allergic",
"     </li>",
"     <li>",
"      Signs and symptoms the child might experience during an allergic reaction",
"     </li>",
"     <li>",
"      Appropriate treatment instructions from the child's clinician",
"     </li>",
"     <li>",
"      Emergency contact information for the child's",
"      <span class=\"nowrap\">",
"       parents/caregivers",
"      </span>",
"      and clinician (including cell phone numbers or pagers)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This document helps assure that the critical information has been reviewed and management individualized for the child in question. This document can also form the basis of a detailed discussion between parent and clinician, and subsequently, between parent and staff member about the child's condition and past reactions.",
"   </p>",
"   <p>",
"    The nature of the care to be provided may vary among individual children. As an example, a 6 year old child with severe peanut allergy may need more supervision than a 15 year old. Additionally, the severity of allergic reactions varies from child to child and will dictate the type of management plan needed for each child. One child may be exquisitely allergic to milk and may develop local hives upon skin contact, while another may only develop symptoms upon ingestion.",
"   </p>",
"   <p>",
"    Finally, the plan should be reviewed and updated regularly, to reflect changes in the child's allergies as well as the age-appropriateness of medication doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinician's responsibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should educate patients about the importance of strict avoidance of the allergens. Parents should be given written instructions, reviewed and signed by the clinician, for how to handle an allergic reaction. These should include what medications and doses to use and timing instructions.",
"   </p>",
"   <p>",
"    In some cases, the clinician may be involved in educating school and camp staff and others who may be providing care for the allergic child.",
"   </p>",
"   <p>",
"    Most parents welcome information about lay organizations, such as the Food Allergy and Anaphylaxis Network (FAAN), which can link them to the patient education community and provide ongoing education. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Staff's responsibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;All individuals on the school or camp staff should understand food allergy, should be able to recognize symptoms and respond to a reaction, and should be vigilant and proactive in eliminating food allergens from the allergic student's meals, educational tools, arts and crafts projects, or incentives.",
"   </p>",
"   <p>",
"    Generally, school or camp nurses conduct training sessions prior to the start of the school year or camp term. During these sessions, relevant staff members can review information about the food-allergic child, treatment protocols, reading food labels, and other risk-reduction strategies designed to keep the child safe.",
"   </p>",
"   <p>",
"    Nurses and other staff members should be trained in the proper use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    injectors. They should have access to training devices and should practice using them, so that they are confident and capable of administering epinephrine quickly and properly. All staff members should know where epinephrine autoinjectors are stored and should either be trained or be aware of another staff member who has been trained and will be reliably available. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Epinephrine location'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Staff should contact the local municipal emergency response team and find out if ambulances in the area are equipped with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    and the attendants are allowed to administer it. Emergency teams differ in this respect and schools should summon a team that is able to provide this treatment when possible. They should also notify the response team periodically that there are students at the school with life-threatening food allergies. If none of the local emergency teams are able to administer epinephrine, we suggest informing the child's parent of this in writing, so that the situation is properly addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bus safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bus drivers are often not employed by the school or camp, but rather are employees working for privately-run transportation companies. In many cases, bus drivers are not trained to recognize and respond to allergic reactions. If bus drivers are not trained, staff and parents have been able to ensure the safe transport of food-allergic children using any or all of the following strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Equipping the driver with communication devices (cell phone, walkie-talkie) in case of an emergency",
"     </li>",
"     <li>",
"      Enforcing a \"no eating\" policy on the bus",
"     </li>",
"     <li>",
"      Assigning the food-allergic child to the front seat",
"     </li>",
"     <li>",
"      Having a nurse's aide, teacher, or other sort of adult chaperone ride the bus with the food-allergic child",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Parent's responsibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should regularly provide the staff with updated information concerning their child's food allergy. Ideally, this should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A current and detailed food allergy action plan for their child",
"     </li>",
"     <li>",
"      Suggested alternatives (ie, soy nut butter instead of peanut butter) or a box of \"safe\" foods",
"     </li>",
"     <li>",
"      Medication to be left at the school or camp (ie, auto-injectable",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , etc)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parents should also inform the responsible clinician about any reactions, so that the child's food allergy action plan can be modified if necessary.",
"   </p>",
"   <p>",
"    Parents can be strong advocates of change. A motivated parent can help to convince a school to be more proactive about food allergy policies and can help to evaluate and modify classroom activities. Parents should approach school and camp staff with a positive and informed outlook about food allergy and offer their time and knowledge on an ongoing basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Child's responsibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon age and maturity level, food-allergic children should be taught to do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Not to trade food with other children",
"     </li>",
"     <li>",
"      Avoid eating anything likely to contain the allergen or any food with unknown ingredients",
"     </li>",
"     <li>",
"      Wash hands thoroughly before and after eating",
"     </li>",
"     <li>",
"      Be involved in the care and management of their food allergies",
"     </li>",
"     <li>",
"      Notify an adult immediately if they suspect they may be having a reaction",
"     </li>",
"     <li>",
"      Know how to use auto-injectable",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"     </li>",
"     <li>",
"      Notify an adult if they are being bullied or harassed because of their food allergy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H132445\">",
"    <span class=\"h2\">",
"     Bullying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullying, particularly at school, is a common problem faced by children with food allergies that can have a negative impact on quality of life. School staff should adopt a zero tolerance policy for bullying and have a plan for quickly handling any reports of this behavior.",
"   </p>",
"   <p>",
"    A survey of parents of children with food allergy and of teens and young adults with food allergy (n = 353) showed that 24 percent (or 35 percent of participants over age five years) had been victims of bullying, teasing, or harassment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/25\">",
"     25",
"    </a>",
"    ]. The majority of victims were male (61 percent). The most common trigger for this behavior was simply the individual having a food allergy (79 percent). Other cited causes included their carrying medications, sitting at separate tables, or having other forms of special treatment. The teasing, harassment and bullying occurred multiple times for most of these individuals (86 percent), primarily in the school settings (82 percent) by classmates (80 percent). Unfortunately, one-fifth of those bullied, teased, or harassed were subjected to this behavior by school staff members. The children and young adults were verbally teased and physically threatened with the food to which they are allergic. Two-thirds of respondents reporting consequences indicated that they or their child felt sad, depressed, and embarrassed or humiliated because of the teasing, bullying, and harassment.",
"   </p>",
"   <p>",
"    Similar results were found in another survey of parents and children aged 8 to 17 years with food allergy, with 25 percent of parents and 32 percent of children reporting bullying due to food allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/26\">",
"     26",
"    </a>",
"    ]. Quality of life and distress levels were negatively impacted by bullying in both children and parents, although the effect was lessened in children whose parents were aware of the bullying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Strategies for minimizing risks at school",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies for managing food allergies in schools have been devised. Approaches vary depending on the size of the school, whether or not there is a full-time nurse, the proximity to emergency rescue services (rural versus urban), and the number and age of the students with food allergies. Below are some of the policies that are commonly adopted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No food trading.",
"     </li>",
"     <li>",
"      No food in the classrooms.",
"     </li>",
"     <li>",
"      No home-made food allowed for class celebrations or parties (commercially-prepared foods with preprinted ingredients lists intact are allowed).",
"     </li>",
"     <li>",
"      Designating the parent of the allergic student to be responsible for selecting food for class celebrations (difficult if there are multiple food-allergic children).",
"     </li>",
"     <li>",
"      Celebration of birthdays or other special events with books or music instead of food.",
"     </li>",
"     <li>",
"      Designated peanut- or milk-free tables in the cafeteria.",
"     </li>",
"     <li>",
"      School-wide food allergy education and management plans.",
"     </li>",
"     <li>",
"      Education of all students and implementation of student-focused allergy awareness programs. Children should be taught from a young age that teasing other children because of any medical condition is not acceptable. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Resources'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Camp-specific policies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several respects, the management of food allergy in the camp setting is similar to that in school. Camp staff must be educated in the recognition and treatment of food allergies and anaphylaxis. A personalized Food Allergy Action plan should be provided for each child.",
"   </p>",
"   <p>",
"    Selecting a camp that can monitor food and work with the parents to identify risks to the child is critical for success. Parents should discuss their child's food allergies with camp staff as they are choosing a camp. Ideally, the camp should have a full-time nurse and easy access to a medical facility. The parents of the allergic camper are an excellent source of information and guidance for developing a plan for a safe camp experience. Other issues are specific for the camp setting, and may vary according to the type and size of the camp, and the severity of the camper's allergies. Guidelines for managing food allergies at camp have been published (",
"    <a class=\"graphic graphic_table graphicRef71557 \" href=\"UTD.htm?26/13/26846\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Camp-specific issues include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ensure that there is phone access in case of a reaction requiring a call to 911",
"     </li>",
"     <li>",
"      Keep medications within easy access and stored in appropriate temperature",
"     </li>",
"     <li>",
"      Label each camper's medication and put it in an individual bag that can easily be carried from place to place or allow each camper to carry their own medications",
"     </li>",
"     <li>",
"      Review foods to be used in craft projects to ensure they do not contain an allergen that may cause a reaction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Special considerations are needed for overnight adventures in the wilderness, such as bringing extra supplies of safe food for the allergic camper and ample supplies of medications needed to treat a reaction. The supervising staff member should carry a well-charged cell phone and assure that the group will remain in cell phone-accessible territory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Eating safely at camp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some parents provide food for their child to minimize the chances of a reaction. For campers staying overnight, parents can ship or personally deliver food at the beginning of each week. The food should be clearly labeled with the child's name and cabin information.",
"   </p>",
"   <p>",
"    For children eating camp-provided food, strategies for minimizing risks include separating and labeling \"safe\" products in the kitchen with stickers so that food can be prepared and served without cross-contamination. Alternatively, if the allergic camper must avoid certain dishes, then allowing that child to be the first in the buffet line and discouraging return trips through the food line for \"seconds\" should help reduce the risk of a reaction from cross contact through serving utensils.",
"   </p>",
"   <p>",
"    The sharing of care packages of homemade foods should be avoided by those with food allergies, unless prepared by their own parents. Children with food allergies should only consider eating food from care packages if it is commercially prepared and an ingredients list is provided on the packaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Peanut bans",
"    </span>",
"    &nbsp;&mdash;&nbsp;School staff and parents may decide to ban peanuts, given the number of students with peanut allergy and the severity of the reactions from this food. Unfortunately, reactions have been reported in schools with active peanut bans, indicating that bans are not sufficient to protect allergic children from exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, banning one specific food tends to divide and polarize the school or camp community, either because of the inconvenience to the parents of non-allergic children, or because children with other food allergies are not given the same consideration. Food bans may also impart a false sense of security upon the staff, who may be less vigilant for reactions.",
"   </p>",
"   <p>",
"    We favor an approach based upon education and cooperation from the entire school community, rather than blanket bans of certain foods [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/21\">",
"     21",
"    </a>",
"    ]. The specific recommendations presented previously should be effective in preventing the majority of reactions and successfully managing the rest. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Managing food allergy in schools and camps'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Epinephrine location",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    was generally required to be kept in a locked cabinet in the nurse's office. However, more than half of the states in the United States now have specific laws or regulations allowing a child to carry an epinephrine autoinjector during the school day, provided that certain conditions (such as parental, clinician, school nurse, and school board consent) are met [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, several states have enacted laws pertaining to campers and the ability to carry prescribed epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/28\">",
"     28",
"    </a>",
"    ]. These policies help to assure that life-saving epinephrine will be quickly accessible during an anaphylactic reaction.",
"   </p>",
"   <p>",
"    In the event that the food-allergic child is not",
"    <span class=\"nowrap\">",
"     mature/responsible",
"    </span>",
"    enough to carry their own",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , every effort should be made to ensure that epinephrine is kept in a secure, but unlocked location, known to all staff members and accessible within minutes. This sometimes involves epinephrine being \"handed off\" from teacher to teacher or between camp staff as the child changes locations throughout the day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Removing food allergens from surfaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents and school staff are often concerned about the best methods for removing food from desks, tables, hands, and other surfaces. In one study, investigators sampled the efficacy of a variety of cleaning methods in removing 5 mL of peanut butter from tabletops [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/5\">",
"     5",
"    </a>",
"    ]. The following products effectively reduced peanut allergen to undetectable levels:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plain water",
"     </li>",
"     <li>",
"      Formula 409 cleaner",
"     </li>",
"     <li>",
"      Lysol sanitizing wipes",
"     </li>",
"     <li>",
"      Target brand cleaner with bleach",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Various liquid dish-washing detergents were only partially effective. The investigators concluded that routine cleaning of tables and desks with common cleansers, with the exception of dish-washing liquids, was sufficient to minimize the risk to allergic individuals.",
"   </p>",
"   <p>",
"    To remove peanut residue from adults' hands, the following were tested and found effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tidy Tykes Wipes",
"     </li>",
"     <li>",
"      Wet Ones antibacterial wipes",
"     </li>",
"     <li>",
"      Liquid soap",
"     </li>",
"     <li>",
"      Bar soap",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, plain water and alcohol-based hand sanitizer did not remove peanut completely from adults' hands. Small children may need help cleaning their hands effectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain issues relevant to food allergy in schools and camps have been addressed with specific legislation. These include defining the rights of food allergic children, and protecting those who attempt to help an individual during a food allergic reaction from subsequent legal action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Legal rights of food allergic children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with life-threatening food allergies are protected under federal civil rights laws, such as Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Act (ADA) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/21,29\">",
"     21,29",
"    </a>",
"    ]. This is because a severe food allergy meets the legal definition of a \"disability\" or \"handicap,\" ie, a physical impairment that substantially limits one or more major life activities (such as eating or breathing).",
"   </p>",
"   <p>",
"    The spirit of these two federal laws is essentially the same: to prevent discrimination on the basis of a disability. The major difference between the laws lies in their application: Section 504 applies to public schools and other institutions that receive federal funding. The ADA, however, typically applies to institutions that are privately run, such as private child care centers, preschools, private schools, and privately-run recreational camps.",
"   </p>",
"   <p>",
"    Under these laws, schools cannot turn away a child based on the child's food allergies or the school's perceived inability to manage the food allergies. According to the law, facilities must address the health and safety needs of the disabled child, and must provide accommodations to ensure that the child participates safely and equally in all normal facets of the program, including classroom activities, field trips, and eating in the cafeteria [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar legislation has been put into effect in other countries. In Ontario, Canada, an Act to Protect Anaphylactic Pupils (Sabrina's Law), which established minimum standards for managing anaphylaxis in schools, was enacted in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     The fear of liability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liability for harming a child as a result of improper treatment of allergic reactions is sometimes cited as a concern by schools or camps. However, there is no legal precedent involving a school or camp staff member being sued for administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    . In contrast, litigation has been brought against school staff for not responding quickly or appropriately during an anaphylactic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, most states have \"Good Samaritan\" laws, which are designed to protect individuals from liability who render emergency assistance in good faith, with no expectation of payment, and who transfer care of the patient to appropriate medical personnel (eg, emergency medical technicians, the school nurse) as soon as possible. Furthermore, some states have enacted Good Samaritan laws that specifically cover epinephrine administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various professional and governmental organizations have created guidance documents on food allergy management [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Some of these provide in-depth tools for establishing institutional plans for managing food allergy, as well as educational materials, forms, response protocols, and informational posters and signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Professional organizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The National Association of School Nurses (",
"      <a class=\"external\" href=\"file://www.nasn.org/\">",
"       www.nasn.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The American Academy of Pediatrics (",
"      <a class=\"external\" href=\"file://www.aap.org\">",
"       www.aap.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The American Medical Association (",
"      <a class=\"external\" href=\"file://www.ama-assn.org/\">",
"       www.ama-assn.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The American Academy of Allergy, Asthma &amp; Immunology (",
"      <a class=\"external\" href=\"file://www.AAAAI.org\">",
"       www.AAAAI.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Governmental organizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Governmental bodies offering information related to this topic include the United States Department of Agriculture's Food and Nutrition Service, the US Department of Education's Office for Civil Rights, the New York Statewide School Health Services Center, the Massachusetts Department of Education, and the Connecticut Department of Education [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/37-40\">",
"     37-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Other organizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Food Allergy &amp; Anaphylaxis Network (FAAN) is a national, non-profit, member-supported organization dedicated to education, awareness, advocacy, and research in food allergy (",
"    <a class=\"external\" href=\"file://www.foodallergy.org/\">",
"     www.foodallergy.org",
"    </a>",
"    ). FAAN's materials are all reviewed by a panel of scientific advisors, comprised of the world's leading experts in food allergy, to ensure medical accuracy. FAAN offers a range of instructional programs, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The School Food Allergy Program (SFAP)",
"     </li>",
"     <li>",
"      Be A PAL program:",
"      <strong>",
"       P",
"      </strong>",
"      rotect",
"      <strong>",
"       A",
"      </strong>",
"      <strong>",
"       L",
"      </strong>",
"      ife program for educating students about food allergy",
"     </li>",
"     <li>",
"      The Child Care and Preschool Guide to Managing Food Allergies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SFAP includes a video or DVD, autoinjectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    trainer devices, a poster, and a binder of information and standardized forms. This program is available via the FAAN Web site and has been distributed to more than 30,000 schools across the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3705/abstract/28\">",
"     28",
"    </a>",
"    ]. The program provides schools with a template from which they can develop their personalized school food allergy management plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Food allergic reactions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food allergy affects up to 8 percent of school-age children and is increasing in prevalence. Policies to keep food-allergic children safe often affect all members of the student body and staff within a given setting. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food is ubiquitous in most schools, and reactions can occur in unexpected places. Allergic reactions to food are not rare, with approximately 40 percent of schools reporting at least one event in the previous two years. Up to one-quarter of these reactions occurred in children not previously recognized to have food allergy. Milk and peanut are leading causes of school reactions in the United States. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Characteristics of reactions in schools'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peanut causes more fatal reactions in children than any other single food. Severe reactions should be treated with injected",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      administered as rapidly as possible, ideally within a few minutes. Delayed administration of this medication is believed to be a contributing factor in many fatal reactions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fatal food reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strict avoidance of the allergy-causing food is extremely difficult. Patients often develop reactions from foods they thought were safe. For these reasons, reactions are virtually inevitable, and schools and similar settings must have plans in place for effective emergency management. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Efficacy of avoidance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Effective management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The food allergy management plan of a school or camp should include policies regarding where food is allowed, where medications are stored, and protocols for contacting emergency services and parents during a reaction (",
"      <a class=\"graphic graphic_table graphicRef78534 \" href=\"UTD.htm?1/42/1710\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71557 \" href=\"UTD.htm?26/13/26846\">",
"       table 2",
"      </a>",
"      ). It is essential that the staff have access to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , understand when and how to use it, and have permission to administer it without first having to contact the child's parent or retrieve the school nurse. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Institutional food allergy management plan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Each child who has a food allergy requires a personalized management plan that identifies",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      food allergies, outlines treatment for specific symptoms, and serves as a means of transmitting critical information between the clinician, parent, and staff (",
"      <a class=\"external\" href=\"file://www.foodallergy.org/files/FAAP.pdf\">",
"       www.foodallergy.org/files/FAAP.pdf",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_form graphicRef60439 \" href=\"UTD.htm?2/42/2722\">",
"       form 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Personalized food allergy action plan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The roles of the clinician, staff, parent, and child are distinct and must be integrated. Specific strategies for minimizing risks in school and camp settings are provided. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Managing food allergy in schools and camps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain issues arise recurrently, including the implementation of bans on specific foods, the fear of liability, the legal rights of food allergic children, where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      should be stored, and how to effectively remove food from various surfaces. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Other considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/1\">",
"      Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics 2009; 124:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/2\">",
"      Nowak-Wegrzyn A, Conover-Walker MK, Wood RA. Food-allergic reactions in schools and preschools. Arch Pediatr Adolesc Med 2001; 155:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/3\">",
"      Sicherer SH, Furlong TJ, DeSimone J, Sampson HA. The US Peanut and Tree Nut Allergy Registry: characteristics of reactions in schools and day care. J Pediatr 2001; 138:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/4\">",
"      Young MC, Mu&ntilde;oz-Furlong A, Sicherer SH. Management of food allergies in schools: a perspective for allergists. J Allergy Clin Immunol 2009; 124:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/5\">",
"      Perry TT, Conover-Walker MK, Pom&eacute;s A, et al. Distribution of peanut allergen in the environment. J Allergy Clin Immunol 2004; 113:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/6\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/7\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol 2003; 112:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/8\">",
"      Weiss C, Mu&ntilde;oz-Furlong A, Furlong TJ, Arbit J. Impact of food allergies on school nursing practice. J Sch Nurs 2004; 20:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/9\">",
"      McIntyre CL, Sheetz AH, Carroll CR, Young MC. Administration of epinephrine for life-threatening allergic reactions in school settings. Pediatrics 2005; 116:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/10\">",
"      Bock SA, Atkins FM. The natural history of peanut allergy. J Allergy Clin Immunol 1989; 83:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/11\">",
"      Rhim GS, McMorris MS. School readiness for children with food allergies. Ann Allergy Asthma Immunol 2001; 86:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/12\">",
"      Pulcini JM, Sease KK, Marshall GD. Disparity between the presence and absence of food allergy action plans in one school district. Allergy Asthma Proc 2010; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/13\">",
"      Frost DW, Chalin CG. The effect of income on anaphylaxis preparation and management plans in Toronto primary schools. Can J Public Health 2005; 96:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/14\">",
"      Hannaway PJ, Connelly ME, Cobbett RM, Dobrow PJ. Differences in race, ethnicity, and socioeconomic status in schoolchildren dispensed injectable epinephrine in 3 Massachusetts school districts. Ann Allergy Asthma Immunol 2005; 95:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/15\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/16\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/17\">",
"      Sampson MA, Mu&ntilde;oz-Furlong A, Sicherer SH. Risk-taking and coping strategies of adolescents and young adults with food allergy. J Allergy Clin Immunol 2006; 117:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/18\">",
"      Yu JW, Kagan R, Verreault N, et al. Accidental ingestions in children with peanut allergy. J Allergy Clin Immunol 2006; 118:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/19\">",
"      Muraro A, Clark A, Beyer K, et al. The management of the allergic child at school: EAACI/GA2LEN Task Force on the allergic child at school. Allergy 2010; 65:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/20\">",
"      Sicherer SH, Mahr T, American Academy of Pediatrics Section on Allergy and Immunology. Management of food allergy in the school setting. Pediatrics 2010; 126:1232.",
"     </a>",
"    </li>",
"    <li>",
"     The Rehabilitation Act of 1973, Section 504. Public Law 93-112; Rehabilitation Act. 1973. Volume 29 U.S.C. Section 794.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/22\">",
"      Baumgart K, Brown S, Gold M, et al. ASCIA guidelines for prevention of food anaphylactic reactions in schools, preschools and child-care centres. J Paediatr Child Health 2004; 40:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/23\">",
"      Sheetz AH, Goldman PG, Millett K, et al. Guidelines for managing life-threatening food allergies in Massachusetts schools. J Sch Health 2004; 74:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/24\">",
"      Moneret-Vautrin DA, Kanny G, Morisset M, et al. Food anaphylaxis in schools: evaluation of the management plan and the efficiency of the emergency kit. Allergy 2001; 56:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/25\">",
"      Lieberman JA, Weiss C, Furlong TJ, et al. Bullying among pediatric patients with food allergy. Ann Allergy Asthma Immunol 2010; 105:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/26\">",
"      Shemesh E, Annunziato RA, Ambrose MA, et al. Child and parental reports of bullying in a consecutive sample of children with food allergy. Pediatrics 2013; 131:e10.",
"     </a>",
"    </li>",
"    <li>",
"     The Food Allergy and Anaphylaxis Network. Preparing for Camp and Overnight School Trips With Food Allergies. 2000. Fairfax, VA.",
"    </li>",
"    <li>",
"     The Food Allergy &amp; Anaphylaxis Network Web site. www.foodallergy.org/advocacy.html (Accessed on September 13, 2007).",
"    </li>",
"    <li>",
"     Public Law 101-336, Americans with Disabilities Act of 1990 (ADA). Title 42, U.S.C. 12101 et seq. [104], 327-378. 7-26-1990. U.S. Statutes at Large.",
"    </li>",
"    <li>",
"     United States Department of Education for Civil Rights. The Civil Rights of Students with Hidden Disabilities Under Section 504 of the Rehabilitation Act of 1973.",
"    </li>",
"    <li>",
"     Text of Sabrina's Law. www.ontla.on.ca/.../bills_detail.do?locale=en&amp; BillID=135&amp;isCurrent=false&amp;ParlSessionID=38%3A1 (Accessed on August 01, 2007).",
"    </li>",
"    <li>",
"     Virginia de Leon. District 81 settled case for nearly $1 million; witnesses recount details of fatal field trip. The Spokesman Review 2002 Apr 14.",
"    </li>",
"    <li>",
"     National Association of School Nurses. Position Statement: Epinephrine Use in Life-Threatening Emergencies. 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3705/abstract/34\">",
"      American Academy of Pediatrics. Committee on School Health.. American Academy of Pediatrics: Guidelines for emergency medical care in school. Pediatrics 2001; 107:435.",
"     </a>",
"    </li>",
"    <li>",
"     American Medical Association House of Delegates. Resolution 415 (A-04). Allergic Reaction in Schools and Airplanes.",
"    </li>",
"    <li>",
"     American Academy of Allergy, Asthma &amp; Immunology. Position Statement: Anaphylaxis in Schools and other child-care settings.",
"    </li>",
"    <li>",
"     United States Department of Agriculture Food and Nutrition Service. Accommodating Children with Special Dietary Needs in the School Nutrition Programs. Fall, 2001.",
"    </li>",
"    <li>",
"     New York Statewide School Health Services Center. Making the difference...Caring for Students with Food Allergies. School Health Module. June, 2006.",
"    </li>",
"    <li>",
"     Massachusetts Department of Education. Managing Life Threatening Food Allergies in Schools. Fall, 2002.",
"    </li>",
"    <li>",
"     Connecticut State Department of Education. Guidelines for Managing Life-Threatening Food Allergies in Connecticut Schools. 2006.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5739 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3705=[""].join("\n");
var outline_f3_39_3705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Characteristics of reactions in schools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fatal food reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy of avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGING FOOD ALLERGY IN SCHOOLS AND CAMPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Institutional food allergy management plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Personalized food allergy action plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinician's responsibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Staff's responsibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bus safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Parent's responsibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Child's responsibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H132445\">",
"      Bullying",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Strategies for minimizing risks at school",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Camp-specific policies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Eating safely at camp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Peanut bans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Epinephrine location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Removing food allergens from surfaces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Legal issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Legal rights of food allergic children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - The fear of liability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Resources",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Professional organizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Governmental organizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Other organizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Food allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Effective management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5739|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5739|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/42/1710\" title=\"table 1\">",
"      Food allergy school guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/13/26846\" title=\"table 2\">",
"      Food allergy camp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_39_3706="Variant angina";
var content_f3_39_3706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Variant angina",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3706/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3706/contributors\">",
"     John F Beltrame, BSc, BMBS, FRACP, PhD, FESC, FACC, FCSANZ",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3706/contributors\">",
"     Filippo Crea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3706/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3706/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/39/3706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/39/3706/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/39/3706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variant angina, which is also referred to as Prinzmetal or coronary vasospastic angina, is a clinical entity characterized by episodes of angina pectoris, usually at rest and often between midnight and early morning, in association with ST-segment elevation (",
"    <a class=\"graphic graphic_table graphicRef81757 \" href=\"UTD.htm?38/35/39483\">",
"     table 1",
"    </a>",
"    ) on the electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/1\">",
"     1",
"    </a>",
"    ]. Episodes are triggered by coronary artery vasospasm, which generally occurs in the absence of high grade coronary artery stenosis.",
"   </p>",
"   <p>",
"    Variant angina has characteristics that allow it to be distinguished from stable angina pectoris, unstable angina, or microvascular angina. This topic will discuss all aspects of variant angina; other forms of (cardiac) angina are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link&amp;anchor=H3#H3\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\", section on 'Classification of unstable angina'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variant angina is usually caused by focal spasm (of the smooth muscle layer of the arterial wall) of a major coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], resulting in a high-grade obstruction. Transient myocardial ischemia causes angina in many patients; myocardial infarction may develop in some [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Vascular smooth muscle hyper-reactivity is thought to be central to the pathogenesis of variant angina [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spasm occurs in the absence of any preceding increase in myocardial oxygen demand (eg, exercise) and in normal or diseased vessels. It is usually focal in its anatomic distribution, although spasm in more than one site and diffuse spasm have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/5\">",
"     5",
"    </a>",
"    ]. Spasm can occur in angiographically normal coronary vessels and also at the site of atherosclerotic plaques of different severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190313768\">",
"    <span class=\"h2\">",
"     Vascular smooth muscle hyper-reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal and clinical studies have implicated coronary vascular smooth muscle hyper-reactivity as a key factor in the pathogenesis of coronary artery spasm. Important observations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple vasoconstrictors have been used to provoke coronary spasm including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      , serotonin, histamine, noradrenaline, and dopamine, suggesting that a single receptor pathway cannot explain the phenomenon [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Receptor antagonists (eg, ketanserin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      ) do not inhibit spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Inhibition of smooth muscle contractile mechanisms using other (non-receptor) pathways (eg, nitrates, calcium channel blockers) is effective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased calcium sensitivity of the vascular myosin light chain [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/8-10\">",
"       8-10",
"      </a>",
"      ], mediated by enhanced Rho kinase activity and enhanced phospholipase C activity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/11\">",
"       11",
"      </a>",
"      ], have been shown to have a role.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autonomic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precipitation of spasm by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    suggests a role for an imbalance of vagal and sympathetic tone in triggering coronary spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. Episodes of variant angina occur more often from midnight to early morning (when vagal tone is higher). Heart rate variability studies have shown that increased vagal tone and hyperreactivity to sympathetic stimulation occur in VA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. These observations are supported by the observation that surgical sympathetic denervation (plexectomy) may be an effective therapy in medically refractory patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endothelial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction may be a predisposing factor but is not likely the sole reason for coronary spasm, given that typical coronary spasm is a rare condition whereas endothelial dysfunction is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of factors may contribute to endothelial dysfunction in patients with variant angina. These overlap with factors identified in patients without variant angina and include: impairment of flow-dependent coronary dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]; increased release",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activity of the vasoconstrictors endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] and serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/27\">",
"     27",
"    </a>",
"    ]; oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]; structural endothelial abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]; and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link&amp;anchor=H2#H2\">",
"     \"C-reactive protein in cardiovascular disease\", section on 'Possible pathogenic role of CRP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186155139\">",
"    <span class=\"h2\">",
"     Associated microvascular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to spasm of large epicardial vessels, co-existing microvascular (small vessel) dysfunction has been demonstrated in some patients with variant angina and may contribute to myocardial ischemia. In a study of 55 patients, epicardial spasm was provoked by maximal doses of intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/33\">",
"     33",
"    </a>",
"    ]. In 14 of these patients, submaximal doses of acetylcholine provoked myocardial ischemia, documented by the development of chest pain, ischemic ECG changes, and lactate production, in the absence of large epicardial spasm. These patients were predominantly women with a history of prolonged (&gt;30 min) chest pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=see_link\">",
"     \"The coronary microcirculation in disease states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110739137\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND TRIGGERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension and hypercholesterolemia, two major predictors of atherosclerotic cardiovascular disease, do not accurately predict the development of variant angina [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/34\">",
"     34",
"    </a>",
"    ]. Cigarette smoking, however, is a major risk factor for variant angina [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/35\">",
"     35",
"    </a>",
"    ]. There is some evidence that genetic factors and insulin resistance are associated with variant angina [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible triggers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in autonomic activity (detected by heart rate variability monitoring) shortly before an episode [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"       \"Heart rate variability: Uses other than after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"       \"Heart rate variability: Technical aspects\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5\">",
"       'Autonomic nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of multiple drugs including ephedrine-based products, cocaine, marijuana, alcohol, butane,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      , and amphetamines [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/19,39,40\">",
"       19,39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guide wire or balloon dilatation at the time of percutaneous coronary intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Food-born botulism [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link&amp;anchor=H8#H8\">",
"       \"Botulism\", section on 'Foodborne botulism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Magnesium deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Magnesium'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28463569\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of variant angina is not well studied. It appears to be more frequent in individuals from Japan compared to white populations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/43\">",
"     43",
"    </a>",
"    ]. The diagnosis is more often made in individuals less than 50 years of age than in older people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110738375\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with variant angina typically present with a chronic pattern of recurrent episodes of chest pain. The quality of the chest pain is indistinguishable from classical angina pectoris associated with obstructive coronary artery disease; however, the context in which it occurs differs. In particular, patients with variant angina report that their episodes are predominantly at rest and that many occur from midnight to early morning [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/44\">",
"     44",
"    </a>",
"    ]. Each episode of chest pain generally lasts 5 to 15 minutes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\", section on 'Characteristics of the chest discomfort'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic approach to chest pain in adults\", section on 'Quality of the pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link&amp;anchor=H9#H9\">",
"     \"Differential diagnosis of chest pain in adults\", section on 'Coronary artery disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Episodes of chest pain due to myocardial ischemia (angina), including those with variant angina, tend to be similar to each other. The following are some characteristic features, irrespective of whether the mechanism is fixed obstruction or spasm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Discomfort&rdquo; is more often given as a descriptor than &ldquo;pain&rdquo;. Other common descriptors include squeezing, tightness, pressure, constriction, strangling, burning, heart burn, fullness in the chest, a band-like sensation, knot in the center of the chest, lump in the throat, ache, heavy weight on chest.",
"     </li>",
"     <li>",
"      Each episode is typically gradual in onset and offset.",
"     </li>",
"     <li>",
"      There is no change in the quality of pain with respiration or position.",
"     </li>",
"     <li>",
"      The patient may have some difficulty in describing the location of the pain, although the substernal location is common. Radiation to the neck, throat, lower jaw, teeth, upper extremity, or shoulder is common.",
"     </li>",
"     <li>",
"      During each episode, symptoms of nausea, sweating, dizziness, dyspnea, and palpitations may be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the similarities in the description of the pain between patients with variant angina and those with other causes of myocardial ischemia, the history may differ and thus provide some evidence to support the diagnosis of the former [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with variant angina are often younger and exhibit fewer classic cardiovascular risk factors (except for cigarette smoking) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variant angina may be associated with other vasospastic disorders, such as Raynaud's phenomenon and migraine headache or its treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/47-49\">",
"       47-49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A history of drug abuse (such as cocaine) may be present.",
"     </li>",
"     <li>",
"      Hyperventilation can precipitate attacks of vasospastic angina [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise does not usually provoke an episode of spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. However, in patients who are very symptomatic during a &lsquo;hot phase&rsquo; of the condition, spasm may be triggered by the elevated catecholamines associated with exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a physical examination should be performed to establish baseline information about the cardiovascular system, there are no findings characteristic for variant angina. However, during an episode, tachycardia, hypertension, diaphoresis, and a gallop rhythm may be present.",
"   </p>",
"   <p>",
"    A 12-lead electrocardiogram (ECG) should be performed in all patients with a history of chest pain. The electrocardiogram is usually normal between episodes in patients with variant angina. For patients evaluated during an acute episode, electrocardiography usually reveals ST-segment elevation in multiple leads. (See",
"    <a class=\"local\" href=\"#H10492235\">",
"     '12-lead ECG'",
"    </a>",
"    below.) These individuals need to have myocardial infarction ruled out with serial troponin testing. In most cases, troponin values are in the normal range in patients with variant angina, due to the relatively short duration of myocardial ischemia.",
"   </p>",
"   <p>",
"    Similar to patients with stable angina due to fixed obstructive coronary artery disease, asymptomatic episodes occur. In one study of over 1000 episodes in 240 patients, 92 percent of ischemic episodes were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/53\">",
"     53",
"    </a>",
"    ]. The role of screening for asymptomatic episodes is discussed below. (See",
"    <a class=\"local\" href=\"#H110740314\">",
"     'Ambulatory ECG monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of variant angina is made when a patient with recurrent episodes of anginal type chest pain, which generally occur at rest, is found to have transient ST-segment elevation on an electrocardiogram at the time of an episode and subsequently found to not have high grade coronary stenoses at coronary arteriography.",
"   </p>",
"   <p>",
"    All patients with angina, and in particular patients suspected of having variant angina, should have a 12-lead ECG during an episode of pain. Patients with variant angina will often have transient ST-segment elevation. In addition, a &ldquo;baseline&rdquo; ECG should be obtained at a time when the patient is not having pain.",
"   </p>",
"   <p>",
"    For most patients with anginal type chest pain who do not have ST-segment elevation on 12-lead ECG, the evaluation should first focus on fixed obstructive coronary artery disease. Many of these individuals should be referred for a stress test. (See",
"    <a class=\"local\" href=\"#H28462746\">",
"     'Role of stress testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H110739513\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If this evaluation has reasonably excluded significant obstructive coronary artery disease, an ambulatory ECG should be performed. If transient ST-segment elevation is found on ambulatory monitoring, we recommend coronary arteriography to exclude significant coronary artery disease (see",
"    <a class=\"local\" href=\"#H11389111\">",
"     'Role of coronary arteriography'",
"    </a>",
"    below). If the ambulatory monitor does not reveal ST-segment elevation at the time of chest pain, the diagnosis of variant angina is unlikely.",
"   </p>",
"   <p>",
"    We believe that variant angina is underdiagnosed for two main reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients do not present with typical symptoms of either stable ischemic heart disease due to fixed obstruction or variant angina.",
"     </li>",
"     <li>",
"      Many clinicians are not sufficiently familiar with variant angina to consider it as a diagnostic possibility. As fixed obstruction is significantly more common as a cause of angina, that diagnosis is pursued preferentially.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10492235\">",
"    <span class=\"h2\">",
"     12-lead ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient (less than 15 minutes) ST-segment elevation in multiple leads of a 12-lead ECG is usually seen during an episode of chest discomfort. Unlike most other causes of chest pain and ST-segment elevation (",
"    <a class=\"graphic graphic_table graphicRef81757 \" href=\"UTD.htm?38/35/39483\">",
"     table 1",
"    </a>",
"    ), the ST-segment returns to baseline rapidly upon resolution of symptoms. Occasionally, a transient period of T wave inversion may be seen before return of the ECG to baseline.",
"   </p>",
"   <p>",
"    Other reported electrocardiographic abnormalities include a tall and broad R wave, disappearance of the S wave, a taller T wave, and negative U waves [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110740314\">",
"    <span class=\"h2\">",
"     Ambulatory ECG monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory (Holter) monitoring can detect episodes of ST-segment elevation, with or without angina and should be performed in patients in whom the diagnosis is being considered. The finding of ST-segment elevation on the ambulatory monitor, combined with a typical history, makes the diagnosis quite likely.",
"   </p>",
"   <p>",
"    In addition to helping with the diagnosis, ambulatory monitoring should be performed to assess the efficacy of therapy, given that asymptomatic episodes are common and sometimes associated with significant arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/54\">",
"     54",
"    </a>",
"    ]. In one report using 24-hour ambulatory ECG monitoring, 79 percent of episodes were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/53,55\">",
"     53,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28462746\">",
"    <span class=\"h2\">",
"     Role of stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed below, many patients with anginal chest pain and no ST-segment elevation should undergo some form of stress testing to screen for significant fixed coronary artery disease. (See",
"    <a class=\"local\" href=\"#H110739513\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most patients with variant angina will have a normal noninvasive stress test. However, exercise-induced spasm with ST-segment elevation has been reported to occur in 10 to 30 percent of patients with variant angina, particularly during the hot phase of this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/51,52,56\">",
"     51,52,56",
"    </a>",
"    ]. As ST-segment elevation during stress testing is not specific for variant angina, these patients need to be screened for severe fixed disease with coronary arteriography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H18#H18\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'High risk'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Although stress echocardiography with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"     ergonovine",
"    </a>",
"    provocation has been used to diagnose variant angina, we do not recommend provocative testing in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11389111\">",
"    <span class=\"h2\">",
"     Role of coronary arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend diagnostic coronary arteriography for the following patients in whom variant angina is a diagnostic possibility:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with suspected variant angina based on the history and an ECG (rest, stress, or ambulatory) showing transient ST-segment elevation, severe fixed obstruction needs to be excluded. High-grade fixed obstruction may be the cause of the ST-elevation or might be present at an anatomic site not associated with the site of spasm. We do not feel that a negative noninvasive stress test would be sufficient to exclude significant coronary artery disease in this setting.",
"     </li>",
"     <li>",
"      We believe it is reasonable to refer a patient with a strong history consistent with variant angina (see",
"      <a class=\"local\" href=\"#H110738375\">",
"       'Clinical presentation'",
"      </a>",
"      above) for coronary arteriography even if the stress test and ambulatory monitors are normal. This is particularly true if episodes of pain did not occur during ambulatory monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three provocative tests &mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"     ergonovine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    , and hyperventilation &mdash; can be performed in the catheterization laboratory in an attempt to secure the diagnosis. These tests are done only when the diagnosis of variant angina is suspected, but not firmly established. At present, pharmacologic provocative testing is not frequently performed and should be employed only by experienced teams [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"     Ergonovine",
"    </a>",
"    is not available in the United States but it is widely used in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/50,58-61\">",
"     50,58-61",
"    </a>",
"    ]. Provocation with intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    is a useful provocative test [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/13,16,62\">",
"     13,16,62",
"    </a>",
"    ]. It is associated with a low frequency of serious complications (0.6 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/62\">",
"     62",
"    </a>",
"    ]. It is preferred to either ergonovine or hyperventilation, by some but not all of our experts.",
"   </p>",
"   <p>",
"    Testing for variant angina with hyperventilation has been evaluated in studies of electrocardiogram monitored patients and had a high specificity (100 percent) in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/50\">",
"     50",
"    </a>",
"    ] and a sensitivity ranging between 55 and 95 percent, depending on the frequency of daily attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/50,63\">",
"     50,63",
"    </a>",
"    ]. Hyperventilation is rarely used as a provocative test during coronary arteriography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110739513\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients who present with typical chest pain, including those whose episodes occur predominantly at rest (and in whom variant angina is a diagnostic possibility), the diagnostic evaluation should focus on fixed obstructive coronary artery disease. We believe that this is a reasonable approach given the significantly greater likelihood of fixed disease compared with variant angina. This evaluation often involves stress testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, for many patients in whom unstable angina is suspected or for all those in whom a 12-lead electrocardiogram has shown transient ST-segment elevation with an episode of pain, coronary arteriography should be performed to exclude severe fixed coronary artery disease for which revascularization is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H32#H32\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who present with a history consistent with variant angina and in whom electrocardiographic documentation of ST-segment elevation has not been made, other diagnoses (in addition to fixed obstructive disease) that should be considered include gastroesophageal reflux disease with esophageal spasm and cardiac syndrome X. Cardiac syndrome X, also called microvascular angina, differs clinically from variant angina in typically having ST-segment depression on the electrocardiogram during episodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnoses most often confused with variant angina when ST-segment elevation is seen include acute ST-elevation myocardial infarction (STEMI), acute pericarditis (with or without myocardial involvement), stress-induced cardiomyopathy, and non-cardiac chest pain associated with early repolarization.",
"   </p>",
"   <p>",
"    Characteristics which separate these diagnoses from variant angina include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with STEMI, pain and ST-elevation are usually present for more than 15 minutes. Acute therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      or calcium channel blocker does not usually resolve symptoms and ST-elevation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H13#H13\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\", section on 'ST elevation MI'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute pericarditis and stress-induced cardiomyopathy are characterized by pain that has been present for hours or days before presentation, as opposed to variant angina in which the episode of pain is much shorter and in which there is often a history of repetitive episodes over a period of weeks or months. In patients with pericarditis, the chest pain is often dissimilar to that of angina, with individuals often complaining of sharp pain that is affected by position or breathing. Echocardiography is often abnormal in these individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Electrocardiogram'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link\">",
"       \"Electrocardiogram in pericarditis and pericardial effusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link&amp;anchor=H3#H3\">",
"       \"Electrocardiogram in pericarditis and pericardial effusion\", section on 'ST segment elevation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Echocardiography'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link&amp;anchor=H8#H8\">",
"       \"Stress-induced (takotsubo) cardiomyopathy\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-cardiac chest pain associated with early repolarization generally occurs in patients without classic angina pectoris and in whom the ST-elevation is chronic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link&amp;anchor=H6#H6\">",
"       \"Diagnostic approach to chest pain in adults\", section on 'Quality of the pain'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link&amp;anchor=H9#H9\">",
"       \"Differential diagnosis of chest pain in adults\", section on 'Coronary artery disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link&amp;anchor=H7#H7\">",
"       \"Pathophysiology and clinical presentation of ischemic chest pain\", section on 'Characteristics of the chest discomfort'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H2#H2\">",
"       \"ECG tutorial: Miscellaneous diagnoses\", section on 'Early repolarization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of variant angina reduces the frequency of symptomatic episodes and appears to decrease the frequency of serious complications. (See",
"    <a class=\"local\" href=\"#H186155540\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although episodes may terminate spontaneously, sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is effective in reducing the duration of each episode. We recommend that patients use sublingual nitroglycerin with the onset of each episode, both to decrease the duration of symptoms and ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515614541\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As smoking cessation removes one of the triggers for variant angina and leads to a significant decrease in the frequency of episodes, at least in the short term, smoking cessation should be encouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18968?source=see_link\">",
"     \"Benefits and risks of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nitrates and calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) and nitrates are effective as chronic therapies for variant angina. Both prevent vasoconstriction and promote vasodilation in the coronary vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9816?source=see_link&amp;anchor=H2#H2\">",
"     \"Calcium channel blockers in the management of stable angina pectoris\", section on 'Mechanism of action'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link&amp;anchor=H2#H2\">",
"     \"Nitrates in the management of stable angina pectoris\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies comparing one therapy to another. However, in one study the use of a calcium channel blocker therapy was an independent predictor of myocardial infarct-free survival in variant angina patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/66\">",
"     66",
"    </a>",
"    ]. Thus, we begin with a calcium channel blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    at a dose of 240 to 360 mg per day), as this therapy was also effective in alleviating symptoms in over 90 percent of patients in an observational study of nearly 300 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/67\">",
"     67",
"    </a>",
"    ]. While long-acting nitrates are also effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/68\">",
"     68",
"    </a>",
"    ], the occurrence of nitrate tolerance makes them a less desirable first-line approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link&amp;anchor=H6#H6\">",
"     \"Nitrates in the management of stable angina pectoris\", section on 'Nitrate tolerance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who do not have acceptable improvement in symptoms on calcium channel blocker therapy, we add a long-acting nitrate (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    30 or 60 mg once daily).",
"   </p>",
"   <p>",
"    Treatment with guanethidine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    has been reported to be of benefit, especially in patients who are refractory to the combination of high doses of calcium channel blockers and nitrates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/14\">",
"     14",
"    </a>",
"    ]. However, these drugs are not well studied in this setting.",
"   </p>",
"   <p>",
"    Irrespective of therapy chosen, it is important to document suppression of both symptomatic and asymptomatic episodes with ambulatory electrocardiographic monitoring, given the frequency of the latter. Persistence of asymptomatic episodes should lead to an intensification of therapy if possible, in an attempt to lower the risk of ventricular arrhythmias. (See",
"    <a class=\"local\" href=\"#H110738375\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H110740314\">",
"     'Ambulatory ECG monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12066689\">",
"    <span class=\"h2\">",
"     Rho kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasudil is a rho kinase inhibitor that has been shown to inhibit",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    -induced spasm in patients with vasospastic angina [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins have been shown to be effective in preventing coronary spasm and may exert their benefits via endothelial nitric oxide or direct effects on the vascular smooth muscle.",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    30 mg daily was evaluated in a randomized, open-label trial in 64 patients with possible variant angina in whom there were no significant fixed coronary artery stenoses on coronary arteriography and in whom coronary spasm was induced by intracoronary injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    (ACh) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/69\">",
"     69",
"    </a>",
"    ]. After six months, in which all patients received calcium channel blocker therapy, the percentage of patients with ACh-induced coronary artery spasm was significantly lower in the group who received fluvastatin compared to those who did not (48 versus 79 percent). Further studies are required to assess clinical outcomes before we recommend routine statin therapy in patients who do not have other indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnesium deficiency may play a role in coronary vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/42\">",
"     42",
"    </a>",
"    ]. In one study of 22 patients with variant angina, those administered intravenous magnesium (n = 14) compared with placebo (n = 8) exhibited coronary vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/70\">",
"     70",
"    </a>",
"    ]. When re-challenged with intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    , they had less severe chest pain and ST-segment elevation. We do not recommend magnesium as therapy for patients with variant angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Percutaneous coronary intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous coronary intervention (PCI) is not routinely indicated for patients with focal spasm and minimal obstructive disease. However, PCI may be helpful if significant obstructive coronary disease is present and thought to be a potential trigger for focal spasm. Results are variable in this setting and depend, in part, upon the severity of the fixed obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/45,71\">",
"     45,71",
"    </a>",
"    ]. Coronary artery stenting may be an effective therapy for selected patients with medically refractory vasospasm that is associated with mild to moderate coronary disease and in whom the vasospastic segment can be clearly identified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, many patients with variant angina, including those with documented spasm at the site of coronary stenoses, have multivessel spasm; the role of revascularization in this setting is uncertain. This was addressed in a study of 45 patients with documented vasospastic angina and a severe stenosis who underwent balloon only angioplasty or stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/73\">",
"     73",
"    </a>",
"    ]. After a seven-month follow-up, no restenosis was observed and repeat provocative testing with intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     acetylcholine",
"    </a>",
"    did not induce spasm at the site of the initial stenosis; however, spasm at a different site in the dilated vessel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in another vessel occurred in 77 percent of patients and multivessel spasm occurred in 62 percent. These data suggest that effective medical therapy, such as calcium channel blockers, should be continued after percutaneous revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190313955\">",
"    <span class=\"h2\">",
"     Concerns about specific drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective beta blockers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    can exacerbate vasospasm and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should be used with caution and at low doses, as it is an inhibitor of prostacyclin production at high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/75\">",
"     75",
"    </a>",
"    ]. However, for patients with atherosclerotic cardiovascular disease, we give aspirin 75 to 81 mg daily.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    is used to treat acute migraine headache. However, its use has been associated with coronary vasospasm and myocardial infarction. We suggest avoiding all medications of the triptan class in patients with known or suspected coronary artery vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/39,76\">",
"     39,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link&amp;anchor=H20#H20\">",
"     \"Acute treatment of migraine in adults\", section on 'Sumatriptan combined with naproxen sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    5-Fluorouracil has been described to induce coronary artery spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186155540\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction and life-threatening arrhythmias may occur in approximately 25 percent of untreated patients with variant angina. Therapy that reduces the frequency of symptomatic episodes appears to decrease the frequency of life-threatening events, but the evidence is not robust [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186155547\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction (MI) in patients with variant angina is usually due to concurrent obstructive coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. With variant angina alone, coronary vasospasm may trigger thrombus formation. Lipoprotein(a) may play a role in this setting. It interferes with fibrinolysis by competing with plasminogen binding to molecules and cells, and elevated serum Lp(a) is associated with a history of prior myocardial infarction in patients with coronary vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186155554\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are common and may be life-threatening during an episode of coronary spasm. Patients may report palpitations or experience pre-syncope or syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/82\">",
"     82",
"    </a>",
"    ]. Screening with ambulatory ECG monitoring is discussed above. The management of such patients should be carried out by a multidisciplinary team with expertise in the care of patients with this disease and this complication. In some cases, seeking expert opinion may be useful. &nbsp;",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H110740314\">",
"     'Ambulatory ECG monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The type of arrhythmia is determined in part by the vessel involved and the territory that has become ischemic. Heart block due to ischemia of the atrioventricular node occurs more often with spasm of the right coronary artery, while ventricular tachycardia due to ischemia of a large portion of the left ventricle occurs more often with spasm of the left anterior descending artery.",
"   </p>",
"   <p>",
"    The optimal approach to patients with variant angina and sudden cardiac arrest is unknown. In an observational study of 23 patients with variant angina in whom an ICD was placed for a documented ventricular arrhythmia, all patients were alive during a median follow-up of 2.1 years (four ventricular fibrillations and one episode of pulseless electrical activity occurred in five patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with sudden cardiac arrest and variant angina, we often suggest placement of an implantable cardioverter defibrillator, since it is often difficult to prove that the coronary vasospasm predated or was the trigger for the arrest.",
"   </p>",
"   <p>",
"    For patients with high risk features such as obstructive coronary artery disease, large ST-segment elevations, focal proximal epicardial coronary artery spasm, increased vasospastic and arrhythmic activity, and multivessel coronary artery spasm who are on maximal or submaximal doses of calcium channel blockers (CCB), our experts refer the patient for placement of an implantable cardioverter defibrillator (ICD). For patients without such high risk features who are on submaximal doses of CCB, some of our experts maximize CCB and refer the patient for an ICD, while others maximize the dose of CCB and monitor the patient carefully for ventricular arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infarct-free survival at 10 years in patients with variant angina has been reported to be over 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/66\">",
"     66",
"    </a>",
"    ]. Furthermore, independent predictors of infarct-free survival include (a) extent and severity of CAD, (b) multi-vessel spasm, and (c) use of calcium channel blockers. Studies have also described a persistence of symptoms with a study reporting that half the patients continue to experience angina at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with variant angina who also have obstructive coronary artery disease have a worse prognosis that is, in large part, determined by the severity of the underlying disease. In a study of variant angina patients with one-vessel disease or a stenosis of 70 percent or less in any major coronary artery, one- and five-year survival rates of 99 and 95 percent were seen, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/80\">",
"     80",
"    </a>",
"    ]. By comparison, patients with multivessel disease had one- and five-year survival rates of 87 and 77 percent.",
"   </p>",
"   <p>",
"    Patients who experience an arrhythmic complication, especially ventricular fibrillation and sudden cardiac arrest, during an episode of spasm have a poor prognosis. Medical therapy with a calcium channel blocker in survivors of sudden cardiac arrest due to spasm may not be sufficient, since this therapy reduces, but it does not prevent, episodes of spasm. Two small studies of such patients treated medically have provided contradictory information. One series of seven patients with ventricular tachycardia or fibrillation due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"     ergonovine",
"    </a>",
"    -documented spasm found that six patients remained free of symptoms on calcium channel blockers after an average follow-up of 58 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/85\">",
"     85",
"    </a>",
"    ]. In contrast, in another series, eight patients treated with calcium channel blockers had recurrent ventricular arrhythmia after a median of 15 months. An implantable cardioverter-defibrillator was inserted in seven of these patients; four patients received an appropriate shock during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/39/3706/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H186155554\">",
"     'Arrhythmias'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725820446\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variant angina (also called vasospastic or Prinzmetal angina) is characterized by spontaneous episodes of angina in association with ST-segment elevation on the electrocardiogram (ECG). The cause is a transient, abrupt, and marked reduction in the luminal diameter of an epicardial coronary artery due to spasm, leading to transient myocardial ischemia.",
"     </li>",
"     <li>",
"      Patients with variant angina typically present with a chronic pattern of episodes of chest pain, with each episode having many of the characteristics of angina seen in patients with obstructive coronary artery disease. However, patients with variant angina will report that their episodes are predominantly at rest and that many occur from midnight to early morning. Each episode of rest pain generally lasts 5 to 15 minutes. Patients with variant angina typically have ST-segment elevation on an electrocardiogram during an episode of chest discomfort which returns to baseline on symptom resolution. This finding can be detected on a 12-lead or ambulatory ECG. (See",
"      <a class=\"local\" href=\"#H110738375\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients presenting with anginal chest pain (including those with episodes predominantly at rest) and no ST-segment elevation on an ECG, we recommend an evaluation for fixed obstructive coronary artery disease prior to an evaluation directed at variant angina. If significant fixed obstructive disease is reasonably excluded, the diagnosis of variant angina can be pursued. This usually starts with ambulatory ECG monitoring. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend diagnostic coronary arteriography for most patients in whom the diagnosis is likely or secured (based on a typical history and findings of ST-segment elevation on ECG). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arrhythmias and myocardial infarction are potentially life-threatening complications of variant angina. (See",
"      <a class=\"local\" href=\"#H186155540\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without obstructive coronary disease have a good long-term prognosis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of variant angina includes cessation of smoking and pharmacologic therapy (use of calcium channel blockers or nitrates). For patients with variant angina:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest initiating therapy with a calcium channel blocker, rather than nitrate therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). All calcium channel blockers appear effective; we often start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      at a dose of 240 to 360 mg per day. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      to abort episodes of angina in an attempt to decrease the frequency of myocardial infarction and life-threatening arrhythmia associated with these episodes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H186155540\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonselective beta blockers, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      should be",
"      <strong>",
"       avoided",
"      </strong>",
"      . In addition,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      should be used with caution, since at high doses it is an inhibitor of prostacyclin production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16996785\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. Joseph Delehanty for his many contributions to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/1\">",
"      PRINZMETAL M, KENNAMER R, MERLISS R, et al. Angina pectoris. I. A variant form of angina pectoris; preliminary report. Am J Med 1959; 27:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/2\">",
"      Kaski JC, Crea F, Meran D, et al. Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. Circulation 1986; 74:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/3\">",
"      Kaski JC, Maseri A, Vejar M, et al. Spontaneous coronary artery spasm in variant angina is caused by a local hyperreactivity to a generalized constrictor stimulus. J Am Coll Cardiol 1989; 14:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/4\">",
"      PRINZMETAL M, EKMEKCI A, KENNAMER R, et al. Variantform of angina pectoris, previously undelineated syndrome. JAMA 1960; 174:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/5\">",
"      Okumura K, Yasue H, Matsuyama K, et al. Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin. J Am Coll Cardiol 1996; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/6\">",
"      De Caterina R, Carpeggiani C, L'Abbate A. A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Evidence against a role for serotonin in the genesis of coronary vasospasm. Circulation 1984; 69:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/7\">",
"      Winniford MD, Filipchuk N, Hillis LD. Alpha-adrenergic blockade for variant angina: a long-term, double-blind, randomized trial. Circulation 1983; 67:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/8\">",
"      Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999; 43:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/9\">",
"      Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 2000; 101:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/10\">",
"      Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/11\">",
"      Nakano T, Osanai T, Tomita H, et al. Enhanced activity of variant phospholipase C-delta1 protein (R257H) detected in patients with coronary artery spasm. Circulation 2002; 105:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/12\">",
"      Yasue H, Touyama M, Shimamoto M, et al. Role of autonomic nervous system in the pathogenesis of Prinzmetal's variant form of angina. Circulation 1974; 50:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/13\">",
"      Sueda S, Ochi N, Kawada H, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol 1999; 83:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/14\">",
"      Yasue H, Touyama M, Kato H, et al. Prinzmetal's variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: documentation by coronary arteriography. Am Heart J 1976; 91:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/15\">",
"      Ricci DR, Orlick AE, Cipriano PR, et al. Altered adrenergic activity in coronary arterial spasm: insight into mechanism based on study of coronary hemodynamics and the electrocardiogram. Am J Cardiol 1979; 43:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/16\">",
"      Yasue H, Horio Y, Nakamura N, et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 1986; 74:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/17\">",
"      Bertrand ME, Lablanche JM, Tilmant PY, et al. Complete denervation of the heart (autotransplantation) for treatment of severe, refractory coronary spasm. Am J Cardiol 1981; 47:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/18\">",
"      Lanza GA, Pedrotti P, Pasceri V, et al. Autonomic changes associated with spontaneous coronary spasm in patients with variant angina. J Am Coll Cardiol 1996; 28:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/19\">",
"      Stern S, Bayes de Luna A. Coronary artery spasm: a 2009 update. Circulation 2009; 119:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/20\">",
"      Saitoh T, Kishida H, Hanashi A, et al. Coronary hyperreactivity to adrenergic stimulation and increased nocturnal vagal tone trigger coronary vasospasm. Jpn Circ J 1998; 62:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/21\">",
"      Bertrand ME, Lablanche JM, Tilmant PY. Treatment of Prinzmetal's variant angina. Role of medical treatment with nifedipine and surgical coronary revascularization combined with plexectomy. Am J Cardiol 1981; 47:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/22\">",
"      Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996; 94:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/23\">",
"      Kugiyama K, Ohgushi M, Motoyama T, et al. Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 1997; 30:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/24\">",
"      Nakayama M, Yasue H, Yoshimura M, et al. T-786--&gt;C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99:2864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/25\">",
"      Levin ER. Endothelins. N Engl J Med 1995; 333:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/26\">",
"      Cox ID, B&oslash;tker HE, Bagger JP, et al. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. J Am Coll Cardiol 1999; 34:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/27\">",
"      Figueras J, Domingo E, Cortadellas J, et al. Comparison of plasma serotonin levels in patients with variant angina pectoris versus healed myocardial infarction. Am J Cardiol 2005; 96:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/28\">",
"      Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol 1998; 32:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/29\">",
"      Hirashima O, Kawano H, Motoyama T, et al. Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. J Am Coll Cardiol 2000; 35:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/30\">",
"      Miyao Y, Kugiyama K, Kawano H, et al. Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 2000; 36:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/31\">",
"      Suzuki H, Kawai S, Aizawa T, et al. Histological evaluation of coronary plaque in patients with variant angina: relationship between vasospasm and neointimal hyperplasia in primary coronary lesions. J Am Coll Cardiol 1999; 33:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/32\">",
"      Hung MJ, Cherng WJ, Yang NI, et al. Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease. Am J Cardiol 2005; 96:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/33\">",
"      Sun H, Mohri M, Shimokawa H, et al. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol 2002; 39:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/34\">",
"      Nobuyoshi M, Abe M, Nosaka H, et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. Am Heart J 1992; 124:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/35\">",
"      Takaoka K, Yoshimura M, Ogawa H, et al. Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. Int J Cardiol 2000; 72:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/36\">",
"      Suzuki S, Yoshimura M, Nakayama M, et al. A novel genetic marker for coronary spasm in women from a genome-wide single nucleotide polymorphism analysis. Pharmacogenet Genomics 2007; 17:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/37\">",
"      Murase Y, Yamada Y, Hirashiki A, et al. Genetic risk and gene-environment interaction in coronary artery spasm in Japanese men and women. Eur Heart J 2004; 25:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/38\">",
"      Shinozaki K, Suzuki M, Ikebuchi M, et al. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation 1995; 92:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/39\">",
"      Stricker BH. Coronary vasospasm and sumatriptan. BMJ 1992; 305:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/40\">",
"      Lange RA, Cigarroa RG, Yancy CW Jr, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989; 321:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/41\">",
"      Forman MB, Blass M, Jackson EK. Variant angina in the setting of food-borne botulism. Clin Infect Dis 2011; 53:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/42\">",
"      Satake K, Lee JD, Shimizu H, et al. Relation between severity of magnesium deficiency and frequency of anginal attacks in men with variant angina. J Am Coll Cardiol 1996; 28:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/43\">",
"      Kusama Y, Kodani E, Nakagomi A, et al. Variant angina and coronary artery spasm: the clinical spectrum, pathophysiology, and management. J Nippon Med Sch 2011; 78:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/44\">",
"      Ogawa H, Yasue H, Oshima S, et al. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 1989; 80:1617.",
"     </a>",
"    </li>",
"    <li>",
"     Heart Disease: A Textbook of Cardiovascular Medicine, 9th ed, Braunwald E.  (Ed), Elsevier Saunders, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/46\">",
"      Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/47\">",
"      Rosamond W. Are migraine and coronary heart disease associated? An epidemiologic review. Headache 2004; 44 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/48\">",
"      Nakamura Y, Shinozaki N, Hirasawa M, et al. Prevalence of migraine and Raynaud's phenomenon in Japanese patients with vasospastic angina. Jpn Circ J 2000; 64:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/49\">",
"      Koh KK, Roe IH, Lee MM, et al. Variant angina complicating ergot therapy of migraine. Chest 1994; 105:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/50\">",
"      Previtali M, Ardissino D, Barberis P, et al. Hyperventilation and ergonovine tests in Prinzmetal's variant angina pectoris in men. Am J Cardiol 1989; 63:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/51\">",
"      Matsuda Y, Ozaki M, Ogawa H, et al. Coronary arteriography and left ventriculography during spontaneous and exercise-induced ST segment elevation in patients with variant angina. Am Heart J 1983; 106:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/52\">",
"      Minoda K, Yasue H, Kugiyama K, et al. Comparison of the distribution of myocardial blood flow between exercise-induced and hyperventilation-induced attacks of coronary spasm: a study with thallium-201 myocardial scintigraphy. Am Heart J 1994; 127:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/53\">",
"      Kishida H, Tada Y, Fukuma N, et al. Significant characteristics of variant angina patients with associated syncope. Jpn Heart J 1996; 37:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/54\">",
"      Enseleit F, Duru F. Long-term continuous external electrocardiographic recording: a review. Europace 2006; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/55\">",
"      Araki H, Koiwaya Y, Nakagaki O, Nakamura M. Diurnal distribution of ST-segment elevation and related arrhythmias in patients with variant angina: a study by ambulatory ECG monitoring. Circulation 1983; 67:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/56\">",
"      Lahiri A, Subramanian B, Millar-Craig M, et al. Exercise-induced S-T segment elevation in variant angina. Am J Cardiol 1980; 45:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/57\">",
"      Song JK, Park SW, Kang DH, et al. Safety and clinical impact of ergonovine stress echocardiography for diagnosis of coronary vasospasm. J Am Coll Cardiol 2000; 35:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/58\">",
"      Hamilton KK, Pepine CJ. A renaissance of provocative testing for coronary spasm? J Am Coll Cardiol 2000; 35:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/59\">",
"      Yamada T, Okamoto M, Sueda T, et al. Ergonovine-induced alterations in coronary flow velocity preceding onset of occlusive spasm in patients without significant coronary artery stenoses. Am J Cardiol 1998; 81:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/60\">",
"      Pepine CJ, Feldman RL, Conti CR. Action of intracoronary nitroglycerin in refractory coronary artery spasm. Circulation 1982; 65:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/61\">",
"      Bertrand ME, LaBlanche JM, Tilmant PY, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation 1982; 65:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/62\">",
"      Sueda S, Saeki H, Otani T, et al. Major complications during spasm provocation tests with an intracoronary injection of acetylcholine. Am J Cardiol 2000; 85:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/63\">",
"      Nakao K, Ohgushi M, Yoshimura M, et al. Hyperventilation as a specific test for diagnosis of coronary artery spasm. Am J Cardiol 1997; 80:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/64\">",
"      Miwa K, Fujita M, Miyagi Y. Beneficial effects of smoking cessation on the short-term prognosis for variant angina--validation of the smoking status by urinary cotinine measurements. Int J Cardiol 1994; 44:151.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for the Heart, 4th ed, Opie LH (Ed), WB Saunders, Philadelphia 1995. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/66\">",
"      Yasue H, Takizawa A, Nagao M, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation 1988; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/67\">",
"      Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation 1981; 63:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/68\">",
"      Lombardi M, Morales MA, Michelassi C, et al. Efficacy of isosorbide-5-mononitrate versus nifedipine in preventing spontaneous and ergonovine-induced myocardial ischaemia. A double-blind, placebo-controlled study. Eur Heart J 1993; 14:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/69\">",
"      Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 2008; 51:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/70\">",
"      Teragawa H, Kato M, Yamagata T, et al. The preventive effect of magnesium on coronary spasm in patients with vasospastic angina. Chest 2000; 118:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/71\">",
"      Corcos T, David PR, Bourassa MG, et al. Percutaneous transluminal coronary angioplasty for the treatment of variant angina. J Am Coll Cardiol 1985; 5:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/72\">",
"      Gaspardone A, Tomai F, Versaci F, et al. Coronary artery stent placement in patients with variant angina refractory to medical treatment. Am J Cardiol 1999; 84:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/73\">",
"      Tanabe Y, Itoh E, Suzuki K, et al. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. J Am Coll Cardiol 2002; 39:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/74\">",
"      Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982; 65:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/75\">",
"      Miwa K, Kambara H, Kawai C. Effect of aspirin in large doses on attacks of variant angina. Am Heart J 1983; 105:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/76\">",
"      Wasson S, Jayam VK. Coronary vasospasm and myocardial infarction induced by oral sumatriptan. Clin Neuropharmacol 2004; 27:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/77\">",
"      Maseri A, Lanza G. Fluorouracil-induced coronary artery spasm. Am J Med 2001; 111:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/78\">",
"      Kishida H, Tada Y, Tetsuoh Y, et al. A new strategy for the reduction of acute myocardial infarction in variant angina. Am Heart J 1991; 122:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/79\">",
"      Bory M, Pierron F, Panagides D, et al. Coronary artery spasm in patients with normal or near normal coronary arteries. Long-term follow-up of 277 patients. Eur Heart J 1996; 17:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/80\">",
"      Walling A, Waters DD, Miller DD, et al. Long-term prognosis of patients with variant angina. Circulation 1987; 76:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/81\">",
"      Miwa K, Nakagawa K, Yoshida N, et al. Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm. J Am Coll Cardiol 2000; 35:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/82\">",
"      Myerburg RJ, Kessler KM, Mallon SM, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 1992; 326:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/83\">",
"      Matsue Y, Suzuki M, Nishizaki M, et al. Clinical implications of an implantable cardioverter-defibrillator in patients with vasospastic angina and lethal ventricular arrhythmia. J Am Coll Cardiol 2012; 60:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/84\">",
"      Ong P, Athanasiadis A, Borgulya G, et al. 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up. J Am Coll Cardiol 2011; 57:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/85\">",
"      Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients. J Am Coll Cardiol 1998; 31:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/39/3706/abstract/86\">",
"      Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implantable cardioverter-defibrillators in refractory variant angina pectoris complicated by ventricular fibrillation in patients with angiographically normal coronary arteries. Am J Cardiol 2002; 89:1114.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1481 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3706=[""].join("\n");
var outline_f3_39_3706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H725820446\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190313768\">",
"      Vascular smooth muscle hyper-reactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autonomic nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186155139\">",
"      Associated microvascular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110739137\">",
"      RISK FACTORS AND TRIGGERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28463569\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110738375\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10492235\">",
"      12-lead ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110740314\">",
"      Ambulatory ECG monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28462746\">",
"      Role of stress testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11389111\">",
"      Role of coronary arteriography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110739513\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515614541\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nitrates and calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12066689\">",
"      Rho kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190313955\">",
"      Concerns about specific drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186155540\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186155547\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186155554\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H725820446\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16996785\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1481\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1481|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/35/39483\" title=\"table 1\">",
"      Causes of ST segment elevation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18968?source=related_link\">",
"      Benefits and risks of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9816?source=related_link\">",
"      Calcium channel blockers in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=related_link\">",
"      Nitrates in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=related_link\">",
"      The coronary microcirculation in disease states",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_39_3707="Systemic inflammatory response";
var content_f3_39_3707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for the systemic inflammatory response syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The systemic inflammatory response syndrome (SIRS) is clinically recognized by the presence of",
"        <strong>",
"         two or more",
"        </strong>",
"        of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Temperature &gt;38&ordm;C or &lt;36&ordm;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heart rate &gt;90 beats/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Respiratory rate &gt;20 breaths/min or PaCO2 &lt;32 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        WBC &gt;12,000 cells/mm3, &lt;4000 cells/mm3, or &gt;10 percent immature (band) forms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3707=[""].join("\n");
var outline_f3_39_3707=null;
var title_f3_39_3708="Estimated global prevalence";
var content_f3_39_3708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated prevalence of fire-related burn injuries* in 2004, by World Health Organization region",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Africa",
"       </td>",
"       <td class=\"subtitle1\">",
"        The Americas",
"       </td>",
"       <td class=\"subtitle1\">",
"        EMR&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Europe",
"       </td>",
"       <td class=\"subtitle1\">",
"        SEAR&Delta;",
"       </td>",
"       <td class=\"subtitle1\">",
"        WPR&loz;",
"       </td>",
"       <td class=\"subtitle1\">",
"        World",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Population (000)",
"       </td>",
"       <td>",
"        737,536",
"       </td>",
"       <td>",
"        874,380",
"       </td>",
"       <td>",
"        519,688",
"       </td>",
"       <td>",
"        883,311",
"       </td>",
"       <td>",
"        1,671,904",
"       </td>",
"       <td>",
"        1,738,457",
"       </td>",
"       <td>",
"        6,436,826",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns (000)",
"       </td>",
"       <td>",
"        17,733",
"       </td>",
"       <td>",
"        7,850",
"       </td>",
"       <td>",
"        14,919",
"       </td>",
"       <td>",
"        15,668",
"       </td>",
"       <td>",
"        44,344",
"       </td>",
"       <td>",
"        15,531",
"       </td>",
"       <td>",
"        116,284",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevalence rate",
"       </td>",
"       <td>",
"        2.40",
"       </td>",
"       <td>",
"        0.90",
"       </td>",
"       <td>",
"        2.87",
"       </td>",
"       <td>",
"        1.77",
"       </td>",
"       <td>",
"        2.65",
"       </td>",
"       <td>",
"        8.93",
"       </td>",
"       <td>",
"        1.81",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes only burns covering 20 percent or more of total body surface area.",
"     <br>",
"      &bull; Eastern Mediterranean region.",
"      <br>",
"       &Delta; South-East Asia region.",
"       <br>",
"        &loz; Western Pacific region.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: World Health Organization. Disease and injury estimates for 2004. Morbidity and Mortality. Prevalence. Prevalence (000s) for selected causes, in WHO regions, estimates for 2004. www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3708=[""].join("\n");
var outline_f3_39_3708=null;
var title_f3_39_3709="Cutaneous anthrax Rx";
var content_f3_39_3709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of cutaneous anthrax associated with bioterrorism*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Drug regimen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Adults*",
"      </td>",
"      <td>",
"       Ciprofloxacin 500 mg orally twice daily (preferred agent)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       60 days&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Doxycycline 100 mg orally twice daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Children*&Delta;",
"      </td>",
"      <td>",
"       Ciprofloxacin 15 mg/kg orally twice daily (not to exceed 500 mg/dose)&loz;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       60 days&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Doxycycline:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;8 yrs old and &gt;45 kg: 100 mg orally twice daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;8 yrs old and &le;45 kg: 2.2 mg/kg orally twice daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &le;8 yrs old: 2.2 mg/kg orally twice daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Pregnant women*&Delta;",
"      </td>",
"      <td>",
"       Ciprofloxacin 500 mg orally twice daily (preferred agent)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       60 days&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Doxycycline 100 mg orally twice daily&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunocompromised hosts*",
"      </td>",
"      <td>",
"       Same as for immunocompetent adults and children",
"      </td>",
"      <td>",
"       60 days&bull;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      Important note:",
"     </strong>",
"     Cutaneous anthrax with signs of systemic involvement, extensive edema, or lesions on the head or neck require intravenous therapy and a multidrug approach as recommended for inhalation anthrax (see separate table on inhalation anthrax).",
"     <br>",
"      &bull;Previous guidelines have suggested treating cutaneous anthrax for 7-10 days, but 60 days is recommended in the setting of of a bioterrorism event, given the likelihood of exposure to aerosolized B. anthracis.",
"      <br>",
"       &Delta;Although doxycycline and ciprofloxacin are not usually recommended during pregnancy or in children, their use may be indicated for life-threatening illness, such as following exposure to B. anthracis. Adverse effects on developing teeth and bones are dose-related; therefore, doxycycline might be used for a short time (7-14 days) before 6 months gestation.",
"       <br>",
"        &loz; Ciprofloxacin or doxycycline are considered first-line therapy. Oral amoxicillin (500 mg every 8 hours in adults or 45 mg/kg/day divided every 8 hours for children) may be used to complete the remainder of the 60 day regimen to provide a full course of PEP against inhalation anthrax following clinical improvement if the B. anthracis isolate is proven susceptible with an amoxicillin MIC&lt;0.125 mcg/mL.",
"        <br>",
"         &sect; Doxycycline should only be used in pregnant women when ciprofloxacin is contraindicated.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909 and",
"     <br>",
"      Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1014 and",
"      <br>",
"       Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50:960 and",
"       <br>",
"        Stern, EJ, Uhde, KB, Shadomy, SV, Messonnier, N. Conference report on public health and clinical guidelines for anthrax [conference summary]. Emerg Infect Dis [serial on the Internet] 2008; 14. file://www.cdc.gov/EID/content/14/4/07-0969.htm (Accessed February 11, 2008).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3709=[""].join("\n");
var outline_f3_39_3709=null;
var title_f3_39_3710="Contents: Rheumatology";
var content_f3_39_3710=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Rheumatology",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Rheumatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?34/43/35519\">",
"         Adult orthopedics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/1/43037\">",
"         Crystal diseases",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?16/63/17406\">",
"         Diagnostic issues rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?20/36/21071\">",
"         Disorders of bone",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/12/15567\">",
"         Immunodeficiency states non HIV",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/45/23262\">",
"         Immunology basic science",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?6/48/6927\">",
"         Lupus",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?28/34/29231\">",
"         Neuromuscular disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/31/42493\">",
"         Osteoarthritis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/44/5839\">",
"         Other topics in rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?39/54/40813\">",
"         Pain disorders in rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/47/12016\">",
"         Rheumatoid arthritis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/7/30845\">",
"         Rheumatology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/42/27310\">",
"         Scleroderma",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?3/58/4014\">",
"         Soft tissue rheumatic disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/41/23197\">",
"         Soft tissue rheumatism",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/6/10350\">",
"         Spinal disease and back pain",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/39/8830\">",
"         Spondyloarthropathies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/62/37870\">",
"         Treatment issues rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/62/6127\">",
"         Vasculitis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?19/26/19873\">",
"         What's new in rheumatology",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F86360107F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_39_3710=[""].join("\n");
var outline_f3_39_3710=null;
var title_f3_39_3711="Red cell ion transport mechanisms";
var content_f3_39_3711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Red blood cell ion transport mechanisms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 328px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the transport mechanisms regulating red cell hydration. The extracellular concentrations of sodium and calcium are higher than those within the cell, creating favorable gradients for entry, while the intracellular concentration of potassium is higher than that in the extracellular fluid, creating a favorable gradient for potassium exit by the K-Cl cotransporter or the calcium-activated (Gardos) potassium channel. The red transporters are active, the blue transporters are passive. Band 3 protein primarily functions as a Cl-HCO3 exchanger. Its primary physiological function is to facilitate CO2 transport from tissues to alveoli; it also plays an important role in defining red cell shape and membrane stability. Water movement passively follows that of cations and anions, or changes in tonicity of the red cell's environment. Transport of water can occur at a much faster rate via water channels (aquaporin-1, Aqp-1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_39_3711=[""].join("\n");
var outline_f3_39_3711=null;
